Chemical and Chemoenzymatic Synthesis of Outer Core Oligosaccharide of Escherichia Coli R3 and a Library of Human Milk Oligosaccharides & Design and Synthesis of Glycoconjugates by Xiao, Zhongying
Georgia State University
ScholarWorks @ Georgia State University
Chemistry Dissertations Department of Chemistry
5-9-2016
Chemical and Chemoenzymatic Synthesis of
Outer Core Oligosaccharide of Escherichia Coli R3
and a Library of Human Milk Oligosaccharides &
Design and Synthesis of Glycoconjugates
Zhongying Xiao
Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss
This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been
accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information,
please contact scholarworks@gsu.edu.
Recommended Citation
Xiao, Zhongying, "Chemical and Chemoenzymatic Synthesis of Outer Core Oligosaccharide of Escherichia Coli R3 and a Library of
Human Milk Oligosaccharides & Design and Synthesis of Glycoconjugates." Dissertation, Georgia State University, 2016.
https://scholarworks.gsu.edu/chemistry_diss/122
CHEMICAL AND CHEMOENZYMATIC SYNTHESIS OF OUTER CORE 
OLIGOSACCHARIDE OF ESCHERICHIA COLI R3 AND A LIBRARY OF HUMAN MILK 
OLIGOSACCHARIDES 
& 
DESIGN AND SYNTHESIS OF GLYCOCONJUGATES 
by 
 
 
ZHONGYING XIAO 
 
 
Under the Direction of Peng George Wang, Ph.D. 
 
 
ABSTRACT 
Lipopolysaccharides (LPS), major virulence determinants in Gram–negative 
bacteria, are responsible for many pathophysiological responses and can elicit 
strong immune responses. In order to better understand the role of LPS in host–
pathogen interactions and elucidate the immunogenic properties of LPS outer core 
oligosaccharide, an all α–linked Escherichia coli R3 outer core pentasaccharide 
was first synthesized with a propyl amino linker at the reducing end. This 
oligosaccharide was also covalently conjugated to a carrier protein (CRM197) via 
the reducing end propyl amino linker. An immunological analysis demonstrated 
that this glycoconjugate can elicit specific anti-pentasaccharide antibodies with in 
vitro bactericidal activity. These findings will contribute to further exploring this 
pentasaccharide antigen as a vaccine candidate. 
Human milk oligosaccharides (HMOs) are a family of diverse unconjugated 
glycans that exist in human milk as one of the major components. Characterization, 
quantification and biofunctional studies of HMOs remain a big challenge due to their 
diversity and complexity. The accessibility of homogenous HMOs library is essential to 
solve these issues which have beset academia for several decades. In this study, an 
efficient chemoenzymatic strategy, namely Core Synthesis/Enzymatic Extension (CSEE), 
for rapid production of diverse HMOs was reported. Based on 3 versatile building blocks 
and 4 robust glycosyltransferases, a library of 31 HMOs were chemoenzymatically 
synthesized and characterized by MS and NMR. CSEE indeed provides a practical 
approach to harvest structurally defined HMOs for various applications.   
Glycoproteins are extremely important for all life on the planet. Glycoproteins play 
important roles in various biological processes. Increasing evidences demonstrate that 
glycosylation of proteins could improve stability of proteins by stabilizing their tertiary 
structure and protecting them from proteolysis. Besides, glycosylation of proteins could 
provide targeting effects through glycan-lectin interaction. Furthermore, carbohydrates 
play crucial roles in humoral immunity in that many sugar epitopes are identified as 
antigens for antibodies. Glycoprotein could boost strong T cells mediated intercellular 
immune responses because homogeneous antigens present on the surface of proteins 
by multivalent bonds. In this study, the three advantages of glycoproteins, namely 
stabilizing proteins, targeting effects and eliciting immunological response, were 
extensively explored by broad collaboration with other groups.   
 
INDEX WORDS: LPS, Outer Core, HMOs, CSEE, Glycosylation of Proteins, 
Carbohydrate Epitopes.  
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1. Chemical Synthesis of Outer Core Oligosaccharide of Escherichia coli R3 and 
Immunological Evaluation 
1.1 Introduction 
Lipopolysaccharides (LPS) are important cell envelope components of Gram–
negative bacteria, embedded in the outer leaflet of the asymmetric outer membrane and 
exposed on the cell surface.1 LPS contribute to the integrity of outer membrane and 
protect the cells against various environmental stresses including lipophilic antibiotics and 
host immune system.2 Moreover, LPS act as strong stimulators of innate and adaptive 
immunity in diverse eukaryotic species ranging from insects to humans.2-5 Therefore, the 
study of LPS has attracted considerable interest with respect to the development of 
vaccines, therapeutics and diagnostics.6-8 LPS typically consist of three parts: an 
endotoxic lipid A comprising a bisphosphorylated and acylated β–(1→6)–linked 
glucosamine disaccharide backbone, a core oligosaccharide, and a distal polysaccharide 
called O–antigen whose composition widely varies in different bacterial species.4, 9, 10 
Structurally, the core oligosaccharide region can be further subdivided into an inner core 
region typically consisting of 3–deoxy–D-manno–oct–2–ulosonic acid (Kdo) and L–
glycero–D–manno–heptopyranonse (Hep) residues, and an outer core region that 
contains various hexoses and hexosamines.4, 11, 12 
In Escherichia coli (E. coli), the core oligosaccharides have limited variation with 
only five core structures named R1, R2, R3, R4 and K12.13 The R3 core type is of 
biomedical interest because it is found in most verotoxigenic isolates such as 
O157:H7,14 which causes approximately 210 million cases of diarrhea and 380,000 
deaths in the developing world each year.15 The structure of E. coli O157:H7 LPS 
2 
has been determined and reported in previous literatures (Figure 1A).14, 16, 17 E. coli 
O157:H7 has a typical LPS consisting of a lipid moiety, a core oligosaccharide 
(inner core and outer core) and an O–antigen. The development of LPS–based 
vaccines, therapeutics, and diagnostics requires well-defined oligosaccharides 
conjugated to carrier proteins for immunological studies to identify the structural 
motifs that can elicit protective antibody responses.8, 18-21 Although 
oligosaccharides can be isolated from bacteria, the homogeneity cannot be 
achieved due to the variations of natural oligosaccharides during the processes of 
isolation and conjugation to carriers.22 Chemical synthesis of well-defined 
oligosaccharides can overcome this problem by utilizing an artificial linker at the 
reducing end that allows conjugation to carrier proteins.20, 23-27 Moreover, it can 
provide various sub–structures for structure–activity relationships study to 
determine the minimal epitope that can elicit protective immune response.19, 28 
Herein, an all α–linked pentasaccharide of E. coli R3 outer core was chemically 
synthesized with a propyl amino linker at the reducing end (Figure 1.1B), and was 
conjugated to the nontoxic mutant of diphtheria toxin CRM197 to afford a 
glycoprotein. Furthermore, levels of IgG and IgM antibodies against the 
pentasaccharide and in vitro bactericidal activity of these antibodies against E. coli 
O157:H7 were evaluated. 
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Figure 1.1. (A) The structure of E. coli O157:H7 LPS; (B) The structure of E. coli R3 
outer core oligosaccharide with propyl amino linker 
 
1.2 Results and discussion 
1.2.1 Synthesis of Fragments of outer core 
In the early stage of the project, we planned to develop vaccines based on fragments 
of outer core of E. coli R3 rather than the whole core, which could decrease the difficulties 
of preparation of vaccines. Furthermore, to explore the possible immunogenicity of inner 
core, we tried to couple the outer core with the first Hep residue of inner core, which was 
substituted by mannose (Man) block because Man is structurally similar with Hep. Based 
on our initial ideas, linear backbones of outer core linked with a propyl amino linker, 
4 
Compound 1-17 and 1-18, were designed. These simplified outer cores were conjugated 
with CRM197 for immunological tests. 
 
 
Figure 1.2. Fragments of Outer Core 
 
The synthesis of trisaccharide 1-21 was started with glycosylation of donor 1-2 with 
acceptor 1-8 promoted by TMSOTf under stable -20 °C to furnish disaccharide 1-19, it 
was separated with its β-isomer by silica gel (α/β = 6:1). Oxidative cleavage of the 
anomeric 4–methoxyphenyl (MP) moiety of 1-19 by ceric ammonium nitrate gave a lactol, 
which was converted into the corresponding trichloroacetimidate 1-20 under 
CCl3CN/DBU condition in 73% yield over two steps. A TMSOTf–mediated coupling of 
trichloroacetimidate 1-20 with the acceptor 1-15 in a diethyl ether/dichloromethane (1:1) 
solvent system led to desired -linked trisaccharide  1-17 (1JH-H = 3.2 Hz, α/β = 10:1) in 
60% yield. The primary amine of trisaccharide 1-17 was reacted with an excess of 
succinic anhydride in the presence of triethylamine and DMF to afford monoacid linker 1-
21 for next step’s conjugation (Scheme 1.1). 
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Scheme 1.1. Synthesis of Trisaccharide 1-21 
 
The tetrasaccharide 1-23 was synthesized by a convergent [2+2] block coupling 
strategy (Scheme 1.2). Glycosylation of Donor 1-20 and Acceptor 1-21 in DCM/Et2O 
solvent system was proceeded fast catalyzed by TMSOTf to afford tetrasaccharide 1-22. 
O-Deacetylation of compound 1-22 was performed under Zemplén conditions, followed 
by the global deprotection of Benzyl group (Bn) and azido group by catalytic 
hydrogenolysis with Pd(OH)2/H2 in MeOH. The tetrasaccharide 1-18 was produced in a 
total yield of 90% over the two steps. The primary amine of tetrasaccharide 1-18 was 
reacted with an excess of succinic anhydride in the presence of triethylamine to achieve 
monoacid linker 1-23 for next step’s conjugation (Scheme 1.2). 
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Scheme 1.2. Synthesis of Tetrasaccharide 1-23 
 
With these two oligosaccharides in hand, we need to explore a good method to 
couple them onto the carrier protein CRM197. N, N, N′, N'-tetramethyl (succinimido) 
uranium tetrafluoroborate (TSTU) was found to be an ideal reagent for the formation of 
carboxiamide from acid.29 This reagent is compatible with polar solvent such as aqueous 
solvent and DMF. As a result, NHS ester was accomplished by treating acid 1-21 and 1-
23 with TSTU in the presence of Et3N in DMF solvent. Both TLC and MS confirmed the 
completion of the reaction in 1 hour. During this activation step, only minimal amount of 
TSTU (1.1 eq) and base (1.1 eq) were applied and completion of reaction was confirmed 
by TLC. The crude product was directly used for next step after concentrated to dryness. 
The modified oligosaccharide with an activated ester was then conjugated to amino 
groups of lysine residues of the protein (the molar ratio: carbohydrate/protein 50:1) in PBS 
buffer (pH 7.4) to afford the glycoproteins. These two glycoproteins were confirmed by 
SDS–PAGE analysis, displaying a shift toward a higher mass of glycoprotein compared 
with unconjugated CRM197. Unfortunately, these two glycoproteins did not show strong 
7 
immunological activities in mice test and we have to move forward to synthesize the whole 
pentaccharide E. coli R3. 
 
 
Figure 1.3. Preparation of Oligosaccharide-CRM197 Glycoconjugates 
 
1.2.2 Initial attempt to synthesize outer core pentasaccharide 
The chemical synthesis of the outer core pentasaccharide of E. coli R3 is challenging, 
because it is highly branched and consists of all α–linked glycosidic bonds. Furthermore, 
the pentasaccharide contains a number of glycosides that are difficult to install in a 
stereo–selective fashion. Especially, the introduction of α–glucosides and α–galactosides 
often leads to the formation of a mixture of anomers, which are difficult to separate and 
result in lower yields of the desired products. Installing the highly crowded cis–1,2,3–α–
linked galactose (B) with glucose (C) and N-acetylglucosamine (D) needs to establish an 
optimal order of glycosylation. As illustrated in Figure 1.4, the fully protected 
pentasaccharide was initially envisioned to be synthesized by a convergent and stereo–
controlled [2 + 3] approach. Unfortunately, the desired product was not detected by ESI 
mass spectrometry analysis, and substantial decomposition of the glycosyl donor 
(trichloroacetimidate) and acceptor were observed by TLC. It was considered that the 
steric hindrance resulted in inaccessibility of C–2 hydroxy group for the third glycosylation 
8 
after C–1 and C–3 hydroxy groups of galactose (B) were glycosylated. Therefore, a [4 + 
1] coupling approach was carried out by initially installing C–2 hydroxy group of galactose 
(B), followed by glycosylation of C–3 and C–1 hydroxy groups. Stereo–controlled 
glycosylations were assisted by solvent effects and temperature control.  Moreover, C–3 
and C–1 of the galactose building block (B) were modified by orthogonal protecting 
groups benzoyl ester (Bz) and 4–methoxyphenyl (MP), respectively. The orthogonal 
protecting groups made it possible to establish the proper order of glycosylation to 
assemble the highly branched pentasaccharide. 
 
Figure 1.4. Retrosynthetic analysis of outer core oligosaccharide of E. coli R3 
  
9 
1.2.3 Synthesis of Disaccharide 1-7 
 Having established the optimal order of glycosylation, cis–1,2–α–linked 
disaccharide donor 1-7 needed to be synthesized (Scheme 1.3). Assisted by 
solvent effects (diethyl ether as co-solvent with dichloromethane), glycosylation of 
the donor 1-2 with a nonparticipation benzyl ether at C–2 and the acceptor 1-3 
synthesized in our previous report 30 predominantly afforded –anomer (1JH-H = 3.6 
Hz, α/β=10:1) at –40 oC.31-34 The isolated disaccharide 1-4 was contaminated by 
the rearrangement product of trichloroacetimidate donor 1-2. The contaminated 
compound 1-4 was directly subjected to removal of the benzylidene acetal using 
trifluoroacetic acid (TFA) in a mixture of CH2Cl2 and water,35, 36 which made it easy 
to separate the byproduct to give desired diol 1-5. Benzylation of compound 1-5 
with benzyl bromide and NaH in DMF gave the purified benzyl ether 1-6 in 53% 
yield over three steps. The compound 1-6 was treated with N–bromosuccinimide 
(NBS) to afford the resulting lactol,37, 38 which was converted into the corresponding 
trichloroacetimidate 1-7 using trichloroacetonitrile and 1, 8–diazabicycloundec–7–
ene (DBU) in 68% yield over two steps. 
 
Scheme 1.3. Synthesis of Disaccharide 1-7.  
 
10 
1.2.4 Assembly of pentasaccharide 1-1 
A successful synthetic strategy of compound 1-1 was illustrated in Scheme 1.4. With 
the disaccharide donor 1-7 in hand, coupling of the trichloroacetimidate 1-7 with the 
acceptor 1-8 in the presence of catalytic amount of TMSOTf as the promoter in diethyl 
ether/dichloromethane (1:1) solvent system provided a trisaccharide at –20 oC, which was 
purified to afford 1-9 as main α–anomer (1JH-H = 3.6 Hz, α/β ≥20:1) in 55% yield.31-34 
Removal of benzoyl group (Bz) was easily accomplished by treatment with base (NaOMe) 
to afford trisaccharide acceptor 1-10 in 96% yield. The partially benzylated donor 1-11 
was much more stable and easier to use compared to the corresponding extremely 
reactive fully benzylated donor.30 The trisaccharide 1-10 was coupled with glycosyl donor 
1-11 using a catalytic amount of TMSOTf in diethyl ether/dichloromethane (1:1) solvent 
system to afford the desired -linked tetrasaccharide 1-12 (1JH-H = 3.2 Hz) in 76% yield, 
no β–anomer byproduct was detected. The azide moiety of 1-12 was reduced with NaBH4 
and NiCl2.H2O to give amine, which was immediately acetylated to afford the resulting 1-
13 in excellent yield (94%).39 Oxidative cleavage of the anomeric MP (4–methoxyphenyl) 
moiety of 1-13 using ceric ammonium nitrate gave a lactol, which was converted into the 
corresponding trichloroacetimidate 1-14 using trichloroacetonitrile and DBU in 53% yield 
over two steps.40, 41 A TMSOTf–mediated coupling of trichloroacetimidate 1-14 with the 
acceptor 1-15 in a diethyl ether/dichloromethane (1:1) solvent system led to desired -
linked pentasaccharide  1-16 (1JH-H = 3.2 Hz, α/β ≥20:1) in 42% yield. Finally, the 
deprotection of 1-16 started with removal of the acetyl groups using base (NaOMe), 
followed by using Pearlman’s catalyst (Pd(OH)2/C) and H2 to afford the desired target 
compound 1-1 in 72% yield. 
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Scheme 1.4. Synthesis of Pentasaccharide 1-1.  
 
1.2.5 Conjugation of the pentasaccharide to carrier protein 
To perform immunological experiments, the outer core pentasaccharide of E. coli R3 was 
conjugated to the nontoxic mutant of diphtheria toxin CRM197.29, 42-44 CRM197 is an 
immunogenic carrier protein, which can improve the immunogenicity of oligosaccharide 
antigens and induce a T-cell dependent immune response.45 This particular carrier protein 
has been used as a constituent of licensed conjugate vaccines against Neisseria 
meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type B.46 The outer 
core pentasaccharide–CRM197 glycoconjugate was prepared as illustrated in Scheme 3. 
The primary amine in the propyl amino linker of pentasaccharide 1 was treated with an 
excess of di–N–hydroxysuccinimidyl suberate in the presence of triethylamine and DMF 
to afford activated monoester.47 The modified pentasaccharide with an activated ester 
was then conjugated to amino groups of the protein (the molar ratio: carbohydrate/protein 
50:1) in PBS buffer (pH 7.4) to give the glycoprotein.48 This glycoprotein was confirmed 
by SDS–PAGE analysis, displaying a shift toward a higher mass of glycoprotein 
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compared with unconjugated CRM197. The corresponding saccharide loading ratio was 
17.5 by MALDI–TOF mass spectrometry analysis, and the conjugation efficiency was 
35%.24 Based on the same procedure, another glycoprotein pentasaccharide–BSA was 
also prepared as a coating antigen to install the plates for reflecting specific binding 
between penatsaccharide moiety and the induced anti–penatascchride antibody in 
following ELISA assay.21 
 
Scheme 1.5. Preparation of the pentasaccharide-proteins conjugate 
 
1.2.6 Immunological evaluation of the pentasaccharide-CRM197 glycoconjugate 
The resulting pentasaccharide–CRM197 glycoconjugate was evaluated for its ability 
to elicit antibody responses to pentasaccharide 1-1 in a mouse model. Freund’s adjuvant 
was selected, because it is an effective adjuvant in mice that has been used to improve 
antibody responses to a synthetic oligosaccharide antigen.44 The initial immunization was 
performed with Freund’s complete adjuvant (FCA), and the second and third 
immunizations were performed with Freund’s incomplete adjuvant (FIA). Female BALB/c 
mice were subcutaneously immunized three times at biweekly intervals with 2.5 μg 
carbohydrate based doses of pentasaccharide–CRM197 conjugate formulated with 
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adjuvant (FCA/FIA). The same dose of CRM197 formulated with adjuvant (FCA/FIA), 
adjuvant (FCA/FIA), and only PBS were used as negative controls. The serum antibodies 
of immunized mice against pentasaccharide were measured by ELISA assay (Figure 
1.5). The total IgG titers were significantly increased in the serum of mice immunized with 
pentasaccharide–CRM197 compared with the other immunized groups (P<0.001). 
Moreover, higher IgM titers were also detected in the serum of mice immunized with 
pentasaccharide–CRM197 compared with the other immunized groups (P<0.01). These 
results indicated that the pentasaccharide–CRM197 glycoconjugate effectively elicited 
humoral response in this mouse model.  
 
Figure 1.5. Evaluation of anti–pentasaccharide antibody titers (IgG and IgM) after 
the third immunization. 
 
In order to illuminate the nature of immune response produced in mice immunized 
with pentasaccharide–CRM197 and its potential relevance to overall T cell phenotype, IgG 
subclass profiles were evaluated by ELISA assay (Figure 1.6). In pentasaccharide–
CRM197 immunized mice, the antibody titers of IgG1 and IgG2b were dramatically 
increased (Figure 1.6A & C), indicating a Th2–type response.49 Moreover, predominantly 
higher titers of IgG2a were produced in serum of the immunized mice with 
14 
pentasaccharide–CRM197 compared with other groups (Figure 4B), which indicated that 
a Th1–type response was evoked in mice immunized with pentasaccharide–CRM197.49 In 
addition, an increase in IgG3 titers in group of pentasaccharide–CRM197 was also 
observed (Figure 1.6D), which is correlated with a Th1–type response.49 The IgG 
subclass profiles indicated that not only a Th2–type response but also a Th1–type 
response was induced in mice immunized with pentasaccharide–CRM197. 
 
Figure 1.6. Antibody IgG subclass profiles after the third immunization, (A) IgG1 
titers, (B) IgG2a titers, (C) IgG2b titers, (D) IgG3 titers. 
1.2.7 Bactericidal activity 
 To evaluate the bactericidal activity induced by pentasaccharide–CRM197 
conjugate against an E. coli strain containing R3 outer core structure, diluted 
mouse serum samples were incubated with E. coli O157:H7 in rabbit sera and then 
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developed by Cell Counting Kit–8 (CCK–8), which allows sensitive colorimetric 
assays for the determination of cell viability.50  An approximate 50% killing of E. 
coli O157:H7 was observed with a 160–fold dilution of the serum from mice 
immunized with pentasaccharide–CRM197, while 50% bactericidal activity was not 
achieved even with only a 20–fold dilution of the serum from the other groups. 
When the serum was diluted 80–fold from mice immunized with pentasaccharide–
CRM197, about 80% of bacteria were killed (Figure 1.7). These results indicated 
that the serum from mice immunized with pentasaccharide–CRM197 showed 
remarkable bactericidal activity against E. coli O157:H7. 
 
Figure 1.7. Bactericidal activity of serum from the immunized mice against 
E. coli O157:H7. 
 
1.3 Conclusion 
In summary, we described the first total synthesis of the outer core pentasaccharide 
of E. coli R3 using a [4 + 1] coupling strategy. The orthogonal protecting groups modified 
galactose building block (B) made it possible to establish the optimal order of 
glycosylation for synthesis of the highly crowded 1,2,3–cis configured oligosaccharide. 
Furthermore, solvent effects and temperature were exploited to control the anomeric 
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selectivity of glycosylation. These strategies will be significant for preparation of other 
highly branched oligosaccharides. The immunological evaluation of the pentasaccharide–
CRM197 glycoconjugate indicated that this glycoconjugate was able to elicit specific anti-
pentasaccharide antibodies with in vitro bactericidal activity against E. coli O157:H7. 
Overall, this work represented a new perspective in the design and synthesis of 
carbohydrate antigens to be explored as vaccine candidates. 
1.4 Experimental Section 
All reagents were purchased from commercially sources and were used without 
further purification. All solvents were available with commercially dried or freshly dried 
and distilled prior to use. Reactions were monitored by thin layer chromatography (TLC) 
using silica gel GF254 plates with detection by short wave UV light (λ = 254 nm) and 
staining with 10% phosphomolybdic acid in EtOH or p–anisaldehyde solution (ethanol/p–
anisaldehyde/acetic acid/sulfuric acid 135:5:4:1.5), followed by heating on a hot plate. 
Column chromatography was conducted by silica gel (200–300 mesh) with ethyl acetate 
and hexane as eluent. Optical rotation values were measured using a JASCO DIP-360 
polarimeter at the ambient temperature in specified solvents. 1H NMR and 13C NMR were 
recorded with Bruker AV 400 spectrometer at 400 MHz (1H NMR), 100 MHz (13C NMR) 
using CDCl3 and CD3OD as solvents. Chemical shifts were reported in δ (ppm) from 
CDCl3 (7.26 ppm for 1H NMR, 77.00 ppm for 13C NMR), CD3OD (3.31 ppm for 1H NMR, 
49.00 ppm for 13C NMR). Coupling constants were reported in hertz. High–resolution 
mass spectra (HRMS) were obtained on a Varian QFT–ESI mass spectrometer, and 
glycoproteins were analyzed by Bruker ultrafleXtreme MALDI TOF/TOF mass 
spectrometer.  
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Phenyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–3,4,6–tri–O–
benzyl–1–thio–β–D–glucopyranoside (1-6)  
A mixture of donor 1-2 (1.39 g, 2.03 mmol) and acceptor 1-3 (610 mg, 1.36 mmol) 
and 4 Å molecular sieves (2.0 g) in 10 mL dry Et2O/CH2Cl2 (1:1) was stirred at room 
temperature under Ar for 30 min. Then this mixture was cooled –40 oC, and TMSOTf (35 
µL, 0.20 mmol) was added. The reaction was slowly warmed  to room temperature in 1 
h, TLC analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 5:1, Rf = 0.36). The reaction was quenched by the addition of 0.1 
mL triethylamine and filtered. The filtrate was concentrated in vacuum and purified by 
silica gel chromatography (hexane/ethyl acetate 10:1) to afford a syrup 1-4 (965 mg) 
contaminated by the rearrangement product of trichloroacetimidate donor 1-2. ESI 
HRMS: m/z calcd for C60H64NO10S [M +NH4]+ 990.4251, found 990.4254. 
This disaccharide syrup 1-4 (965 mg, 0.99 mmol) was dissolved in 10 mL CH2Cl2, 1 
mL trifluoroacetic acid and 0.1 mL water was added. The mixture was stirred for 30 min 
at room temperature. TLC analysis showed complete conversion of starting material to a 
major product (hexane/ethyl acetate 1:1, Rf = 0.42). The reaction was quenched by the 
addition of 1.0 mL triethylamine. The mixture was washed with water, the organic layer 
was dried (Na2SO4) and filtered. The filtrate was concentrated in vacuum and purified by 
silica gel chromatography (hexane/ethyl acetate 2:1) to afford corresponding diol 1-5 as 
syrup (698 mg). ESI HRMS: m/z calcd for C53H56O10SNa [M +Na]+ 907.3492, found 
907.3478. 
The above isolated diol (698 mg, 0.79 mmol) was dissolved in 10 mL DMF, and benzyl 
bromide (0.28 mL, 2.36 mmol) was added. Sodium hydride (60% dispersion in mineral 
18 
oil, 94 mg, 2.36 mmol) was then added slowly at 0 oC. The reaction mixture was stirred 
at room temperature overnight. TLC analysis showed complete conversion of starting 
material to a major product (hexane/ethyl acetate 8:1, Rf = 0.17). The reaction was 
quenched with MeOH and concentrated in vacuum. The residue was dissolved with 
CH2Cl2, and the organic layer was washed with water, followed by drying and filtration. 
The filtrate was concentrated in vacuum and purified by silica gel chromatography 
(hexane/ethyl acetate  8:1) to afford a purified syrup 1-6 (768 mg, 53% from 1-3, three 
steps). [α]D20 = +61.5 (c = 0.2, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 3.14 (dd, J = 2.0 Hz, 
J = 10.4 Hz, 1 H), 3.25 (d, J = 10.0 Hz, 1 H), 3.53–3.55 (m, 1 H), 3.64–3.78 (m, 6 H), 
3.92–4.01 (m, 2 H), 4.09 (d, J = 10.4 Hz, 1 H), 4.24 (d, J = 12.0 Hz, 1 H), 4.36 (d, J = 11.2 
Hz, 1 H), 4.48–4.60 (m, 4 H), 4.73 (d, J = 11.6 Hz, 1 H), 4.76–4.83 (m, 4 H), 4.87 (d, J = 
9.6 Hz, 1 H, H–1C), 4.92 (d, J = 11.6 Hz, 1 H), 4.76-4.83 (m, 2 H), 5.94 (d, J = 3.6 Hz, 1 
H, H–1E), 7.00–7.05 (m, 4 H), 7.10–7.14 (m, 3 H), 7.17–7.32 (m, 31 H), 7.50–7.52 (m, 2 
H); 13C NMR (CDCl3, 100 MHz): δ 67.75, 68.73, 70.08, 73.05, 73.21, 73.30, 74.51, 74.65, 
74.75, 75.43, 75.52 77.45, 78.52, 78.77, 79.61, 81.67, 84.62, 86.86 (C–1C), 95.61(C–1E), 
127.12, 127.18, 127.22, 127.33, 127.39, 127.42, 127.46, 127.57, 127.67, 127.76, 127.87, 
127.94, 127.99, 128.09, 128.17, 128.26, 128.81, 131.11, 133.34, 137.66 , 137.70, 137.74 
, 137.87, 138.02, 138.61, 138.72 ESI HRMS: m/z calcd for C67H72NO10S [M +NH4]+ 
1082.4877, found 1082.4865. 
 
2,3,4,6–Tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–3,4,6–tri–O–
benzyl–β–D–glucopyranosyl trichloroacetimidate (1-7) 
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To a solution of 1-6 (750 mg, 0.7 mmol) in acetone (10 mL) and water (1.0 mL) 
was added NBS (250 mg, 1.4 mmol) at 0 oC. The mixture was stirred for 3 h at room 
temperature. TLC analysis showed complete conversion of starting material to a major 
product (hexane/ethyl acetate 3:1, Rf = 0.25). The reaction was quenched by the addition 
of 10 mL Na2S2O3(sat.) solution. The acetone was removed in vacuum, the crude product 
was diluted with CH2Cl2 (30 mL), washed with H2O (10 mL). And the aqueous phase was 
extracted by CH2Cl2 (20 mL), the organic fractions were combined, dried over Na2SO4 
and filtered. The filtrate was concentrated in vacuum and purified by silica gel 
chromatography (hexane/ethyl acetate 3:1) to afford corresponding hemiacetal as syrup 
(540 mg). ESI HRMS: m/z calcd for C61H68NO11 [M +NH4]+ 990.4792, found 990.4805. 
A mixture of the above isolated hemiacetal (540 mg, 0.55 mmol), CCl3CN (1 mL) and 
DBU (0.1 mL) in anhydrous CH2Cl2 (8 mL) was stirred for 2 h at room temperature. TLC 
analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 3:1, Rf = 0.70). The mixture was concentrated in vacuum and 
purified by silica gel chromatography (hexane/ethyl acetate 5:1) to afford a syrup 1-7 (532 
mg, 68%, two steps) for next coupling step quickly. 
 
4–Methoxyphenyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–
3,4,6–tri–O–benzyl–α–D–glucopyranosyl–(1→2)–3–O–benzoyl–4,6–O–
benzylidene–β–D–galactopyranoside (1-9) 
A mixture of donor 1-7 (503 mg, 0.45 mmol) and acceptor 1-8 (258 mg, 0.54 mmol) 
and 4 Å molecular sieves (1.0 g) in 8 mL anhydrous Et2O/CH2Cl2 (1:1) was stirred at room 
temperature under Ar for 30 min. Then this mixture was cooled –20 oC, TMSOTf (12 µL, 
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0.068 mmol) was added. The reaction was warmed slowly room temperature in 1 h, TLC 
analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 3:1, Rf = 0.25). The reaction was quenched by the addition of 0.1 
mL triethylamine and filtered. The filtrate was concentrated in vacuum and purified by 
silica gel chromatography (hexane/ethyl acetate 5:1) to afford a syrup trisaccharide 1-9 
(354 mg, 55%). [α]D20 = +83.5 (c = 0.2, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 3.26 (dd, J 
= 3.6 Hz, J = 9.6 Hz, 1 H), 3.46 (dd, J = 3.2 Hz, J = 10.0 Hz, 1 H), 3.54–3.64 (m, 3 H), 
3.67–3.70 (m, 2 H), 3.74 (s, 3 H, PhOCH3), 3.86–3.87 (m, 2 H), 3.95–4.08 (m, 4 H), 4.18 
(d, J = 12.4 Hz, 1 H), 4.23 (d, J = 11.6 Hz, 1 H), 4.31 (d, J = 11.6 Hz, 1 H), 4.40–4.43 (m, 
3 H), 4.46–4.52 (m, 2 H), 4.57–4.66 (m, 5 H), 4.67–4.72 (m, 2 H, H–1B, PhCH2), 4.74–
4.86 (m, 4 H),  5.06 (d, J = 3.6 Hz, 1 H,  H–1C), 5.28 (dd, J = 3.6 Hz, J = 10.0 Hz, 1 H), 
5.48 (s, 1 H, PhCH), 5.92 (d, J = 2.0 Hz, 1 H, H–1E), 6.75–6.85 (m, 6 H), 6.94–6.98 (m, 2 
H), 7.08–7.13 (m, 3 H), 7.17 (m, 5 H), 7.19–7.25 (m, 10 H), 7.27–7.36 (m, 14 H), 7.40–
7.48 (m, 7 H), 8.01-8.03 (m, 2 H); 13C NMR (CDCl3, 100 MHz): δ 55.55 (PhOCH3), 65.76, 
68.14, 68.34, 68.64, 69.10, 70.21, 70.33, 71.43, 73.07, 73.27, 73.31, 73.44, 73.73, 74.26, 
74.78, 75.33, 76.13, 77.64, 79.45, 80.32, 81.69, 92.88 (C–1C), 93.58 (C–1E), 100.69 
(PhCH), 101.22 (C–1B), 114.49, 117.00, 126.17, 127.02, 127.08, 127.29, 127.38, 127.49, 
127.51, 127.67, 127.75, 127.86, 127.95, 128.00, 128.11, 128.18, 128.28, 128.31, 128.63, 
128.80, 129.55, 129.78, 133.18, 137.63, 137.99, 138.15, 138.21, 138.53, 138.68, 138.72, 
139.32, 150.37, 154.99, 166.22 (PhCO); ESI HRMS: m/z calcd for C88H88O18Na [M +Na]+ 
1455.5868, found 1455.5809. 
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4–Methoxyphenyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–
3,4,6–tri–O–benzyl–α–D–glucopyranosyl–(1→2)–O–4,6–benzylidene–β–D–
galactopyranoside (1-10) 
A solution of trisaccharide (215 mg, 0.15 mmol) in dry methanol (4 mL) was added 
sodium methoxide (10 mg, 0.18 mmol). The solution was stirred at 45 oC overnight. TLC 
analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 2:1, Rf = 0.23). Then the acid resin (Dowex® 50WX2 H+–form) was 
added and stirred to adjust pH 7, followed by filtration. The filtrate was concentrated in 
vacuum and purified by silica gel chromatography (hexane/ethyl acetate 2:1) to afford a 
syrup 1-10 (191 mg, 96%). [α]D20 = +75.0 (c = 0.2, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 
3.13 (s, br, 1 H, OH), 3.23–3.26 (m, 2 H), 3.42–3.49 (m, 2 H), 3.63–3.78 (m, 9 H), 3.95 
(dd, J = 4.0 Hz, J = 9.6 Hz, 1 H), 4.01–4.08 (m, 3 H), 4.11 (dd, J = 3.2 Hz, J = 9.2 Hz, 1 
H), 4.16 (dd, J = 7.6 Hz, J = 9.6 Hz, 1 H), 4.23–4.28 (m, 3 H), 4.36 (d, J = 11.6 Hz, 1 H), 
4.43–4.49 (m, 3 H), 4.54–4.61 (m, 2 H), 4.62–4.65 (m, 2 H, H–1B, PhCH2), 4.70 (d, J = 
11.6 Hz), 4.75–4.79 (m, 2 H), 4.81–4.86 (m, 2 H), 4.98 (d, J = 10.4 Hz, 1 H), 5.22 (d, J = 
3.2 Hz, 1 H, H–1C), 5.55 (s, 1 H, PhCH), 5.79 (d, J = 4.0 Hz, 1 H, H–1E), 6.75–6.77 (m, 2 
H), 6.85–6.87 (m, 2 H), 7.01–7.05 (m, 2 H), 7.13–7.17 (m, 10 H) 7.23–7.34 (m, 26 H), 
7.48–7.56 (m, 2 H); 13C NMR (CDCl3, 100 MHz): δ 55.57 (PhOCH3), 66.21, 68.60, 68.79, 
70.02, 70.51, 71.38, 73.15, 73.23, 73.95, 74.00, 74.77, 75.34, 75.73, 76.24, 77.71, 78.15, 
79.79, 81.22, 81.58, 92.57 (C–1C), 94.41 (C–1E), 100.61 (PhCH), 101.37 (C–1B), 114.51, 
116.92, 126.32, 127.09,  127.30, 127.38, 127.49, 127.61, 127.67, 127.92, 128.08, 128.13, 
128.15, 128.24, 128.30, 128.61, 129.04, 137.49, 137.87, 138.25, 138.35, 138.37, 138.55, 
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138.75, 139.15, 150.62, 154.94;  ESI HRMS: m/z calcd for C81H84O17Na [M +Na]+ 
1351.5606, found 1351.5599. 
 
4–Methoxyphenyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–
3,4,6–tri–O–benzyl–α–D–glucopyranosyl–(1→2)–[6–O–acetyl–2–azido–3,4–di–O–
benzyl–2–deoxy–α–D–glucopyranosyl–(1→3)]–4,6–O–benzylidene–β–D–
galactopyranoside (1-12) 
A mixture of donor 1-11 (103 mg, 0.18 mmol) and acceptor 1-10 (160 mg, 0.12 
mmol) and 4 Å molecular sieves (200 mg) in 8 mL anhydrous Et2O/CH2Cl2 (1:1) was 
stirred at room temperature under Ar for 30 min. Then this mixture was cooled –20 oC, 
TMSOTf (3.3 µL, 0.018 mmol) was added. The reaction was slowly warmed room 
temperature in 2 h, TLC analysis showed complete conversion of starting material to a 
major product (hexane/ethyl acetate 2:1, Rf = 0.18). The reaction was quenched by the 
addition of 0.1 mL triethylamine and filtered. The filtrate was concentrated in vacuum and 
purified by silica gel chromatography (hexane/ethyl acetate 2:1) to afford as a syrup 
tetrasaccharide 1-12  (158 mg, 76%). [α]D20 = +86.0 (c = 0.2, CHCl3); 1H NMR (CDCl3, 
400 MHz): δ 1.95 (s, 3 H, CH3CO), 3.12–3.35 (m, 2 H), 3.49 (dd, J = 3.2 Hz, J = 10.4 Hz, 
1 H), 3.57 (dd, J = 2.4 Hz, J = 9.2 Hz, 1 H), 3.63–3.69 (m, 2 H), 3.74–3.76 (m, 4 H), 3.81–
3.87 (m, 2 H), 3.88–3.93 (m, 2 H), 3.98–3.99 (m, 2 H), 4.02–4.08 (m, 3 H), 4.12 (dd, J = 
4.4 Hz, J = 10.4 Hz, 1 H), 4.25–4.28 (m, 2 H), 4.31–4.35 (m, 2 H), 4.38–4.44 (m, 2 H), 
4.45–4.50 (m, 3 H), 4.53–4.57 (m, 5 H), 4.59–4.64(m, 4 H, H–1B, PhCH2), 4.75–4.81 (m, 
6 H), 4.84–4.89 (m, 2 H), 5.02 (d, J = 3.2 Hz, 1 H, H–1D),  5.25 (d, J = 3.6 Hz, 1 H, H–1C), 
5.56 (s, 1 H, PhCH), 6.06 (s, 1 H, H–1E), 6.76–6.78 (m, 2 H), 6.83–6.85 (m, 2 H), 6.97–
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7.00 (m, 6 H), 7.08–7.13 (m, 10 H), 7.15–7.25 (m, 15 H), 7.27–7.33 (m, 17 H), 7.54–7.56 
(m, 2 H); 13C NMR (CDCl3, 100 MHz): δ 20.79 (CH3CO), 55.56 (PhOCH3), 62.19, 63.20, 
65.85, 68.31, 68.47, 68.96, 69.66, 70.07, 70.27, 70.43, 71.68, 73.27, 73.49, 74.43, 74.80, 
75.05, 75.11, 75.35, 75.94, 77.22, 77.74, 78.10, 79.33, 80.17, 81.19, 81.83, 93.01 (C–
1E), 93.15 (C–1C), 93.26 (C–1D), 100.58 (PhCH), 101.71 (C–1B), 114.55, 117.16, 126.01, 
127.09, 127.18, 127.27, 127.31, 127.37, 127.43, 127.47, 127.62, 127.73, 127.82, 127.90, 
127.96, 128.09, 128.17, 128.24, 128.36, 128.49, 128.75, 137.43, 137.49, 137.84, 138.16, 
138.24, 138.44, 138.75, 138.77, 139.05, 150.46, 155.08, 170.20 (CH3CO); ESI HRMS: 
m/z calcd for C103H107N3O22Na [M +Na]+ 1760.7244, found 1760.7251. 
4–Methoxyphenyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–
3,4,6–tri–O–benzyl–α–D–glucopyranosyl–(1→2)–[6–O–acetyl–2–acetamido–3,4–
di–O–benzyl–2–deoxy–α–D–glucopyranosyl–(1→3)]–4,6–O–benzylidene–β–D–
galactopyranoside (1-13) 
To a stirred solution of tetrasaccharide 1-12 (140 mg, 0.08 mmol) in 5 mL 
DCM/MeOH (1:1.5) was cooled at 0 oC, NiCl2.6H2O (114 mg, 0.48 mmol) and NaBH4 (30 
mg, 0.8 mmol) was added. The color of the solution changed from green to black. The 
reaction mixture was maintained at 10 oC for 2 h, TLC analysis showed the starting 
material disappeared, followed by adding Ac2O (0.1 mL) at 10 oC. The reaction mixture 
was stirred at 10 oC for 1 h, TLC analysis showed a major product (hexane/ethyl acetate 
1:2, Rf = 0.42), then the reaction was quenched with 0.1 mL triethylamine. The mixture 
was concentrated in vacuo to give a residue, which was purified by silica gel 
chromatography (hexane/ethyl acetate 2:3) to afford a syrup 1-13 (132 mg, 94%). [α]D20 
= +83.8 (c = 0.16, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 1.33 (s, 3 H, NHCOCH3), 2.01 
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(s, 3 H, CH3CO), 3.23 (dd, J = 3.6 Hz, J = 9.6 Hz, 1 H), 3.29 (dd, J = 3.6 Hz, J = 10.8 Hz, 
1 H), 3.56–3.66 (m, 3 H), 3.73 (s, 3 H, PhOCH3), 3.76–3.82 (m, 2 H), 3.89–4.03 (m, 7 H), 
4.09–4.15 (m, 2 H), 4.22 (d, J = 12.4 Hz, 1 H), 4.32–4.33 (m, 1 H), 4.38–4.48 (m, 6 H), 
4.51–4.58 (m, 6 H), 4.60–4.66 (m, 5 H, H–1B, PhCH2), 4.71–4.88 (m, 8 H), 5.07 (d, J = 
3.6 Hz, 1 H, H–1D), 5.09 (d, J = 4.0 Hz, 1 H, H–1C), 5.42 (s, 1 H, PhCH), 5.99 (d, J = 2.8 
Hz, 1 H, H–1E),  6.54 (d, J = 10.0 Hz, 1 H, AcNH), 6.75–6.83 (m, 4 H), 6.95–7.07 (m, 9 
H), 7.09–7.21 (m, 20 H), 7.25–7.30 (m, 17 H), 7.37–7.43 (m, 4 H); 13C NMR (CDCl3, 100 
MHz): δ 20.76 (NHCOCH3), 22.20 (CH3CO), 52.12, 55.42, 62.32, 65.71, 68.21, 68.41, 
68.86, 69.79, 69.92, 71.67, 72.22, 72.36, 72.90, 73.02, 73.58, 74.75, 74.84, 74.87, 75.21, 
76.07, 76.88, 77.00, 77.55, 77.81, 79.54, 81.29, 81.44, 81.50, 92.31 (C–1C), 92.65 (C–
1D), 93.01 (C–1E), 101.19 (C–1B), 101.25 (PhCH), 114.44, 116.72, 126.26, 126.75, 
127.19, 127.28, 127.37, 127.44, 127.52, 127.64, 127.89, 127.93, 128.00, 128.06, 128.11, 
128.16, 128.24, 128.29, 129.02, 137.39, 137.61, 137.68, 137.76, 138.02, 138.11, 138.31, 
138.34, 138.47, 139.01, 150.20, 154.96, 170.36 (NHCOCH3),170.46 (CH3CO); ESI 
HRMS: m/z calcd for C105H111NO23Na [M +Na]+ 1776.7445, found 1776.7452. 
 
2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–3,4,6–tri–O–benzyl–
α–D–glucopyranosyl–(1→2)–[6–O–acetyl–2–acetamido–3,4–di–O–benzyl–2–
deoxy–α–D–glucopyranosyl–(1→3)]–4,6–O–benzylidene–β–D–galactopyranosyl 
trichloroacetimidate (1-14) 
To a solution of 1-13 (123 mg, 0.07 mmol)  in 1:1.5:1 toluene–MeCN–water (7 ml) 
was added  ceric ammonium nitrate (192 mg, 0.35 mmol) at 0 oC. The mixture was stirred 
vigorous and was warmed room temperature in 30 min. TLC analysis showed complete 
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conversion of starting material to a major product (hexane/ethyl acetate 1:2, Rf = 0.40), 
then the mixture was diluted with ethyl acetate, washed with water, saturated NaHCO3 
(aq), and brine, dried (Na2SO4) and filtered. The filtrate was concentrated in vacuum and 
purified by silica gel chromatography (hexane/ethyl acetate 2:3) to afford the 
corresponding hemiacetal (83 mg). ESI HRMS: m/z calcd for C98H105NO22Na [M +Na]+ 
1670.7026, found 1670.7032. 
To a solution of the above isolated hemiacetal (83 mg, 0.05 mmol) in dry DCM was 
added 0.5 mL CCl3CN and 0.05 mL DBU. The mixture solution was stirred at room 
temperature for 3 h under the Ar atmosphere. TLC analysis showed complete conversion 
of starting material to a major product (hexane/ethyl acetate 1:2, Rf = 0.74). The mixture 
was concentrated in vacuum to give a residue, which was purified by silica gel 
chromatography (hexane/ethyl acetate 1:1) to afford a yellow syrup 1-14 (66 mg, 53% 
from 1-13) for next coupling step quickly. 
3–Azidopropyl 2,3,4,6–tetra–O–benzyl–α–D–glucopyranosyl–(1→2)–O–
3,4,6–tri–O–benzyl–α–D–glucopyranosyl–(1→2)–[6–O–acetyl–2–acetamido–3,4–
di–O–benzyl–2–deoxy–α–D–glucopyranosyl–(1→3)]–O–4,6–benzylidene–β–D–
galactopyranosyl–(1→3)–2,4,6–tri–O–benzyl–α–D–glucopyranoside (1-16) 
A mixture of donor 1-14 (65 mg, 0.036 mmol) and acceptor 1-15 (28.8 mg, 0.054 
mmol) and 4 Å molecular sieves (100 mg) in dry 6 mL Et2O/CH2Cl2 (1:1) was stirred at 
room temperature under Ar for 30 min. Then this mixture was cooled –25 oC, TMSOTf (1 
µL, 0.0054 mmol) was added. The reaction was slowly warmed room temperature in 2 h, 
TLC analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 1:1, Rf = 0.37). The reaction was quenched by the addition of 0.1 
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mL triethylamine and filtered. The filtrate was concentrated in vacuum and purified by 
silica gel chromatography (hexane/ethyl acetate 3:2) to afford a syrup 1-16 (33 mg, 42%). 
[α]D20 = +87.4 (c = 0.8, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 1.33 (s, 3 H, NHCOCH3), 
1.72 (s, 3 H, CH3CO), 1.92 (m, 2 H, OCH2CH2CH2N3), 3.32 (m, 2 H), 3.43 (m, 3 H), 3.62–
3.71 (m, 8 H), 3.76–3.80 (m, 6 H), 3.91–4.08 (m, 7 H), 4.10–4.14 (m, 2 H), 4.23 (m, 3 H), 
4.33–4.38 (m, 5 H), 4.43–4.90 (m, 3 H), 4.54–4.60 (m, 5 H), 4.66–4.76 (m, 6 H), 4.83–
4.87 (m, 5 H), 4.89–4.98 (m, 4 H), 5.16 (d, J = 3.6 Hz, 1 H, H–1D), 5.22 (s, 1 H, PhCH), 
5.31 (d, J = 3.2 Hz, 1 H, H–1B), 5.51-5.58 (m, 2 H, H–1C and AcNH), 5.91 (s, 1 H, H–1E), 
6.97–7.00 (m, 2 H), 7.11–7.22 (m, 24 H), 7.29–7.42 (m, 37 H), 7.57 (m, 2 H); 13C NMR 
(CDCl3, 100 MHz): δ 20.69 (NHCOCH3), 22.58 (CH3CO), 28.79 (OCH2CH2CH2N3), 48.20 
(OCH2CH2CH2N3), 52.30, 61.43, 62.02, 64.57, 68.48, 68.88, 69.27, 69.57, 70.00, 70.12, 
70.47, 71.73, 72.62, 73.00, 73.44, 74.93, 75.00, 75.20, 75.47, 76.15, 77.26, 77.73, 78.89, 
79.09, 80.60, 81.37, 81.82, 93.58 (C–1C), 93.71 (C–1B), 93.78 (C–1D), 95.87 (C–1E), 
95.88 (C–1A), 100.98 (PhCH), 126.23, 127.19, 127.31, 127.35, 127.44, 127.48, 127.53, 
127.64, 127.75, 127.86, 128.08, 128.12, 128.17, 128.23, 128.26, 128.31, 128.37, 128.44, 
128.57, 128.73, 129.07, 137.72, 137.77, 137.88, 138.13, 138.23, 138.29, 138.40, 138.84, 
139.22, 170.04 (NHCOCH3), 170.08 (CH3CO); ESI HRMS: m/z calcd for C128H139N4O27 
[M +H]+ 2163.9627, found 2163.9648. 
3–aminopropyl α–D–glucopyranosyl–(1→2)–α–D–glucopyranosyl–(1→2)–
[2–acetamido–2–deoxy–α–D–glucopyranosyl–(1→3)]–α–D–galactopyranosyl–
(1→3)–α–D–glucopyranoside (1-1) 
A solution of 16 (22 mg, 0.01 mmol) in dry methanol (2 mL) was added catalytic 
amount of sodium methoxide (pH 9–10). The solution was stirred at room temperature for 
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2 h. TLC analysis showed complete conversion of starting material to a major product 
(hexane/ethyl acetate 1:2 Rf = 0.33). Then the acid resin (Dowex® 50WX2 H+–form) was 
added and stirred to adjust pH 7, followed by filtration. The filtrate was concentrated in 
vacuum to afford a syrup (16 mg). ESI HRMS: m/z calcd for C126H137N4O26 [M +H]+ 
2121.9521, found 2121.9507.  
To a stirred solution of the above syrup (16 mg, 0.0075 mmol) in 2 mL methanol 
was added Pd(OH)2/C (20 mg) at 50 psi H2 atmosphere for 3 days. The catalyst was 
filtered off, the filtrate was concentrated to afford a white solid 1-1 (6.7 mg, 72% from 1-
16). [α]D20 = +178.0 (c = 0.2, H2O); 1H NMR (CD3OD, 400 MHz): δ 1.97–2.00 (m, 2 H, 
OCH2CH2CH2N3), 2.02 (s, 3 H, NHCOCH3), 3.15–3.20 (m, 2 H), 3.35–3.44 (m, 6 H), 3.58–
3.61 (m, 3 H), 3.68–3.77 (m, 10 H), 3.85–3.87 (m, 2 H), 3.91–3.99 (m, 6 H), 4.09 (m, 2 
H), 4.25–4.30 (m, 3 H), 5.04–5.05 (m, 2 H, H–1A and H–1D ), 5.17 (d, J = 3.6 Hz, 1 H, H–
1B), 5.47 (d, J = 3.2 Hz, 1 H, H–1C), 5.79 (s, H–1E), 13C NMR (CD3OD, 100 MHz): δ 20.43 
(CH3CO), 28.34 (OCH2CH2CH2N3), 37.91 (OCH2CH2CH2N3), 52.91, 59.42, 60.10, 60.56, 
60.73, 64.29, 66.30, 66.83, 68.93, 69.01, 69.18, 69.60, 70.23, 70.40, 70.55, 71.03, 71.21, 
71.28, 71.49, 71.66, 72.18, 72.57, 75.15, 76.84, 90.77 (C–1C), 91.96 (C–1B), 93.67 (C–
1D), 95.98 (C–1E), 98.76 (C–1A), 167.49 (CH3CO); ESI HRMS: m/z calcd for 
C35H62N2O26Na [M +Na]+ 949.3489, found 949.3484. 
Preparation of NHS activated pentasaccharide 
A solution of the propyl amino–linked pentasaccharide 1-1 (2.0 mg, 0.002 mmol) 
in DMF (0.5 mL) containing triethylamine (50 µL), was added dropwise to a stirred solution 
of di–N–hydroxysuccinimidyl suberate (7.4 mg, 0.02 mmol) in DMF (0.5 mL). The reaction 
was kept under gentle stirring at room temperature for 3 h. TLC analysis showed complete 
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conversion of starting material to a major product (ethyl acetate/methanol/water/acetic 
acid 5:1.5:0.75:0.15, Rf = 0.50). The reaction was then concentrated, the residue was 
added 0.5 mL water, extracted with EtOAc (1 mL x 4). The aqueous layer was lyophilized 
to give NHS activated pentasaccharide as a white power (2.0 mg). ESI HRMS: m/z calcd 
for C47H77N3O31Na [M +Na]+ 1202.4439, found 1202.4453. 
 
Conjugate NHS activated pentasaccharide to CRM197 and BSA 
The NHS activated pentasaccharide was conjugated to CMR197 (or BSA) at a 
molar ratio 50:1 in 3 x PBS buffer (pH 7.4). The solution was incubated overnight at room 
temperature. Then the resultant solution was ultrafiltrated and washed with 1 x PBS buffer 
using Amicon Centrifugal Filter Devices (Ultracel 10, 000). The glycoproteins solution was 
lyophilized to give a white solid. Glycoproteins were analyzed by Bruker ultrafleXtreme 
MALDI TOF/TOF mass spectrometer.  
 
SDS–PAGE  
The glycoproteins (5 µg) and CRM197 (or BSA)  (5 µg) were suspended in 10 µL of 
sample buffer (5% (w/v) SDS, 10% (v/v) glycerol, 25 mM Tris–HCl, pH 6.8, 10 mM DTT, 
0.01% (w/v) bromophenol blue), loaded into different lanes of a 1.5–mm–thick, 12% (w/v) 
SDS–PAGE gel, and visualized by Coomassie Brilliant Blue R–250 staining. 
 
Immunization of mice 
The mice were purchased from Vital River Laboratories. Groups of 5 female 
BALB/c mice (6–8 week old) were subcutaneously (several different sites with a total of 
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150 µL) immunized on days 0, 14, and 28 with 2.5 μg carbohydrate antigen based doses 
of pentasaccharide–CRM197 conjugate formulated with Freund’s adjuvant (mixing equal 
volume of conjugate and Freund’s adjuvant, v/v,1:1). PBS, Freund’s adjuvant and 
CRM197/Freund’s adjuvant (v/v,1:1） were used as controlled groups. For immunizations 
with Freund’s adjuvant, the first immunization was performed with Freund’s complete 
adjuvant (FCA) (Sigma–Aldrich, F5881), and the second and third immunizations with 
Freund’s incomplete adjuvant (FIA) (Sigma–Aldrich, F5506). Seven days after the third 
immunization, the blood was taken via lateral saphenous, and then centrifuged for 20 min 
at 4,000 RPM to collect the sera (without anticoagulants). These collected sera were 
ready to the following ELISA assay and bactericidal activity assay. 
 
ELISA assay  
The ELISA 96–well plates (Corning®, #3590) were coated with 1 μg/mL 
pentasaccharide–BSA in 1 x PBS buffer (pH 7.4) overnight at 4 °C. The coated plates 
were washed three times with PBS buffer containing 0.05% (v/v) Tween 20 (PBST) (pH 
7.4), and then blocked for 2 hours at room temperature with 2% BSA (w/v) in PBST. The 
coated plates were incubated with 100 μL of sera diluted with dilution buffer (1% BSA, 
PBST) 2–fold from 1:200 to 204,800 for 2 hours at room temperature after being washed 
three times with PBST. Then quintuple PBST washing  was performed, and 100 μL/well 
of 1:3000-1:20000 HRP–conjugated goat anti-mouse IgG (Invitrogen, USA), IgG1, IgG2a, 
IgG2b, IgG3 and IgM (Abcam) were added respectively, and  incubated 1 hour at room 
temperature. After the plates were washed with PBST, 100 μL/well of enzyme substrate 
tetramethylbenzidine (TMB) solution was added and incubated for 15 min (a blue color 
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developed for the sera with antibodies) before the enzymatic reaction was terminated by 
adding 1 M HCl, and the OD of each sample was measured at 450 nm with a microplate 
spectrophotometer (Biorad). Antibody titers were expressed by evaluating the logarithm 
of the reciprocal of sera dilution based two. The statistical and graphical analysis was 
performed using GraphPad Prism 5 software.  
 
Bactericidal activity  
Complement-dependent bactericidal activity was measured in serum of day 35 
(one week after the third immunization). E. coli O157:H7 containing R3 outer core was 
used as the test strain. 104 bacteria per mL suspended in 1% peptone supplemented with 
5% 3–week–old rabbit sera as the complement source were added to 96–well plates 
(Costar®, # 3590), and mixed with serum diluted with 2–folds PBS (pH 7.4) from 1:20 to 
1:12,800. The mixture was incubated at 37°C for 1 h. 10 μL/well of the CCK8 was added, 
and plates were incubated for 6 h. The absorbance of plates at 450 nm was read by a 
microplate spectrophotometer (Biorad). Percent bactericidal activity was calculated as the 
proportion of the dead bacteria exposed to immunized–serum compared with the number 
of bacteria in control culture condition.  
 
Statistical analysis 
All the statistical analyses and figures were generated by GRAPHPAD PRISM 
software version 5.0. Data were shown as means ± standard deviation (SD). The 
difference between two groups was compared by t test. For multiple comparisons, one–
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way ANOVA was used. A probability (P) value ≤ 0.05 was considered statistically 
significant. 
This chapter is reproduced from Ref. Shang, W., Xiao, Z., Yu, Z., Wei, N., Zhao, 
G., Zhang, Q., Wei, M., Wang, X., Wang, P., Li, T., (2015), Org. Biomol. Chem. with 
permission from the Royal Society of Chemistry. (Link: 
http://pubs.rsc.org/en/Content/ArticleLanding/2015/OB/C5OB00177C#!divAbstract) 
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2. Chemoenzymatic Synthesis of a library of Human Milk Oligosaccharides 
2.1 Introduction 
2.1.1 History of HMOs 
At the end of the 19th century, the overall infant first-year mortality rates were as high 
as 30%. Surprisingly, it was observed that breast-fed infants had a much lower chance of 
death and had lower incidences of infectious diarrhea and many other diseases than 
“bottle-fed” infants. At that time, Escherich, an Austrian pediatrician and microbiologist, 
had discovered a relationship between intestinal bacteria and human milk, which 
components remained unknown until more than half a century later. In 1926, Schönfeld 
had reported that the whey fraction of human milk contains a growth-promoting factor for 
Lactobacillus bifidus (later reclassified as Bifidobacterium bifidus).1  In 1954, Kuhn and 
György confirmed that the chemical nature of “bifidus factor” is oligosaccharides.2, 3 
During the following fifty years, more than 100 HMOs were isolated and characterized by 
scientists.  
2.1.2 Structures of HMOs 
Human milk oligosaccharides (HMOs) are the third major component in human milk, 
only after lactose and lipid.4-6 Concentrations and components of HMOs vary depending 
on the stages of lactation.1, 7 Particularly, one liter mature human milk contains about 12-
14 grams HMOs.8-14 The structures of about 130 discovered HMOs have been 
elucidated.15-17 The major building blocks of HMOs are 5 monosaccharides, including D-
glucose (Glc), D-galactose (Gal), N-acetylglucosamine (GlcNAc), L-Fucose (Fuc), and N-
acetyl neuraminic acid (Neu5Ac). All HMOs contain lactose (Galβ1-4Glc) at their reducing 
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end, which can be extended by the addition of β1-3 or β1-6-linked lacto-N-biose (Galβ1-
3GlcNAc) or N-acetyllactosamine (Galβ1-4GlcNAc). A β1-3 linkage generates linear 
HMOs. A β1-6 linkage between two disaccharide units introduces chain branching. 
Lactose or the elongated oligosaccharide chain can be sialylated in α 2-3 or α 2-6 linkage 
and/or fucosylated in α1-2, α1-3 or α1-4 linkage. (Figure 2.1) 
 
Figure 2.1. Representative fucosylated or sialylated HMOs 
 
Even though HMOs were first discovered and confirmed in 1950s, a comprehensive 
understanding of their functions is still out of reach, due to their inherit diversity and 
complexity.  Increasing evidences show that HMOs can provide significant beneficial 
effects to the health of breast-fed infants through several mechanisms. For instance, 
HMOs could serve as prebiotics to promote the growth of desired bacteria in infant’s 
intestine.1, 6, 18-21 Besides, HMOs are antiadhesive antimicrobials by serving as a receptor 
to prevent pathogen attachment to infant mucosal surfaces.22-26 In addition, evidence has 
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demonstrated that HMOs can modulate epithelial and immune cell responses, and reduce 
excessive mucosal leukocyte infiltration and activation, which in turn decreases the risk 
of necrotizing enterocolitis (NEC), one of the most common fatal disorders in preterm 
infants.27, 28 Furthermore, sialylated HMOs may also provide necessary nutrients for the 
development of brain and cognition of infants.29-32 
 
2.1.3 Previous Synthesis of HMOs 
Even though the general functions of HMOs has been explored and discovered, the 
functional roles of individual HMOs are far less clear because of very limited accesses 
towards sufficient amount of structurally defined HMOs. To date, only a handful of short-
chain HMOs can be produced in large scale and the supply of more complicated and 
branched HMOs is highly demanded.  
Until now, only a few approaches has been developed for the synthesis of a small 
number of well-defined HMOs.1, 33-42 For example, Schmidt developed a convergent 
strategy to synthesize highly branched structure of human milk octasaccharide 1 by 
solution-phase. 36 In this study, target compound was assembled by six building blocks 
with consistent using trichloroacetimidate as glycosylation donors. The coupling efficiency 
is achieved due to the convergency as well as to several regioselective and 
stereoselective glycosylation steps. Based on their previous work, Schmidt developed 
more versatile methodologies to produce complex HMOs based on solid-phase 
synthesizer.39 First, they designed a cleavable linker attached to resin. Then sugar moiety 
and linker was coupled by trichloroacetimidate/TMSOTf condition, followed by sequential 
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adding of other building blocks to furnish the targeted hexasaccharide. Enzymatic 
methods have also been employed to achieve relatively simple structures.35  
One of the biggest roadblocks in previous synthesis remains to be small quantity 
and limited variety of HMOs needed for biofunctional studies. Recently, we have 
developed an efficient Core Synthesis/Enzymatic Extension (CSEE) strategy for rapid 
preparation of N-glycan libraries.43 In this study, similar strategy was successfully applied 
for HMOs synthesis. Briefly, 3 core oligosaccharides with one or two GlcNAc residue(s) 
at the non-reducing end were first synthesized by convergent assembly of 3 simple 
building blocks followed by extension of the cores by 4 robust glycosyltransferases to 
produce a library of 31 HMOs (Figure 2.2).  
 
Figure 2.2. HMOs synthesized by the Core Synthesis/Enzymatic Extension (CSEE) 
strategy starting with 3 chemically prepared core structures (boxed). 
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2.2 Convergent Core Synthesis 
Previous studies highlighted the complexity and challenges associated with 
synthesizing HMOs via block coupling strategy. Schmidt developed sequential synthesis 
of lactose-containing oligosaccharides, including HMO lacto-N-tetraoside based on Solid-
Phase Synthesis concept.38 Madsen used one-pot glycosylations to achieve several 
human milk oligosaccharides.37 Both of the methods can synthesize linear and simple 
oligosaccharides with obvious limitations in achieving more complex HMOs, especially 
highly branched ones.  In this study, we developed an efficient and versatile methodology 
that utilized oligosaccharyl thioethers and oligosaccharyl bromides as convergent donors 
for glycosylation, enabling branching assembly in one or two steps of glycosylations with 
excellent stereoselectivity and yields.  
We envisaged that protected lactose 1 (Figure 2.3) would be a versatile precursor 
for the synthesis of core structures, including symmetric and asymmetric ones, as C4, 
C6-hydroxyl groups (OH) on Gal are protected by benzylidene and the C3-OH is 
unprotected for chemical glycosylation. In order to achieve the selective protection of 
building block 1, C3-OH group was selectively protected by 4-Methoxybenzyl ether (PMB) 
using standard condition, followed by C4, C6-OH protection with benzylidene group. In 
order to furnish the target cores, two oligosaccharyl thioethers and oligosaccharyl 
bromide were prepared (Figure 2.3).  
 
Figure 2.3. The three versatile building blocks for the assembly of the three core 
structures. 
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2.3 Synthesis of Building Blocks 
The synthesis of precursor 2-1 began with lactose peracetate, which was converted 
to the β-lactoside 2-4 by reaction with benzyl alcohol in the presence of BF3∙Et2O, followed 
by deacetylation with NaOMe/MeOH condition to furnish compound 2-5.  Then 2-5 was 
treated with dibutyltin oxide, followed by the reaction with 4-Methoxybenzyl chloride to 
provide selective 3’-O-PMB protected lactoside with fair yield, which has been extensively 
studied.41, 44  The following Benzylidene protection on 4’, 6’-OH was conducted with 
Benzaldehyde dimethyl acetal, catalyzed by Camphorsulfonic acid (CSA), to get 
compound 2-6. The perbenzylation of the remaining hydroxyls of 2-6 was performed by 
using sodium hydride and benzyl bromide in anhydrous DMF to give compound 2-7. After 
removing PMB protecting group of 2-7 treated with 2, 3-Dichloro-5, 6-dicyano-1, 4-
benzoquinone (DDQ), building block 2-1 was achieved (Scheme 2.1). 
 
Scheme 2.1. Synthesis of Building Block 2-1.  
 
  Lactosamine building block 2-3 was initially envisioned to be synthesized using a 
straightforward fashion by coupling monosaccharide 2-9 and 2-10 (Scheme 2.2A). 
Unfortunately, only minor desired product was isolated by silica gel chromatography, and 
substantial amount of byproduct 2-11 was generated through a thioether migration 
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reaction.45 Therefore, a Koenigs–Knorr reaction coupling approach was carried out by 
installing C4 hydroxy group of glucosamine with high yield (Scheme 2.2B). Building block 
2-2 would be conveniently used in the synthesis of two asymmetric core oligosaccharides. 
  
Scheme 2.2 Synthesis of Building Block 3. 
    
    
                                                      
2.4 Synthesis of Core Oligosaccharides 
With all building blocks in hand, we began to assemble the three core 
oligosaccharides using our convergent strategy. The synthesis of HMO1 was depicted in 
Scheme 3. Disaccharide 2-13 was obtained in a good yield (85%) by selective opening 
of the benzylidene ring at C6 of building block 2-1 using Et3SiH/PhBCl2. Oligosaccharyl 
bromide 2-2 was freshly prepared using HBr/AcOH condition. Silver triflate (AgOTf) 
promoted glycosylation of 2-13 with donor 2-2 in dichloromethane resulted in the 
formation of tetrasaccharide 2-14 in an excellent yield of 85%. Deprotection of 2-14 with 
ethylene diamine, followed by treatment with acetic anhydride, furnished peracetylated 
tetrasaccharide 2-15 in 75% yield. O-Deacetylation of compound 2-15 was performed 
42 
under Zemplén conditions, followed by the global deprotection of Benzyl group (Bn) by 
catalytic hydrogenolysis with Pd(OH)2/H2 in MeOH/H2O (10 : 1). The core structure HMO1 
was produced in a total yield of 80% over the two steps.  
 
Scheme 2.3 Synthesis of HMO1. 
 
Glycosylation of 3’-O-unprotected acceptor 2-1 with donor 2-3 proceeded at -20°C 
under AgOTf/NIS conditions to furnish the desired tetrasaccharide 2-16 in 85% yield. 
Then selective opening of the benzylidene ring at C6 of 2-16 using Et3SiH/PhBCl2 
condition provided 6’-O-unprotected acceptor 2-17 in 80% yield. The fully protected 
pentasaccharide was initially attempted to be synthesized by a convergent glycosylation 
of acceptor 2-17 and thiol donor 2-18. Unfortunately, the desired product was not detected 
by TLC and ESI mass spectrometry analysis (Scheme 2.4A). Several other donors 
including oligosaccharyl trichloroacetimidate and thioethers donors were tried to install 
the pentasaccharide, but no product was detected. The big challenge should be caused 
by the bulky benzyl group on 4’-OH position, which has very large steric hindrance and 
stops the glycosylation on 6’-OH position, even though primary alcohol is very 
nucleophilic. Therefore, 4’, 6’-O-unprotected lacto-N-tetraose 2-19 was proposed as 
acceptor for the glycosylation. Removal of the 4’, 6’-O-benzylidene of 2-16 by treatment 
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with ethanethiol in the presence of TsOH afforded acceptor 2-19. Glycosylation of 
acceptor 2-19 with glycosyl bromide 2-2 to achieve the protected target pentasaccharide 
20 proceeded smoothly and regioselectively by use of AgOTf as Lewis acid at -20 °C in 
an excellent yield (85%). The two phthalimides of 2-20 were then converted into 
acetamides 2-21, followed by the global deprotection of Ac and Bn groups. The core 
oligosaccharide HMO2 was produced in a total yield of 53% over the four steps (Scheme 
2.4B). 
 
Scheme 2.4. Synthesis of HMO2. 
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AgOTf promoted Glycosylation of 3’-O-unprotected acceptor 2-1 with donor 2-2 
proceeded at -20°C to furnish the trisaccharide 2-22 in a good yield of 85%. Then 
deprotection of the 4’, 6’-O-benzylidene of 2-22 by treatment of EtSH/TsOH provided the 
dialcohol 2-23. Glycosylation of acceptor 2-23 with thiol donor 2-3 by treatment of 
AgOTf/NIS condition at -20°C to achieve the protected target pentasaccharide 2-24 in 
70% yield.  The two phthalimides of 2-24 were then converted into acetamides 2-25.  
Complete deprotection of 2-25 was achieved by hydrogenolytic debenzylation 
(Pd(OH)2/C, H2) and complete de-O-acetylation using sodium methoxide in methanol, 
resulting in core oligosaccharide HMO3 in a total yield of 67% over the four steps 
(Scheme 2.5). 
 
Scheme 2.5 Synthesis of HMO3. 
 
2.5 Enzymatic Extension of Core Strucures 
    A total of 31 HMOs were enzymatically synthesized starting from the 3 core 
structures (HMO1, HMO2, HMO3) via an enzymatic extension approach using 4 robust 
GTs: 1,4 galactosyl-transferase from Neisseria meningitidis (LgtB),46 2,6-
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sialyltransferase from Photobacterium damselae (Pd2,6ST),47 C-terminal 66 amino acids 
truncated 1,3-fucosyltransferase from Helicobacter pylori (Hp1,3FT),48 and 1,2-
fucosyltransferase from Helicobacter mustelae (Hm1,2FT).49  All GTs were from 
bacteria and had high expression levels in Escherichia coli, high activity, and relatively 
relaxed substrate tolerance. As shown in Figure 2.4A, glycans HMO11-HMO16 were 
prepared starting with the chemically prepared core HMO1. Briefly, in a 2 mL reaction 
system, 30 mg of HMO1 (20 mM) was incubated with Gal (20 mM), MgCl2 (20 mM), ATP 
(20mM), UTP (20mM) and variant amount of BiGalK, BiUSP and LgtB.50 (Figure 2.4D) 
After overnight reaction, the mixture was terminated by boiling for 10min and analyzed by 
MAlDI-MS which shows a single peak at m/z 1095.748, corresponding to HMO11 [M+Na] 
+. Meanwhile, on the HPLC-ELSD (Evaporative Light Scattering Detector) profile, a new 
peak (TR= 11.946 min) was observed. The reaction mixture was purified by HPLC using a 
water/acetonitrile gradient elution, yielding 40mg of HMO11 (93% yield). The purified 
HMO11 (99% pure) was then utilized for the syntheses of HMO12-HMO16 (Figure 2.4A) 
catalyzed by Pd2,6ST, and 1,2FT, 1,2FT respectively (see ESI for details). 
Interestingly 1,3FT can specifically distinguish the GlcNAc from terminal GalGlcNAc 
and 1,2FT preferentially attach to terminal Gal. We basically use this feature to 
biosynthesize Lewis X (Lex) and Lewis Y (Ley). In addition, difucosylated LacNAc motif 
[Fuc1, 2-Gal-1, 4-(Fuc1, 3-)GlcNAc] was also generated while using Hm1,2FT.  The 
synthesis of asymmetric bi-antennary HMO2x and HMO3x (Figure 2.4B&C) were carried 
out by enzymatic extension of core HMO2 and HMO3. Asymmetric Core HMO2 and 
HMO3 can more efficiently take advantage of different substrate specificities of GTs over 
symmetric HMO1 via coupling a Gal to the terminal GlcNAc of one antennary. For 
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example, to obtain HMO311, the Gal from GlcNAc branch was sequentially extended 
by Hm1,2FT, Hp1,3FT and LgtB . (Figure 2.4C) In contrast, HMO310 were 
sequentially synthesized by Hm1,2FT, LgtB and Hp1,3FT (Figure 2.4C). Such 
synthetic routes were designed according to the substrate specificities of GTs to avoid 
undesirable glycosylation. 
 
Figure 2.4. Enzymatic extension of human milk oligosaccharides. 
Conditions: (a) LgtB, BiGalK, AtUSP, Gal, ATP, UTP, Mg2+; (b) Pd2,6ST, NmCSS, Neu5Ac, CTP, Mg2+; (c) 
Pd2,6ST, NmCSS, Neu5Gc, CTP, Mg2+; (d) Hp1,3FT, GDP-Fuc, Mn2+; (e) Hm1,2FT, GDP-Fuc, Mn2+. 
LgtB, Neisseria meningitidis 1,4 galactosyltransferase; BiGalk, Bifidobacterium infantis galactokinase; 
AtUSP, Arabidopsis thaliana pyrophosphorylase; Pd2,6ST, Photobacterium damselae 2,6-sialyltrans-
ferase; NmCSS, Neisseria meningitidis CMP-sialic acid synthetase; Hp1,3FT, C-terminal 66 amino acids 
truncated Helicobacter pylori 1,3-fucosyltransferase; Hm1,2FT, Helicobacter mustelae 1,2-
fucosyltransferase. 
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2.6 Conclusion 
In summary, we have utilized our well-developed CSEE strategy for efficient 
synthesis of a library of structure-defined HMOs, which was assisted with rapid HPLC 
purification.  The combination of CSEE and HPLC purification allows us to deliver diverse 
and high purity of 31 homogenous HMOs. These HMOs are valuable materials for 
bioactivity evaluation as well as glycan analysis. In this work, oligosaccharyl thioethers 
and oligosaccharyl bromide were consistently utilized as chemical glycosylation donors 
for the convergent installation of branched lactose-terminated antennae. This general and 
efficient method furnished 3 core oligosaccharides with high stereoselectivity and 
excellent yields. This work further confirmed that any GlcNAc-terminated glycans could 
be extended to 5 or more glycans, including LeX and SLeX, which are very important 
epitopes in glycobiology.  The CSEE demonstrated a practical way to harvest diverse and 
complex HMOs with defined structures for various applications. The “mass” production of 
more homogenous HMOs and bioactivity evaluation are underway.  
2.7 Experimental Section 
General Methods: All chemicals were purchased as reagent grade and used 
without further purification. Anhydrous dichloromethane (CH2Cl2), acetonitrile (CH3CN), 
tetrahydrofuran (THF), N, N-dimethyl formamide (DMF), toluene, and methanol (MeOH) 
were purchased from a commercial source without further distillation. Pulverized 
Molecular Sieves MS-4 Å (Aldrich) for glycosylation was activated by heating at 350 °C 
for 3 h. All reactions were performed with dry solvents and under nitrogen unless 
otherwise stated. Thin-layer chromatography (TLC) with 60 F254 silica gel plastic plates 
was detected visualized under UV (254 nm) and/or by staining with a solution of 10 ml 
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anisaldehyde and 10 ml 95% H2SO4 in 400 mL Ethanol, followed by heating on a hot 
plate. Column chromatography was carried out on silica gel (EMD 230-400 mesh ASTM) 
and P2 gel (Biorad). Optical rotation values were measured using a PerkinElmer Model 
343 polarimeter at the ambient temperature in specified solvents.  1H NMR spectra were 
recorded on a Bruker AVANCE 400 (400 MHz) or Bruker AVANCE 500 (500 MHz) 
spectrometer at 25 °C. All 1H Chemical shifts (in ppm) were assigned according to CDCl3 
(δ= 7.24 ppm) or D2O (δ = 4.79 ppm). 13C NMR spectra were obtained with Bruker 
AVANCE 400 spectrometer and calibrated with CDCl3 (δ = 77.00 ppm). Coupling 
constants (J) are reported in hertz (Hz). Splitting patterns are described using the 
following abbreviations: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; dd, 
doublet of doublet; m, multiplet. 1H NMR spectra are reported in the following order: 
chemical shift, multiplicity, coupling constant(s), and number(s) of protons.  All NMR 
signals were assigned on the basis of 1H NMR and 13C NMR experiments. High resolution 
MALDI mass spectra were recorded on a Bruker Ultraflextreme spectrometer.  
Neu5Ac and Neu5Gc were purchased from Carbosynth Limited. ATP and CTP 
were purchased from Sigma. Thermosensitive Alkaline Phosphatase from shrimp 
(FastAP) was purchased from Thermo Scientific. Other enzymes including  Neisseria 
meniningitidis 1,4-galactosyltransferase (NmLgtB), 2,6-sialyltransferase from 
Photobacterium damslae (Pd2,6ST) , C-terminal 66 amino acids truncated Helicobacter 
pylori  1,3-fucosyltransferase (Hp1,3FT) , Helicobacter mustelae 1,2-
fucosyltransferase (Hmα1,2FT), CMP-sialic acid synthetase from N. meningitides 
(NmCSS) were expressed and purified as previously described. Enzymes were then 
desalted against 50 mM Tris-HCl, 100 mM NaCl, and 50% glycerol, and stored at -20 °C 
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for long term use. Sugar nucleotides uridine 5’-diphospho-galactose (UDP-Gal), cytidine 
5’-monophospho- N-acetylneuraminic acid (CMP-Neu5Ac), cytidine 5’-monophospho- N-
Glycolylneuraminic acid (CMP-Neu5Gc) and guanoside 5’-diphospho-L-fucose (GDP-
Fuc)  were prepared as described below. 
General Procedures 
A) Transformation of N-Phth to NHAc procedure: A mixture of N-Phth protected 
oligosaccharide was dissolved in n-BuOH at room temperature, followed by addition of 
ethylenediamine (n-BuOH: ethylenediamine = 2:1). After being stirred at 90 °C for 12 h, 
the mixture was evaporated in vacuo to give a residue for the next step without further 
purification. To a solution of the residue in pyridine was added Ac2O. After being stirred 
at room temperature for 12 h, the solution was diluted with EtOAc and washed with 
aqueous 1 M HCl, saturated aqueous NaHCO3, and brine solution. The organic layer was 
dried over Na2SO4, filtered, and evaporated in vacuo to give a residue, which was purified 
by silica gel column chromatography to give NHAc compound. 
B) Deacetylation procedure: Ac-protected oligosaccharide was dissolved in 
MeOH, and NaOMe in MeOH was added until pH was about 10. After stirring at room 
temperature for 12 h, the solution was neutralized with ion-exchange resin (H+), and then 
filtered. The residue was concentrated under vacuo to afford the desired deacetylated 
product.  
C) Deprotection of benzyl group: Pd(OH)2 on carbon was added to a solution of 
protected oligosaccharide in MeOH/H2O (10/1). The mixture was stirred under 1 
atmosphere of hydrogen. After being stirred for 24 h, the mixture was filtered through a 
PTFE syringe filter and concentrated in vacuo. The residue was purified by Bio-Gel P-2 
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(BIO-RAD) column chromatography using water as eluent. The product was then 
lyophilized to get target compound as white powder.  
D) Production of oligosaccharyl bromide: Add peracetylated oligosaccharide 
portionwise to a stirred solution of HBr (33%) in glacial acetic acid (20.0 ml) at 0 °C. After 
all the sugar has been added, the reaction mixture was stirred at room temperature for 
45 min.  TLC analysis (Hexanes: Ethyl acetate=1:1) indicates formation of product and 
consumption of starting material. Then the reaction was quenched by ice water (200 ml) 
and then extract the product with DCM (2 × 200 ml). Wash the combined organic extracts 
with a solution of NaHCO3 (aq., sat., 2 × 200 ml), dry with Na2SO4, filter and then 
concentrate in vacuo. The crude product was used without further purification. 
E) General methods for enzyme treatment and HPLC purification In general, 31 
HMOs were enzymatically synthesized by 4 glycosyltransferases (NmLgtB, Pd2,6ST, 
Hp 1,3FT, Hm 1,2FT) in the nearly same reaction condition. Reactions contain 50 mM 
Tris-HCl (pH 8.0), 10 mM of acceptor HMOs, 12 mM of sugar nucleotide (or its 
corresponding synthetase), 10 mM of MnCl2, and varying amounts of Glycotransferases. 
FastAP (1 U/200 L) was also added to digest the reaction byproduct UDP to drive 
reaction forward. Reactions incubated at 37 °C for overnight, and monitored by HILIC-
ELSD (Waters XBridge BEH amide column, 130 Å, 4.6 mm × 250 mm under a gradient 
running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; 
flow rate: 1 mL/min; B%: 65-50% within 25 min)). The desired products were detected by 
a high-efficient ELSD (evaporative light scattering detector) which increases the sample 
concentration to minimize the noise and deliver higher sensitivity. After over 90% acceptor 
converted, the reaction was quenched by boiling for 10 min, followed concentration by 
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rotary evaporator. HPLC-A210nm was then used to purify target HMOs using a semi-
preparative column (Waters XBridge BEH amide column, 130 Å, 5 m, 10 mm × 250 mm) 
under a gradient running condition which are solvent A: 100 mM ammonium formate, pH 
3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65-50% within 25 min.43 MS data for 
purified HMOs were obtained by ESI-MS and MALDI-MS.  
    Benzyl O-(4, 6-O-benzylidene-3-O-(4-methoxybenzyl)- β-D-galactopyra-
nosyl)-(1→4)- β-D-glucopyranoside (2-6) 
    A suspension of benzyllactose 2-5 (12.0 g, 27.78 mmol) and Bu2SnO (7.6 g, 
30.54 mmol) in anhydrous MeOH (100 mL) was heated to reflux and stirred for 8 h. The 
solvent was removed in vacuo. Then the residue was dissolved in dry toluene (100 mL). 
p-Methoxybenzyl chloride (3.76 mL, 20.37 mmol), tetrabutylammonium iodide (2.05 g, 
11.10 mmol), and 4 Å molecular sieves (5 g) were added. The resulting mixture was 
heated to reflux for another 8 h and then cooled to room temperature. The suspension 
was filtered through a Celite pad and the filtrate was concentrated and chromatographied 
(dichloromethane-methanol=6:1) to afford 9.2 g of crude product (60% yield).  
    Benzaldehyde dimethyl acetal (2.75 mL, 18.33 mmol) was added to a solution 
of the above crude product (7.8 g, 14.10 mmol) in anhydrous Dimethylformamide (100 
ml), then Camphorsulfonic acid was added to adjust the PH to about 2.0-3.0. The reaction 
mixture was stirred overnight and then quenched with triethylamine. The mixture was 
concentrated in vacuum. The residue was purified by flash column chromatography 
(dichloromethane-methanol=10:1) to give 2-6 as a white solid (8.47 g, 87.0%). [α]D20 = 
+6.7 (c 1.0, CH2Cl2). 1H NMR (CDCl3, 400 MHz): δ 7.48-7.51 (dd, 2H), 7.28-7.38 (m, 10 
H), 6.85-6.87 (m, 2 H), 5.34  (s, 1 H), 4.87 (d, J = 11.95 Hz, 1 H), 4.59-4.63 (m, 4 H), 4.45 
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(d, J = 7.8 Hz, 1 H), 4.36 (d, J = 8.1 Hz, 1 H), 4.21 (d, J = 14.0 Hz, 1 H), 4.10 (s, 1 H), 
3.92-4.00 (m, 3 H), 3.79-3.89 (m, 2 H), 3.78 (s, 3 H), 3.60-3.69 (m, 3 H), 3.40-3.50 (m, 2 
H), 3.27-3.40 (m, 4 H); 13C NMR (CDCl3, 100 MHz): δ 137.6,137.2, 130.0,129.5, 128.5, 
128.3, 128.2, 127.9, 126.3, 113.9, 103.6, 101.8, 101.1, 78.8, 74.9,74.7, 73.5, 72.7, 71.3, 
71.2, 69.1, 69.0, 66.9, 61.9, 55.3. HRMS: [M + Na]+ C34H40NaO12 calcd for 663.2417, 
found 663.2420. 
    Benzyl O-(2-O-Benzyl-4, 6-O-benzylidene-3-O-(4-methoxybenzyl)- β-D-
galactopyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-7) 
    60% NaH (2.25 g, 56.25 mmol) and BnBr (6.66 ml, 56.25 mmol) were added to 
a stirred solution of 2-6 (6.0g, 9.38 mmol) in DMF (60 mL) cooled at 0°C. The color of the 
solution changed to light yellow. The reaction mixture was maintained at room 
temperature for 4 h. Then the solution was quenched with MeOH. The mixture was diluted 
with EtOAc and washed with water. The organic layer was dried with Na2SO4 and 
concentrated. The residue was purified on a silica gel column (Hexanes: EtOAc = 6:1) to 
afford the product 2-7 (1.85 g, 92.5%) as white powder. [α]D20 = +7.4 (c 1.0, CH2Cl2). 1H 
NMR (CDCl3, 400 MHz): δ 7.57-7.59 (m, 2 H), 7.51-7.54 (m, 2 H), 7.42-7.45 (m, 2 H), 
7.31-7.38 (m,23 H), 7.23-7.24 (m, 2 H), 6.90-6.92 (m, 2 H), 5.51 (s, 1H), 5.25 (d, J = 11.0 
Hz, 1 H), 4.98-5.03 (m, 2 H), 4.90 (d, J = 11.1 Hz, 1 H), 4.79-4.85 (m, 3 H),4.71-4.74 (m, 
3 H), 4.63 (d, J = 12.0 Hz, 1 H), 4.52-4.55 (m, 2 H), 4.43 (d, J = 12.0 Hz, 1 H), 4.26 (dd, 
J = 1.4 Hz, 12.4 Hz, 1 H), 4.04-4.08 (m, 2 H), 3.96 (dd, J = 4.2, 11.3 Hz, 1 H), 3.90 (dd, J 
= 1.8, 12.5 Hz, 1 H), 3.85 (s, 3 H), 3.79-3.83 (m, 2 H), 3.69 (t, J = 8.8 Hz, 1 H), 3.56-3.60 
(m, 1 H), 3.40-3.46 (m, 2 H); 13C NMR (CDCl3, 100 MHz): δ 159.3, 139.0, 139.0, 138.7, 
138.6, 138.2, 137.6, 130.5, 129.4, 128.9, 128.7, 128.4, 128.3, 128.1, 128.0, 127.8, 127.8, 
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127.6, 127.6, 127.5, 127.4, 127.3, 126.6, 113.8, 103.0, 102.6, 101.4, 83.1, 81.9, 79.4, 
78.9, 77.7, 75.9, 75.3, 75.2, 75.1, 73.8, 73.0, 71.37, 71.1, 69.0, 68.3, 66.4, 55.3. HRMS: 
[M + Na]+ C62H64NaO12 calcd for 1023.4295, found 1023.4285. 
    Benzyl O-(2-O-Benzyl-4, 6-O-benzylidene- β-D-galactopyranosyl)-(1→4)-2, 
3, 6-tri-O-benzyl- β-D-glucopyranoside (2-1) 
    2, 3-Dichloro-5, 6-dicyano-1, 4-benzoquinone (2.75 g, 12.10 mmol) was added 
to a solution of 2-7 (6.0 g, 6.05 mmol) in 9:1 CH2Cl2– Phosphate-buffered saline (200 mL) 
was added. The solution was stirred for 1.5h at room temperature and diluted with CH2Cl2. 
The solution was washed with aqueous NaHCO3, brine, dried over Na2SO4, and 
concentrated. The residue was was purified on a silica gel column (Hexanes: EtOAc = 
5:1) to afford the product 2-1 (5.02 g, 95%) as white powder.  [α]D20 = +15.4 (c 1.0, 
CH2Cl2). 1H NMR (CDCl3, 400 MHz): δ 7.52-7.55 (m, 4 H), 7.20-7.45 (m, 26 H), 5.56 (s, 
1 H), 5.21 (d, J = 8.0 Hz 1 H), 4.97-5.02 (m, 2 H), 4.78-4.83 (m, 4 H), 4.65-4.73 (m, 2 H), 
4.51-4.54 (m, 2 H), 4.46 (d, J = 12.3 Hz, 1 H), 4.30 (d, J = 12.3 Hz, 1 H), 4.06-4.13 (m, 2 
H), 3.93-3.97 (m, 2 H), 3.79 (dd, J = 1.3, 11.0 Hz, 1 H), 3.68 (m, 1 H), 3.55-3.60 (m, 3 H), 
3.38-3.41 (m, 1 H), 3.14 (s, 1 H) ;  13C NMR (CDCl3, 100 MHz): δ 138.9, 138.7, 138.6, 
138.5, 137.9, 137.5, 129.2, 128.8, 128.4, 128.2, 128.0, 127.8, 127.6, 127.4, 126.5, 102.8, 
102.6, 101.5, 83.1, 81.9, 80.2, 77.6, 75.9, 75.7, 75.2, 75.1, 73.1, 72.9, 71.0, 68.9, 68.2, 
66.5. HRMS: [M + Na]+ C54H56NaO11 calcd for 903.3720, found 903.3725. 
    Ethyl 3, 6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside 
(2-9) 
    A mixture of compound 2-8 (2 g, 4.09 mmol) and 4 Å molecular sieves (2 g) in 
dry CH2Cl2 was stirred at room temperature under nitrogen for 2 h. Triethylsilane (2.1 mL, 
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13.1 mmol) and TfOH (1.05 mL, 11.9 mmol) were sequentially added at - 78 °C. The 
reaction mixture was stirred at -78 °C for 2 h and then quenched with MeOH (2 mL) and 
Et3N (2 mL). The resulting mixture was filtered. The filtrate was diluted with CH2Cl2 and 
washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The residue 
was purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the product 2-9 (1.85 
g, 92.5%) as white powder. [α]D20 = +91.0 (c 1.0, CHCl3). 1H NMR (CDCl3, 400 MHz): δ 
7.82 (d, J = 5.9 Hz, 1 H), 7.66-7.72 (m, 3 H), 7.28-7.42 (m, 5 H), 7.03-7.10 (m, 2 H), 6.92-
7.00 (m, 3 H), 5.32 (d, J = 9.9 Hz, 1 H), 4.80 (d, J = 12.0 Hz, 1 H), 4.54-4.70 (m, 3 H), 
4.25-4.34 (m, 2 H), 3.80-3.89 (m, 3 H), 3.70-3.73 (m, 1 H), 2.59-2.72 (m, 2 H), 1.19 (t, J 
= 7.3 Hz, 3 H); 13C NMR (CDCl3, 100 MHz): δ 168.1, 167.6, 138.2, 137.7, 134.0, 133.9, 
131.6, 128.5, 127.9, 127.9, 127.8, 127.5, 123.5, 123.3, 81.2, 79.7, 78.0, 74.5, 74.2, 73.78, 
70.7, 54.5, 24.0, 15.0. HRMS: [M + Na]+ C30H31NNaO6S calcd for 556.1770, found 
556.1760. 
    Ethyl 2, 3, 4, 6-tetra-O-acetyl- β-D-glucopyranosyl-(1→4)-3, 6-di-O-benzyl-
2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (2-3) 
    2, 3, 4, 6-Tetra-O-acetyl-β-D-galactosyl bromide (3.35 g, 8.17 mmol) was 
prepared by following general procedure (D).  Then the bromide donor (3.35 g, 8.17 
mmol) and 3, 6-di-O-benzyl-2-deoxy- 2-phthalimido-1-thio-β-D-glucopyranoside 2-9 (2.64 
g. 5.43 mmol) were dissolved in a mixture of dry toluene and CH2Cl2 (1:1, 30 mL). 
Powdered molecular sieves (4 Å) were added and the mixture was stirred under nitrogen 
for 1 h. The flask was wrapped in aluminum foil and cooled to −45°C. AgOTf (2.79 g, 
10.86 mmol) dissolved in dry toluene (20 mL) was added during 1 h under the exclusion 
of light. After additional stirring for 30 min at −45°C, the reaction mixture was quenched 
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by aqueous Na2S2O3. The mixture transferred to a separatory funnel via a Celite-packed 
glass filter funnel. The organic phase was separated, dried with Na2SO4, filtered, and 
concentrated. Purification of the residue by silica gel column chromatography 
(Hexanes:EtOAc=4:1) gave compound 2-3 (5.81 g, 80%). [α]D20 = +31.0 (c 1.0, CHCl3). 
1H NMR (CDCl3, 400 MHz): δ 7.77 (d, J = 6.3 Hz, 1 H), 7.62-7.66 (m, 3 H), 7.29-743(m, 
5 H), 7.01(d, J = 7.0 H), 6.82-6.92 (m, 3 H), 5.13-5.28 (m, 3 H), 4.78-4.87 (m, 3 H), 4.62 
(d, J = 7.9 Hz, 1 H), 4.43-4.51 (m, 2 H), 4.20-4.28 (m, 2 H), 4.09 (t, J = 9.5 Hz, 1 H), 3.89-
4.02 (m, 2 H), 3.79 (s, 2 H), 3.64 (t, J = 6.8 Hz, 1 H), 3.56 (d, J = 10.0 Hz, 1 H), 2.55-2.75 
(m, 2 H), 2.06 (s, 3 H), 2.02 (s, 6 H), 1.97 (s, 3 H);  13C NMR (CDCl3, 100 MHz): δ 170.3, 
170.2, 170.0, 169.2, 167.9, 167.4, 138.5, 137.9, 133.9, 133.7, 131.6, 128.6, 128.0, 127.9, 
127.9, 127.1, 123.4, 123.3, 100.3, 81.1, 79.1, 77.8, 77.6, 74.5, 73.6, 70.4, 69.5, 67.7, 
66.9, 60.7, 54.7, 23.9, 20.8, 20.7, 20.6, 20.6, 14.9. HRMS: [M + Na]+ C44H49NNaO15S 
calcd for 886.2721, found 886.2729. 
    Benzyl O-(2, 4-di-O-Benzyl-β-D-galactopyranosyl)-(1 → 4)-2, 3, 6-tri-O-
benzyl- β-D-glucopyranoside (2-13) 
    A mixture of compound 2-1 (2 g, 2.27 mmol) and 4 Å molecular sieves (2 g) in 
dry CH2Cl2 was stirred at room temperature under nitrogen for 2 h. Triethylsilane (0.69 
mL, 4.34 mmol) and PhBCl2 (0.56 mL, 4.34 mmol) were sequentially added at - 78 °C. 
The reaction mixture was stirred at -78 °C for 2 h and then quenched by the addition of 
MeOH (2 mL) and Et3N (2 mL). The resulting mixture was filtered. The filtrate was diluted 
with CH2Cl2 and washed with aqueous NaHCO3, brine, dried over Na2SO4, and 
concentrated. The residue was purified on a silica gel column (Hexanes: EtOAc = 5:1) to 
afford the product 2-13 (1.70 g, 85%) as white powder. [α]D20 = +8.9 (c 1.0, CH2Cl2). 1H 
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NMR (CDCl3, 400 MHz): δ 7.35-7.52 (m, 27 H), 7.26-7.34 (m, 3 H), 5.03-5.16 (m, 3 H), 
4.78-4.97 (m, 6 H), 4.70-4.75 (m, 2 H), 4.59-4.65 (m, 2 H), 4.52 (d, J = 7.0 Hz, 1 H), 4.08 
(t, J = 8.7 Hz, 1 H), 3.92 (d, J = 2.6 Hz, 2 H); 13C NMR (CDCl3, 100 MHz): δ 138.9, 138.7 
(2 C), 138.5, 137.6, 128.6, 128.6, 128.5, 128.5, 128.4, 128.1, 127.9, 127.8, 127.7, 127.6, 
102.8, 102.6, 82.8, 81.9, 80.5, 77.0, 75.8, 75.5, 75.3, 75.2 (2 C), 75.1, 74.4, 73.4, 71.1, 
68.4, 61.7. HRMS: [M + Na]+ C54H58NaO11 calcd for 905.3877, found 905.3867. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(1→3)-[ 3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl]-(1→6)-(2, 4-
di-O-benzyl-β-D-galac-topyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranosi-
de (2-14) 
3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (3.0 g) was added 
to a solution of above bromide donor (4.80 g, 5.44 mmol) and 2-13 (800 mg, 0.907 mmol) 
in anhydrous dichloromethane (20 mL). The suspension was stirred under nitrogen for 
1.5 h at room temperature and then cooled to -30°C. Then 2, 4, 6-collidine (0.72 mL, 5.44 
mmol), and freshly dried AgOTf (1.40 g, 5.44 mmol) was sequentially added to the 
reaction mixture. After stirring for 2 h at -30°C, the mixture was allowed to warm up to rt 
overnight, diluted with CH2Cl2, filtered through Celite. The filtrate was diluted with CH2Cl2 
and washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The 
residue was purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the product 
2-14 (1.33 g, 85%) as white powder. [α]D20 = +6.4 (c 1.0, CH2Cl2). 1H NMR (CDCl3, 400 
MHz): δ 7.85 (t, J = 4.01 Hz, 1 H), 7.72-7.74 (m, 2 H), 7.43-7.56 (m, 2 H), 7.18-7.40 (m, 
27 H), 7.08-7.16 (m, 3 H), 6.97 (m, 2 H), 5.76-5.87 (m, 2 H), 5.62 (d, J = 8.24 Hz, 1 H), 
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5.39(d, J = 8.43, 1H),  5.16-5.24 (m, 2 H), 4.85-4.93 (m, 4 H), 4.75 (d, J = 10.6 Hz, 1 H), 
4.55-4.66 (m, 3 H), 4.35-4.44 (m, 5 H), 4.19-4.33 (m, 5 H), 4.12 (d, J = 12.7 Hz, 1 H), 3.91 
(t, J = 10.1 Hz, 1 H), 3.71-3.86 (m, 5 H), 3.47-3.59 (m, 5 H), 3.33-3.47 (m, 2 H), 3.21 (t, J 
= 5.9 Hz, 1 H), 3.05(dd,  J = 3.2, 9.7 Hz, 1 H), 2.09 (s, 3 H), 2.09 (s, 3 H), 2.02 (s, 3 H), 
1.98 (s, 3 H), 1.87(d, 6 H); 13C NMR (CDCl3, 100 MHz): δ 170.7, 170.6, 170.1, 170.0, 
169.5, 169.5, 139.1, 139.0, 138.6, 138.5, 138.4, 137.7, 134.4, 134.0, 128.4, 128.3, 128.2, 
128.2, 128.1, 128.0, 127.8, 127.6, 127.5, 127.4, 127.4, 127.1, 127.0, 126.9, 126.5, 102.4, 
102.3, 99.0, 97.5, 83.1, 81.7, 81.7, 78.6, 76.2, 76.1, 75.6, 75.2, 75.0, 74.9, 74.1, 73.1, 
72.8 (2 C), 71.7, 71.6, 70.8, 70.8 (2 C), 70.5, 68.9, 68.8, 68.0, 66.8, 61.7, 61.6, 55.1, 54.7, 
20.8, 20.7, 20.7, 20.6, 20.5, 20.4. HRMS: [M + Na]+ C94H96N2NaO29 calcd for 1739.5996, 
found 1739.5980. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl)-(1→
3)-[ 3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl]-(1→ 6)-(2,4-di-O-
benzyl-β-D-galactopyr-anosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-
15) 
Following the general procedure (A) compound 2-14 (1.16 g, 0.66 mmol) yielded 
the compound 2-15 (762mg, 75% over two steps). [α]D20 = -1.9 (c 0.4, CH2Cl2). 1H NMR 
(CDCl3, 400 MHz): δ 7.25-7.48 (m, 27 H), 7.10-7.18 (m, 3 H), 5.78 (d, J = 9.5 Hz, 1 H), 
5.01-5.16 (m, 6 H), 4.90-5.00 (m, 3 H), 4.75-4.91 (m, 4 H), 4.60-4.71 (m, 3 H), 4.41-4.55 
(m, 4 H), 4.29 (d, J = 3.5 Hz, 1 H), 3.96-4.15 (m, 5 H), 3.64-3.86 (m, 8 H), 3.52-3.64 (m, 
4 H), 3.45-3.51 (m, 1 H), 3.23 (d, J = 9.7 Hz, 1 H), 2.07 (s, 3 H), 2.06 (s, 3 H), 2.05 (s, 3 
H), 2.00 (s, 3 H), 1.99 (s, 3 H), 1.98 (s, 3 H), 1.51 (s, 3 H); 13C NMR (CDCl3, 100 MHz): δ 
170.9, 170.8, 170.6, 170.5, 170.3, 169.8, 169.3, 169.2, 139.4, 138.9, 138.8, 138.6, 137.9, 
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137.4, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 
127.5, 126.2, 102.6, 102.5, 102.4, 101.4, 84.3, 82.4, 82.1, 79.5, 76.7, 76.4, 76.2, 75.2, 
74.9, 74.7, 74.5, 74.4, 73.3, 73.2, 72.7, 72.0, 70.9, 70.6, 68.8, 68.5, 67.9, 67.5, 62.0, 61.6, 
54.4, 53.7, 23.6, 22.8, 20.8, 20.8, 20.7, 20.6 (3 C). HRMS: [M + Na]+ C82H96N2NaO27 
calcd for 1563.6098, found 1563.6126. 
    2-deoxy-acetamido-β-D-glucopyranosyl-(1→3)-[ 2-deoxy-acetamido-β-D-
glucopyranos-yl]-(1→6)- β-D-galactopyranosyl-(1→4)-α,β-D-glucopyranose(HMO1) 
    Following the general procedure (B) and (C), compound 2-15 (400 mg, 0.26 
mmol) yielded the compound HMO1 (152 mg, 80% over two steps). 1H NMR (D2O, 400 
MHz): δ 5.15 (d, J = 3.6 Hz, 0.55 H, Glc-1 H-1 of α form), 4.53-4.62 (m, overlap with D2O, 
2.45 H, GlcNAc-1 H-1, GlcNAc-2 H-1 and Glc-1 H-1 of β form), 4.36 (d, J = 7.7 Hz, 1 H, 
Gal-1 H-1), 4.07(d, J = 2.4 Hz, 1 H), 3.58-3.95 (m, 13 H), 3.45-3.58 (m, 5 H), 3.32-3.45 
(m, 4 H), 3.16-3.26 (m, 1 H), 1.99 (s, 3 H), 1.96 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 
174.9, 174.6, 102.9, 102.8 (GlcNAc-1, GlcNAc-2, C-1),101.1 (Gal-1, C-1), 95.7 (Glc-1, C-
1 of β form), 91.8 (Glc-1, C-1 of α form), 81.7, 78.8, 75.8 (2 C), 75.6, 73.8, 74.7, 74.3, 
73.8, 73.5, 73.4, 69.86, 69.8, 69.6, 68.7, 68.4, 60.7, 60.5, 55.6, 55.5, 22.4, 22.2.  HRMS: 
[M + Na]+ C28H48N2NaO21 calcd for 771.2647, found 771.2520. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→ 3)-(2-O-benzyl-4, 6-O-ben-
zylidene-β-D-galac-topyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside 
(2-16) 
Powdered molecular sieves (4 Å) (3.0 g) was added to a solution of Compound 2-
3 (871 mg,  0.96 mmol)  and 2-1 (652 mg, 0.74 mmol)  in anhydrous dichloromethane (20 
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mL). The suspension was stirred under nitrogen for 1.5 h at room temperature and then 
cooled to -30°C. Then NIS (260mg, 1.15mmol), and TMSOTf (35 µl, 0.19 mmol) was 
sequentially added to the reaction mixture. After stirring for 2 h at -30°C, the mixture was 
allowed to warm up to rt. overnight, diluted with CH2Cl2, filtered through Celite. The filtrate 
was diluted with CH2Cl2 and washed with aqueous NaHCO3, brine, dried over Na2SO4, 
and concentrated. The residue was purified on a silica gel column (Hexanes: EtOAc = 
5:1) to afford the product 2-16 (1.04 g, 86%) as white powder. [α]D20 = +12.9 (c 1.0, 
CH2Cl2). 1H NMR (CDCl3, 400 MHz): δ 7.53-7.55 (m, 2 H), 7.45-7.50 (m, 2 H), 7.27-7.45 
(m, 27 H), 7.19 (t, J = 3.6 Hz, 2 H), 7.09-7.16 (m, 3 H), 7.02-7.06 (m, 2 H), 6.84-6.94 (m, 
5 H), 5.49 (s, 1 H), 5.47 (d, J = 7.4 Hz, 1 H), 5.35 (d, J = 3.2 Hz, 1 H), 5.25 (dd, J = 7.9, 
10.4 Hz, 1 H), 5.09 (d, J = 10.7 Hz, 1 H), 4.88-4.99 (m, 3 H), 4.85 (d, J = 12.0 Hz, 1 H), 
4.65-4.78 (m, 4 H), 4.61 (d, J = 12.0 Hz, 1 H), 4.44-4.55 (m, 3 H), 4.30-4.39 (m, 4 H), 
4.18-4.28 (m, 5 H), 4.09 (t, J = 9.3 Hz, 1 H), 3.98-4.04 (m, 2 H), 3.89-3.96 (m, 1 H), 3.80-
3.89 (m 2 H), 3.66-3.79 (m, 3 H), 3.53-3.64 (m, 2 H), 3.44-3.51 (m, 3 H), 3.38 (d, J = 10.1 
Hz, 1 H), 2.93-3.02 (m, 2 H), 2.12 (s, 3 H), 2.10 (s, 3 H), 2.05 (s, 3 H), 2.03 (s, 3 H); 13C 
NMR (CDCl3, 100 MHz): δ 170.3, 170.2, 170.1, 169.2, 139.0, 138.6 (2 C), 138.5, 138.3, 
137.8, 137.6, 133.5, 131.3, 128.7, 128.6 (2 C), 128.4, 128.3 (2 C), 128.2, 128.1 (2 C), 
128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.2, 127.1, 126.7, 126.5, 126.3, 123.1, 102.4 
(2 C), 100.7, 100.6, 99.6, 83.1, 81.8, 80.9, 78.4, 77.7, 76.0, 75.7, 75.0, 74.8, 74.7, 74.5, 
74.3, 73.8 (2 C), 73.0 (2 C), 71.1, 70.9 (2 C), 70.6, 69.7, 68.8, 68.7, 67.9, 67.0, 66.4, 60.8, 
55.8, 20.9, 20.7 (2 C), 20.6. HRMS: [M + Na]+ C96H99NNaO26 calcd for 1704.6353, found 
1704.6383. 
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    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3)-(2-O-benzyl-β-D-galacto-
pyranosyl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-19) 
To a solution of compound 2-16 (800 mg, 0.49 mmol) in anhydrous MeOH (10 mL) 
was added TsOH (8.4 mg) and EtSH (0.21 ml, 2.93 mmol). The reaction mixture was 
stirred at rt. for 6 h and then quenched with triethylamine and evaporated under reduced 
pressure. The mixture was purified with silica column (Hexanes: Acetone = 5:1) to get 
white power compound 2-19 (702 mg, 90%). [α]D20 = +18.4 (c 0.5, CH2Cl2). 1H NMR 
(CDCl3, 400 MHz): δ 7.38-7.52 (m, 11 H), 7.25-7.36 (m, 16 H), 7.22-7.26 (m, 2 H), 7.03-
7.14 (m, 3 H), 6.99-7.03 (m, 2 H), 6.85-6.92 (m, 2 H), 6.78 (d, J = 7.1 Hz, 2 H), 5.29-5.31 
(m, 2 H), 5.19-5.25 (m, 1 H), 4.86-4.98 (m, 4 H), 4.83 (d, J = 12.2 Hz, 1 H), 4.68-4.77 (m, 
3 H), 4.65 (d, J = 8.3 Hz, 1 H), 4.57-4.62 (m, 2 H), 4.46 (t, J = 12.4 Hz, 2 H), 4.34-4.40 
(m, 1 H), 4.26-4.34 (m, 3 H), 4.17-4.26 (m, 3 H), 3.95-4.08 (m, 3 H), 3.81-3.88 (m, 1 H), 
3.72-3.79 (m, 3 H), 3.64-3.72 (m, 2 H), 3.47-3.55 (m, 2 H), 3.34-3.46 (m, 5 H), 3.17-3.23 
(m, 1 H),  3.00-3.06 (m, 1 H), 2.87 (s, 1 H), 2.11 (s, 3 H), 2.08 (s, 3 H), 2.05 (s, 3 H), 2.02 
(s, 3 H); 13C NMR (CDCl3, 100 MHz): δ 170.3, 170.2, 170.1, 169.2, 138.9, 138.4, 138.3 
(2 C), 137.6, 137.5, 133.6, 131.1, 128.8, 128.4, 128.3 (3 C), 128.2 (2 C), 128.1, 127.9, 
127.8, 127.7, 127.6, 127.5, 127.4, 127.2, 126.7, 126.4, 123.2, 102.4, 102.1, 100.6, 99.0, 
83.8, 82.8, 81.5, 78.3, 77.9, 76.6, 76.4, 75.6, 74.9, 74.6, 74.3, 73.8, 73.7, 73.1, 71.0, 70.9, 
70.7, 69.6, 68.3, 67.9, 67.7, 66.9, 62.2, 60.8, 55.6, 20.8, 20.68, 20.6, 20.6. HRMS: [M + 
Na]+ C89H95NNaO26 calcd for 1616.6040, found 1616.6065. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-
benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→3) )-[ 3, 4, 6-tri-O-acetyl-2-
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deoxy-2-phthalimido-β-D-glucopyranosyl]-(1 → 6)-(2-O-benzyl-β-D-galactopyrano-
syl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-20) 
3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (3.0 g) was added 
to a solution of 2-19 (460 mg, 0.29 mmol), 2, 4, 6-collidine (76 µL, 0.58 mmol), and freshly 
dried AgOTf (150 mg, 0.58 mmol) in anhydrous dichloromethane (20 mL). The 
suspension was stirred under nitrogen for 1.5 h at room temperature and then cooled to 
-30°C. Then a solution of above bromide donor (460 mg, 0.29 mmol) in dichloromethane 
(5.0 mL) was added dropwise during 30 min to the reaction mixture. After stirring for 2 h 
at -30°C, the mixture was allowed to warm up to rt. overnight, diluted with CH2Cl2, filtered 
through Celite. The filtrate was diluted with CH2Cl2 and washed with aqueous NaHCO3, 
brine, dried over Na2SO4, and concentrated. The residue was purified on a silica gel 
column (Hexanes: EtOAc = 5:1) to afford the product 2-20 (495 mg, 85%) as white 
powder. [α]D20 = +11.7 (c 1.0, CH2Cl2). 1H NMR (CDCl3, 400 MHz): δ 7.76-7.91 (m, 4 H), 
7.49-7.56 (m, 2 H), 7.41-7.49 (m, 8 H), 7.14-7.20 (m, 2 H), 7.05-7.11 (m, 1 H), 6.97-7.04 
(m, 4 H), 6.85-6.94 (m, 3 H), 6.75 (d, J = 7.4 Hz, 2 H), 5.73 (dd, J = 9.1, 10.61 Hz, 1 H), 
5.43 (d, J = 8.3 Hz, 1 H), 5.33 (d, J = 3.5 Hz, 1 H), 5.12-5.25 (m, 2 H), 4.99 (d, J = 8.9 Hz, 
1 H), 4.77-4.95 (m, 3 H), 4.72-4.84 (m, 3 H), 4.61-4.71 (m, 2 H),  4.48-4.58 (m, 2 H), 4.33-
4.47 (m, 3 H), 4.09-4.31 (m, 8 H), 3.80-4.06 (m, 6 H), 3.65-3.80 (m, 5 H), 3.62 (d, J = 10.0 
Hz, 1 H), 3.50-3.56 (m, 2 H), 3.36-3.45 (m, 3 H),  3.20-3.27 (m, 2 H), 3.09-3.17 (m, 2 H), 
2.87 (s, 1 H), 2.14 (s, 3 H), 2.11 (s, 3 H), 2.09 (s, 3 H), 2.04 (s, 3 H), 2.02 (s, 3 H), 1.99 
(s, 3 H), 1.87(s, 3 H); 13C NMR (CDCl3, 100 MHz): δ 170.7, 170.3, 170.2, 170.0 (2 C), 
169.5, 169.5, 139.1, 138.7, 138.4, 138.3 (2 C), 137.7, 137.6, 131.2, 128.8, 128.4, 128.3 
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(3 C), 128.2, 128.1, 127.9 (2 C), 127.8, 127.7, 127.6 (2 C), 127.4, 127.2, 126.5, 123.2, 
102.4, 101.9, 100.7, 98.5, 97.6, 83.8, 83.1, 81.9, 78.4, 77.8, 76.5, 76.3, 75.7, 75.1, 74.9, 
74.5, 74.4, 74.4, 73.9, 72.9 (2 C), 72.0, 71.7, 71.1, 71.0, 70.8, 70.6, 69.5, 68.8, 68.1, 67.6, 
66.9, 66.6, 61.7, 60.8, 55.4, 54.7, 20.9, 20.8, 20.67, 20.6 (3 C), 20.5. HRMS: [M + Na]+ 
C109H114N2NaO35 calcd for 2033.7100, found 2033.7089. 
    Benzyl O-(2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)- 3, 6-di-O-
benzyl-2-deoxy-acetamido-β-D-glucopyranosyl-(1→3)-[3, 4, 6-tri-O-acetyl-2-deoxy-
acetamido-β-D-glucopy-ranosyl]-(1→6)-(4-O-acetyl-2-O-benzyl-β-D-galactopyrano-
syl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-21) 
Following the general procedure (A), compound 2-20 (400 mg, 0.20 mmol) yielded 
the compound 2-21 (232 mg, 62% over two steps). [α]D20 = -1.0 (c 1.2, CH2Cl2). 1H NMR 
(CDCl3, 400 MHz): δ 7.51 (m, 2H), 7.21-7.43 (m, 33 H), 5.89 (d, J = 9.5 Hz , 1 H), 5.43 
(d, J = 8.4 Hz, 1 H), 5.33 (d, J = 2.8 Hz, 1 H), 4.33-5.24 (m, 23 H), 4.24 (d, J = 8.2 Hz, 1 
H), 3.94-4.10 (m, 6 H), 3.45-3.86 (m, 15 H), 3.23 (d, J = 9.7 Hz, 1 H), 2.12 (s, 3 H), 2.11 
(s, 3 H), 2.05 (s, 3 H), 2.04 (s, 3 H), 2.01 (s, 3 H), 2.00 (s, 3 H), 1.99 (s, 3 H), 1.97 (s, 3 
H), 1.94 (s, 3 H), 1.54 (s, 3 H); 13C NMR (CDCl3, 100 MHz):δ 170.8, 170.7, 170.4, 170.3, 
170.2, 170.0, 170.0 (2 C), 169.7, 169.2, 139.4, 138.7, 138.6 (2 C), 138.0, 137.7, 137.4, 
128.7, 128.6, 128.4, 128.4 (2 C), 128.3, 128.2, 128.1, 128.0, 127.9 (2 C), 127.8, 127.7, 
127.6, 127.0, 102.6, 102.3, 101.1, 100.7, 100.0, 83.8, 82.4, 79.5, 78.3, 77.9, 76.2 (2 C), 
75.6, 75.0, 74.9, 74.6, 74.4, 73.9, 73.5, 73.3, 73.2 (2 C), 73.2, 70.9, 70.8, 70.7, 70.6, 70.0, 
69.4, 68.3, 68.0, 67.9, 67.9, 67.3, 66.9, 61.5, 60.8, 54.5, 53.6, 20.9, 20.8, 20.7 (3 C), 20.6 
(3 C), 20.5 (2 C).  HRMS: [M + Na]+ C99H116N2NaO34 calcd for 1899.7307, found 
1899.7287. 
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    β-D-galactopyranosyl-(1→4)-2-deoxy-acetamido-β-D-glucopyranosyl-(1→
3)-[ 2-deoxy-acetamido-β-D-glucopyranosyl]-(1→6)- β-D-galactopyranosyl-(1→4)-
α,β-D-glucopyranose (HMO2) 
Following the general procedure (B) and (C), compound 2-21 (200 mg, 0.11 mmol) 
yielded the compound HMO2 (87 mg, 90%). 1H NMR (D2O, 400 MHz): δ 5.11 (d, J = 3.6 
Hz, 0.42 H, Glc-1 H-1 of α form), 4.53-4.62 (m, 1.58 H, GlcNAc-1 H-1, Glc-1 H-1 of β 
form), 4.50 (d, J = 8.4 Hz, 1 H, GlcNHAC-2 H-1), 4.36 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 
4.31 (d, J = 8.0 Hz, 1 H, Gal-2 H-1), 4.03 (d, J = 3.0 Hz, 1 H), 3.77-3.92 (m, 5 H), 3.40-
3.77 (m, 21 H), 3.30-3.38 (m, 2 H), 3.17 (t, J = 8.9 Hz, 1 H), 1.95 (s, 3 H), 1.92 (s, 3 H); 
13C NMR (D2O, 100 MHz): δ 174.9, 174.5, 103.0, 102.8, 102.7 (GlcNAc-1, GlcNAc-2, Gal-
2, C-1), 101.0 (Gal-1, C-1), 95.7 (Glc-1, C-1 of β form), 91.8 (Glc-1, C-1 of α form), 81.8, 
78.9, 78.8, 78.1, 75.8, 75.3,  74.7, 74.5, 74.3, 73.8, 73.4, 72.5, 72.1, 71.4, 71.2, 70.9, 
69.6, 68.5, 68.4, 61.0, 60.1, 60.0, 59.8, 55.5, 55.2, 22.4, 22.2. HRMS: [M + Na]+ 
C34H58N2NaO26 calcd for 933.3175, found 933.3195. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(1→3)-(2-O-benzyl-4, 6-O-benzylidene-β-D-galactopyranosyl)-(1→4)-2, 3, 6-tri-O-
benzyl- β-D-glucopy-ranoside (2-22) 
3, 4, 6-Tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucosyl bromide was prepared by 
following the general procedure (D). Powdered molecular sieves (4 Å) (2.0 g) was added 
to a solution of above bromide donor 2-2 (1.2 g, 2.43 mmol) and 2-1 (500 mg, 0.61 mmol) 
in anhydrous dichloromethane (20 mL). The suspension was stirred under nitrogen for 
1.5 h at room temperature and then cooled to -30°C. Then 2, 4, 6-collidine (0.32 mL, 2.43 
mmol), and freshly dried AgOTf (624 mg, 2.43 mmol) was sequentially added to the 
64 
reaction mixture. After stirring for 2 h at -30°C, the mixture was allowed to warm up to rt 
overnight, diluted with CH2Cl2, filtered through Celite. The filtrate was diluted with CH2Cl2 
and washed with aqueous NaHCO3, brine, dried over Na2SO4, and concentrated. The 
residue was purified on a silica gel column (Hexanes: Acetone = 6:1) to afford the product 
2-22 (626 mg, 85%) as white powder. [α]D20 = +12.6 (c 1.0, CH2Cl2). 1H NMR (CDCl3, 400 
MHz): δ 7.30-7.63 (m, 26 H), 7.22-7.27 (m, 3 H), 7.16-7.21 (m, 3 H), 6.89-6.96 (m, 2 H), 
5.90 (dd, J = 9.4, 10.65 Hz, 1 H), 5.76 (d, J = 8.3 Hz, 1 H), 5.59 (s, 1 H), 5.29 (t, J = 9.7 
Hz, 1 H), 5.17 (d, J = 10.6 Hz, 1 H), 4.92-4.99 (m, 2 H), 4.72-4.82 (m, 2 H), 4.63 (t, J = 
11.6 Hz, 1 H), 4.54 (dd, J = 8.3, 10.8 Hz, 1 H), 4.25-4.47 (m, 9 H), 3.93-4.05 (m, 3 H), 
3.61-3.73 (m, 2 H), 3.49-3.60 (m, 3 H),  3.44 (d, J = 11.3 Hz, 1 H), 3.14 (s, 1 H), 2.98-
3.04 (m, 1 H), 2.13 (s, 3 H), 2.12 (s, 3 H), 1.90 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 
170.5, 170.2, 169.6, 139.0, 138.7, 138.6, 138.5, 138.3, 137.6, 134.2, 128.7, 128.4, 128.4, 
128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.3, 126.9, 126.4, 123.4, 102.4 
(2 C), 100.9, 99.3, 83.1, 81.8, 81.3, 76.9, 75.9, 75.8, 75.1, 74.8, 74.3, 73.1, 71.9, 71.0, 
70.8, 69.0, 68.9, 67.9, 66.4, 62.2, 54.8, 53.7, 20.9, 20.8, 20.5. HRMS: [M + Na]+ 
C74H75NNaO20 calcd for 1320.4780, found 1320.4806. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(1 → 3)-(2-O-benzyl-β-D-galactopyranosyl)-(1 → 4)-2, 3, 6-tri-O-benzyl- β-D-
glucopyranoside (2-23) 
To a solution of compound 2-22 (602 mg, 0.46 mmol) in anhydrous MeOH (10 mL) 
was added TsOH (16.0 mg) and EtSH (0.21 mL, 2.93 mmol). The reaction mixture was 
stirred at rt. for 6 hours then quenched with triethylamine and evaporated under reduced 
pressure. The mixture was purified with silica column (Hexanes: Acetone=5:1) to get 
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white power compound 2-23 (445 mg, 80%). [α]D20 = +17.7 (c 1.0, CH2Cl2). 1H NMR 
(CDCl3, 400 MHz): δ 7.51-7.66 (m, 4 H), 7.41-7.45 (m, 2 H), 7.25-7.40 (m, 18 H), 7.06-
7.17 (m, 3 H), 6.83 (d, J = 6.7 Hz, 2 H), 5.86 (dd, J = 9.1, 10.6 Hz, 1 H), 5.65 (d, J = 8.5 
Hz, 1 H), 5.18 (t, J = 9.4 Hz, 1 H), 4.88-4.96 (m, 3 H), 4.69-4.76 (m, 2 H), 4.62 (d, J = 12.0 
Hz, 1 H), 4.43-4.56 (m, 2 H), 4.37-4.41 (m, 1 H), 4.23-4.32 (m, 9 H), 3.95-4.03 (m, 3 H), 
3.87-3.93 (m, 1 H), 3.68-3.75 (m, 1 H), 3.52-3.66 (m, 2 H), 3.38-3.50 (m, 5 H), 3.23-3.29 
(m, 1 H), 3.03-3.08 (m, 1 H), 2.83 (d, J=1.5 Hz, 1 H), 2.15 (s, 3 H), 2.09 (s, 3 H), 1.88 (s, 
3 H); 13C NMR (D2O, 100 MHz): δ 170.8, 170.1, 169.5, 138.8, 138.6, 138.4, 138.3, 134.3, 
128.4 (2 C), 128.3, 128.2, 128.2, 128.0, 127.9, 127.8, 127.7 (2 C), 127.6, 127.5, 126.8, 
126.3, 123.5, 102.4, 102.1, 98.7, 84.3, 82.8, 81.7, 77.8, 76.3, 75.7, 75.0, 74.7, 74.3, 73.9, 
73.1, 72.1, 70.9, 70.5, 69.0, 68.0, 67.7, 62.2, 61.9, 54.6, 20.8, 20.7, 20.4. HRMS: [M + 
Na]+ C67H71NNaO20 calcd for 1232.4467, found 1232.4490. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-
(1→3)-[ 2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)-3, 6-di-O-benzyl-2-
deoxy-acetamido-β-D-glucopyranosyl]-(1 → 6)-(2-O-benzyl-β-D-galactopyranosyl)-
(1→4)-2, 3, 6-tri-O-benzyl- β-D-glu-copyranoside (2-24) 
    Powdered molecular sieves (4 Å) (1.0 g) was added to a solution of Compound 
2-3 (230 mg, 0.27mmol) and 2-23 (261 mg, 0.21 mmol) in anhydrous dichloromethane 
(10 mL). The suspension was stirred under nitrogen for 1.5 hours at room temperature 
and then cooled to -30°C. Then NIS (61 mg, 0.27 mmol), and AgOTf (35 mg, 0.105 mmol) 
was sequentially added to the reaction mixture. After stirring for 2 h at -30°C, the mixture 
was allowed to warm up to rt. overnight, diluted with CH2Cl2, filtered through Celite. The 
filtrate was diluted with CH2Cl2 and washed with aqueous NaHCO3, brine, dried over 
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Na2SO4, and concentrated. The residue was purified on a silica gel column (Hexanes: 
Acetone = 5:1) to afford the product 2-24 (295 mg, 70%) as white powder. [α]D20 = +13.0 
(c 1.0, CH2Cl2). 1H NMR (CDCl3, 400 MHz): δ 7.76-8.08 (m, 5 H), 7.49-7.72 (m, 3 H), 
7.17-7.48 (m, 25 H), 6.96-7.11 (m, 5 H), 6.87-6.95 (m, 3 H), 6.74 (d, J = 7.3 Hz, 2 H), 
5.55-5.61 (dd, J = 9.3, 10.37 Hz, 1 H), 5.30 (d, J = 3.3 Hz, 1 H), 5.11-5.20 (m, 2 H), 5.04 
(d, J = 8.5 Hz, 1 H), 4.69-4.95 (m, 9 H), 4.42-4.66 (m, 6 H), 4.21-4.39 (m, 6 H), 4.03-4.15 
(m, 5 H), 3.91-4.02 (m, 3 H), 3.70-3.88 (m, 4 H), 3.50-3.68 (m, 4 H), 3.23-3.46 (m, 8 H), 
3.00-3.07 (m, 1 H), 2.60-2.69 (m, 1 H), 2.11 (s, 3 H), 2.09 (s, 3 H), 2.08 (s, 3 H), 2.07 (s, 
3 H), 2.03 (s, 3 H), 2.00 (s, 3 H), 1.85 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 171.2, 170.4, 
170.3, 170.1, 170.0, 169.2, 169.2, 138.8, 138.7, 138.5, 138.3, 138.2, 137.7, 137.6, 128.7, 
128.5, 128.4, 128.3, 128.2 (2 C), 128.0 (2 C), 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 
127.3, 126.6, 126.2, 102.5, 101.8, 100.3, 97.8, 97.4, 84.6, 82.9, 81.8, 77.9 (2 C), 77.3, 
76.5, 76.1, 75.7, 75.0, 74.8, 74.7, 74.5, 74.4, 73.7, 73.1, 71.4, 71.0, 70.9, 70.4, 70.1, 70.0, 
69.5, 69.4, 69.2, 67.8, 67.2, 66.9, 65.5, 64.5, 62.2, 60.7, 55.6, 54.1, 20.9, 20.7, 20.7, 20.6 
(3 C), 20.4. HRMS: [M + Na]+ C109H114N2NaO35 calcd for 2033.7100, found 2033.7129. 
    Benzyl O-(3, 4, 6-tri-O-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl)-(1→
3)-[ 2, 3, 4, 6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→4)-3, 6-di-O-benzyl-2-deoxy-
acetamido-β-D-gluc-opyranosyl]-(1→6)-(4-O-acetyl-2-O-benzyl-β-D-galactopyrano-
syl)-(1→4)-2, 3, 6-tri-O-benzyl- β-D-glucopyranoside (2-25) 
    Following the general procedure (A), compound 2-24 (400 mg, 0.20 mmol) 
yielded the compound 2-25 (183 mg, 70% over two steps). [α]D20 = -2.0 (c 1.0, CH2Cl2). 
1H NMR (CDCl3, 400 MHz): δ 7.16-7.51 (m, 35 H), 5.20-5.36 (m, 2 H), 4.97-5.20 (m, 6 
H), 4.89-4.97 (m, 2 H), 4.69-4.89 (m, 8 H), 4.56-4.69 (m, 4 H), 4.29-4.56 (m, 7 H), 4.08-
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4.26 (m, 2 H), 3.41-4.04 (m, 20 H), 3.32-3.40 (m, 1 H), 3.23-3.31 (m, 1 H), 3.08-3.19 (d, 
J = 8.6 Hz, 1 H), 2.10 (s, 3 H), 2.09 (s, 3 H), 2.08 (s, 3 H), 2.04 (s, 3 H), 2.01 (s, 3 H), 
1.98 (s, 9 H), 1.92 (s, 3 H), 1.57 (s, 3 H); 13C NMR (D2O, 100 MHz): δ 171.0, 170.9, 170.6 
(2 C), 170.2, 170.0, 169.8, 169.7, 169.3 (2 C), 139.1, 139.0, 138.7, 138.5, 138.2, 137.9, 
137.4, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (2 C), 
127.6, 127.5, 126.6, 102.4, 102.0, 101.1, 100.0, 99.8, 82.9, 82.0, 79.9, 78.4, 78.2, 77.4, 
76.4, 75.5,  75.0, 74.8, 74.1, 73.7, 73.6, 73.3, 72.7, 72.3, 71.7, 71.0, 70.9, 70.4, 69.5, 
68.3, 67.9, 66.9, 66.7, 61.5, 60.8, 55.2, 54.3, 53.9, 20.9, 20.8 (2 C), 20.7 (2 C), 20.6 (3 
C), 20.50 (2 C). HRMS: [M + Na]+ C99H116N2NaO34 calcd for 1899.7307, found 1899.7357. 
    2-deoxy-acetamido-β-D-glucopyranosyl (1→3)-[β-D-galactopyranosyl-(1→
4)-2-deoxy-acetamido-β-D-glucopyranosyl]-(1 → 6)-β-D-galactopyranosyl-(1 → 4)-
α,β-D-glucopyranose (HMO3) 
    Following the general procedure (B) and (C), compound 2-25 (183 mg, 0.098 
mmol) yielded the compound HMO3 (85 mg, 95%). 1H NMR (D2O, 400 MHz): δ 5.14 (d, 
J = 3.8 Hz, 0.54 H, Glc-1 H-1 of α form), 4.54-4.63 (m, overlap with D2O,  2.46 H, GlcNAc-
1, GlcNAc-2, H-1, Glc-1 H-1 of β form), 4.39 (d, J = 7.8 Hz,  Gal-1, 1 H), 4.35 (d, J = 7.8 
Hz, Gal-1, 1 H), 4.06 (d, J = 3.1 Hz, 1 H), 3.82-3.95 (m, 4 H), 3.42-3.82(m, 22 H), 3.33-
3.42 (m, 2 H), 3.21 (t, J = 8.39 Hz, 1 H), 1.98 (s, 3 H), 1.96 (s, 3 H); 13C NMR (D2O, 100 
MHz): δ 174.9, 174.5, 103.0, 102.9, 102.8 (GlcNAc-1, GlcNAc-2, Gal-2, C-1), 101.0 (Gal-
1, C-1), 95.7 (Glc-1, C-1 of β form), 91.8 (Glc-1, C-1 of α form), 81.7, 79.0, 78.9, 78.4, 
75.7, 75.3, 74.7, 74.7, 74.4, 73.9, 73.6, 73.5, 72.5, 72.4, 71.0, 69.9, 69.7, 68.7, 68.6, 68.4, 
61.0, 60.5, 60.0, 55.7, 55.0, 22.4, 22.2. HRMS: [M + Na]+ C34H58N2NaO26 calcd for 
933.3175, found 933.3161. 
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HMO11   
    1H NMR (D2O, 500 MHz): δ 5.10(d, J = 3.5 Hz, 0.61 H, Glc-1 H-1 of α form), 
4.50-4.60 (m, 2.39 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.33-4.37 (m, 
2 H, Gal-2 H-1, Gal-3 H-1 ), 4.31 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.02 (d, J = 3.1 Hz, 1 H), 
3.78-3.79 (m, 6 H), 3.57-3.76 (m, 18 H), 3.53-3.57 (m, 2 H), 3.39-3.51 (m, 7 H), 3.17 (t, J 
= 8.3 Hz, 1 H), 1.94 (s, 3 H), 1.91 (s, 3 H). MALDI-MS: [M + Na]+ C40H68N2NaO31 calcd 
for 1095.370, found 1095.390. 
 
HMO12  
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.5 Hz, 0.51 H, Glc-1 H-1 of α form), 
4.50-4.58 (m, 2.49 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.36 (m, 
3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.03 (d, J = 3.0 Hz, 1 H), 3.38-3.91 (m,  47H), 3.17 
(t, J = 8.3 Hz, 1 H), 2.52-2.57 (m, 2 H), 1.97 (s, 3 H), 1.93 (s, 3 H), 1.91 (s, 6 H), 1.55-
1.63 (m, 2 H). ESI-MS: [M – 2H]2- C62H100N4O47 calcd for 826.2784, found 826.2760. 
 
HMO13  
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    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.7 Hz, 0.29 H, Glc-1 H-1 of α form), 
4.50-4.63 (m, 2.71 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.36 (m, 
3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.99 (s, 4 H), 3.38-3.91 
(m,  48 H), 3.18 (t, J = 8.3 Hz, 1 H), 2.52-2.60 (m, 2 H), 1.97 (s, 3 H), 1.93 (s, 3 H), 1.55-
1.65 (m, 2 H). ESI-MS: [M – 2H]2- C62H100N4O49 calcd for 842.2734, found 842.2760. 
HMO14  
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.5 Hz, 0.33 H, Glc-1 H-1 of α form), 
4.96-5.02 (m, 2 H, Fuc-1 H-1, Fuc-2 H-1), 4.50-4.61 (m, 2.67 H, GlcNAc-1 H-1, GlcNAc-
2 H-1, Glc-1 H-1 of β form), 4.28-4.36 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.01 (d, 
J = 3.1 Hz, 1 H), 3.63-3.91 (m, 25 H), 3.40-3.63 (m, 21 H), 3.35-3.39 (m, 2 H), 3.17 (t, J 
= 8.4 Hz,  1 H), 1.90-1.93 (d, J = 6.5 Hz, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd 
for 1387.487, found 1387.486. 
HMO15   
    1H NMR (D2O, 500 MHz): δ 5.15-5.22 (m, 2 H, Fuc-1 H-1, Fuc-2 H-1), 5.10(d, J 
= 3.5 Hz, 0.33 H, Glc-1 H-1 of α form), 4.45-4.61 (m, 2.67 H, GlcNAc-1 H-1, GlcNAc-2 H-
1, Glc-1 H-1 of β form), 4.39-4.45 (m, 2 H, Gal-2 H-1, Gal-3 H-1), 4.30 (d, J = 7.9 Hz, 1 
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H, Gal-1 H-1), 4.06-4.13 (m, 2 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.41-3.91 (m, 44 H), 3.30-
3.39 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.91 (s, 3 H), 1.09-1.11 (d, J = 6.7 
Hz, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd for 1387.487, found 1387.490. 
 
HMO16  
    1H NMR (D2O, 500 MHz): δ 5.12-5.18(m, 2 H, Fuc-2 H-1, Fuc-4 H-1), 5.10 (d, J 
= 3.5 Hz, 0.40 H, Glc-1 H-1 of α form), 4.93-5.01 (m, 2 H, Fuc-1 H-1, Fuc-3 H-1), 4.70-
4.78 (m, 2 H), 4.45-4.61 (m, 2.60 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 
4.35-4.41 (m, 2 H, Gal-2 H-1, Gal-3 H-1), 4.31 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.09-4.16 
(m, 2 H), 4.00 (d, J = 3.1 Hz, 1 H), 3.41-3.91 (m, 44 H), 3.28-3.38 (m, 2 H), 3.16 (t, J = 
8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 3 H), 1.10-1.15 (m, 12 H). MALDI-MS: [M + Na]+ 
C64H108N2NaO47 calcd for 1679.602, found 1679.607. 
HMO21  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.22 H, Glc-1 H-1 of α form), 
4.45-4.61 (m, 2.78 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.26-4.36 (m, 
2 H, Gal-1 H-1, Gal-2 H-1), 4.17-4.22 (m, 1 H), 4.09-4.16 (m, 2 H), 4.00 (d, J = 3.1 Hz, 1 
H), 3.36-3.90 (m, 32 H), 3.26-3.36 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.50-2.56 (m, 1 H), 
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1.92 (s, 3 H), 1.91 (s, 3 H), 1.89 (s, 3 H), 1.58 (t, J = 12.3 Hz,  1 H). ESI-MS: [M – H]- 
C45H74N3O34 calcd for 1200.4159, found 1200.4190. 
HMO22  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.27 H, Glc-1 H-1 of α form), 
4.47-4.62 (m, 2.73 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.35 (m, 
2 H, Gal-1 H-1, Gal-2 H-1), 4.06-4.16 (m, 1 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.99 (s, 2 H), 
3.38-3.90 (m, 33 H), 3.29-3.37 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.53-2.58 (m, 1 H), 1.93 
(s, 3 H), 1.92 (s, 3 H), 1.60 (t, J = 12.3 Hz, 1 H). ESI-MS: [M – H]- C45H74N3O35 calcd for 
1216.4108, found 1216.4129. 
HMO23  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.6 Hz, 0.36 H, Glc-1 H-1 of α form), 
5.00 (d, J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.46-4.60 (m, 2.64 H, GlcNAc-1 H-1, GlcNAc-2 H-1, 
Glc-1 H-1 of β form), 4.28-4.36 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.02 (d, J = 3.1 Hz, 1 H), 
3.40-3.90 (m, 31 H), 3.29-3.40 (m, 2 H), 3.16 (t, J = 8.4 Hz,  1 H), 2.50-2.56 (m, 1 H), 1.94 
(s, 3 H), 1.90 (s, 3 H), 1.05 (d, J = 6.7 Hz, 3 H). MALDI-MS: [M + Na]+ C40H68N2NaO30 
calcd for 1079.376, found 1079.371. 
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HMO24  
    1H NMR (D2O, 500 MHz): δ 5.19 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09 (d, J = 3.6 
Hz, 0.50 H, Glc-1 H-1 of α form), 4.46-4.60 (m, 2.50 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-
1 H-1 of β form), 4.42 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.31 (d, J = 8.0 Hz, 1 H, Gal-1 H-
1), 4.07-4.12 (m, 1 H), 4.01 (d, J = 3.1 Hz, 1 H), 3.41-3.90 (m, 28 H), 3.29-3.38 (m, 3 H), 
3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.10 (d, J = 6.5 Hz, 3 H). MALDI-
MS: [M + Na]+ C40H68N2NaO30 calcd for 1079.376, found 1079.379. 
 
HMO25  
    1H NMR (D2O, 500 MHz): δ 5.09(d, J = 3.9 Hz, 0.28 H, Glc-1 H-1 of α form), 
4.48-4.62 (m, 2.72 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.37 (m, 
3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.01 (d, J = 3.1 Hz, 1 H), 3.38-3.90 (m, 41 H), 3.17 
(t, J = 8.4 Hz,  1 H), 2.50-2.57 (m, 1 H),  1.93 (s, 3 H), 1.92 (s, 3 H), 1.90 (s, 3 H), 1.59 (t, 
J = 11.9 Hz, 1 H). ESI-MS: [M – H]- C51H84N3O39 calcd for 1362.4687, found 1362.4759. 
 
HMO26  
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    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.7 Hz, 0.51 H, Glc-1 H-1 of α form), 
4.50-4.63 (m, 2.49 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.37 (m, 
3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 2.9 Hz, 1 H), 3.99 (s, 2 H),  3.39-3.90 
(m, 41 H), 3.17 (t, J = 8.3 Hz,  1 H), 2.54-2.59 (m, 1 H),  1.94 (s, 3 H), 1.93 (s, 3 H), 1.61 
(t, J = 12.2 Hz, 1 H). ESI-MS: [M – H]- C51H84N3O39 calcd for 1378.4637, found 
1378.4660. 
HMO27   
    1H NMR (D2O, 500 MHz): δ 5.10 (d, J = 3.7 Hz, 0.55 H, Glc-1 H-1 of α form), 
5.00 (d, J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.69-4.74 (m, 1 H), 4.50-4.61 (m, 2.45 H, GlcNAc-1 
H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.38 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 
H-1), 4.02 (d, J = 2.9 Hz, 1 H), 3.34-3.91 (m, 32 H), 3.17 (t, J = 8.3 Hz,  1 H), 2.54-2.59 
(m, 1 H), 1.94 (s, 3 H), 1.90 (s, 3 H), 1.05 (d, J = 6.6 Hz, 3 H). MALDI-MS: [M + Na]+ 
C46H78N2NaO35 calcd for 1241.428, found 1241.432. 
 
HMO28  
     1H NMR (D2O, 500 MHz): δ 5.19 (d, J = 2.4 Hz, 1H, Fuc-1 H-1), 5.10 (d, J = 3.7 
Hz, 0.42 H, Glc-1 H-1 of α form), 4.48-4.60 (m, 2.58 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-
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1 H-1 of β form), 4.28-4.45 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.06-4.15 (m, 1 H), 
4.01 (d, J = 2.9 Hz, 1 H), 3.38-3.90 (m, 31 H), 3.31-3.37 (m, 1 H), 3.17(t, J = 8.8 Hz,  1 
H), 1.93 (s, 3 H), 1.91 (s, 3 H), 1.10 (d, J = 6.5 Hz, 3 H). MALDI-MS: [M + Na]+ 
C46H78N2NaO35 calcd for 1241.428, found 1241.423. 
HMO29  
    1H NMR (D2O, 500 MHz): δ 5.15 (d, J = 2.6 Hz, 1 H, Fuc-2 H-1), 5.09(d, J = 3.7 
Hz, 0.36 H, Glc-1 H-1 of α form), 4.99 (d, J = 3.7 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 
4.46-4.61 (m, 2.64 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.42 (d, J = 7.8 
Hz, 1 H, Gal-2 H-1), 4.31 (d, J = 8.0 Hz, 1 H, Gal-1 H-1), 4.10-4.16 (m, 1 H), 4.01 (d, J = 
2.9 Hz, 1 H), 3.40-3.92 (m, 33 H), 3.29-3.37 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 
H), 1.90 (s, 3 H), 1.09-1.16 (m, 6 H). MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 
1225.433, found 1225.438. 
HMO210  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.6 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.5 
Hz, 0.40 H, Glc-1 H-1 of α form), 4.93-5.01 (m, 2 H, Fuc-1 H-1, Fuc-3 H-1), 4.67-4.79 (m, 
2 H), 4.45-4.61 (m, 2.60 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.26-4.41 
(m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.09-4.16 (m, 1 H), 4.00 (d, J = 3.1 Hz, 1 H), 
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3.41-3.91 (m, 44 H), 3.28-3.40 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 
3 H), 1.02-1.17 (m, 9 H). MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 1533.544, found 
1533.538. 
HMO211  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.7 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.7 
Hz, 0.47 H, Glc-1 H-1 of α form), 4.99 (d, J = 3.7 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 
4.49-4.62 (m, 2.53 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.41 (m, 
3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.01 (d, J = 3.2 Hz, 1 H), 3.77-
3.91 (m, 8 H), 3.39-3.77 (m, 35 H), 3.30-3.36 (m, 1 H), 3.17 (t, J = 8.4 Hz,  1 H), 1.94 (s, 
3 H), 1.90 (s, 3 H), 1.09-1.16 (m, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd for 
1387.486, found 1387.490. 
HMO31   
    1H NMR (D2O, 500 MHz): δ 5.09(d, J = 3.7 Hz, 0.31 H, Glc-1 H-1 of α form), 
4.47-4.58 (m, 2.69 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.34 (m, 
2 H, Gal-1 H-1, Gal-2 H-1), 4.06-4.16 (m, 1 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.28-3.91 (m, 35 
H), 3.26-3.36 (m, 2 H), 3.18 (t, J = 8.4 Hz,  1 H), 2.51-2.57 (m, 1 H), 1.96 (s, 3 H), 1.92 
(s, 3 H), 1.91 (s, 3 H), 1.59 (t, J = 12.2 Hz,  1 H). ESI-MS: [M – H]- C45H74N3O34 calcd for 
1200.4159, found 1200.4122. 
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HMO32   
     1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.9 Hz, 0.28 H, Glc-1 H-1 of α form), 
4.50-4.58 (m, 2.72 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.34 (m, 
2 H, Gal-1 H-1, Gal-2 H-1), 4.02 (d, J = 3.2 Hz, 1 H), 3.28-3.91 (m, 35 H), 3.18 (t, J = 8.3 
Hz,  1 H), 2.53-2.58 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 3 H), 1.59 (t, J = 12.2 Hz,  1 H). ESI-
MS: [M – H]- C45H74N3O35 calcd for 1216.4108, found 1216.4139. 
 
HMO33  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.7 Hz, 0.19 H, Glc-1 H-1 of α form), 
4.98 (d, J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.66-4.73 (m, 1 H), 4.48-4.58 (m, 2.81 H, GlcNAc-1 
H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.27-4.35 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.02 
(d, J = 3.1 Hz, 1 H), 3.28-3.90 (m, 38 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.92 (s, 3 H), 1.90 (s, 
3 H), 1.04 (d, J = 6.6 Hz,  3 H). MALDI-MS: [M + Na]+ C40H68N2NaO30 calcd for 1079.376, 
found 1079.380. 
HMO34  
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    1H NMR (D2O, 500 MHz): δ 5.18 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09(d, J = 3.9 
Hz, 0.41 H, Glc-1 H-1 of α form), 4.66-4.73 (m, 1 H), 4.45-4.58 (m, 2.59 H, GlcNAc-1 H-
1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.39-4.44 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.31 (d, 
J = 7.5 Hz, 1 H), 4.06-4.12 (m, 2 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.39-3.90 (m, 28 H), 3.28-
3.38 (m, 3 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.11 (d, J = 6.7 Hz, 3 
H). MALDI-MS: [M + Na]+ C40H68N2NaO30 calcd for 1079.376, found 1079.372. 
HMO35  
1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.53 H, Glc-1 H-1 of α form), 4.51-
4.60 (m, 2.47 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.37 (m, 3 H, 
Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.38-3.91 (m, 41 H), 3.18 (t, 
J = 8.4 Hz,  1 H), 2.50-2.57 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 6 H), 1.59 (t, J = 12.0 Hz,  1 
H). ESI-MS: [M – H]- C51H84N3O39 calcd for 1362.4687, found 1362.4799. 
HMO36  
1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.52 H, Glc-1 H-1 of α form), 4.50-
4.60 (m, 2.48 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.38 (m, 3 H, 
Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.02 (d, J = 3.0 Hz, 1 H), 3.99 (s, 2 H),  3.38-3.91 (m, 
41 H), 3.18 (t, J = 8.4 Hz,  1 H), 2.53-2.59 (m, 1 H), 1.96 (s, 3 H), 1.91 (s, 3 H), 1.59 (t, J 
= 12.0 Hz,  1 H). ESI-MS: [M – H]- C51H84N3O39 calcd for 1378.4637, found 1378.4609. 
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HMO37  
    1H NMR (D2O, 500 MHz): δ 5.09 (d, J = 3.8 Hz, 0.34 H, Glc-1 H-1 of α form), 
4.98 (d, J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.67-4.74 (m, 1 H), 4.50-4.61 (m, 2.66 H, GlcNAc-1 
H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.27-4.38 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 
H-1), 4.01 (d, J = 3.1 Hz, 1 H), 3.30-3.90 (m, 37 H), 3.16 (t, J = 8.6 Hz,  1 H), 1.92 (s, 3 
H), 1.91 (s, 3 H), 1.05 (d, J = 6.6 Hz,  3 H). MALDI-MS: [M + Na]+ C46H78N2NaO35 calcd 
for 1241.428, found 1241.436. 
HMO38  
    1H NMR (D2O, 500 MHz): δ 5.18 (d, J = 2.6 Hz, 1 H, Fuc-1 H-1), 5.09 (d, J = 3.8 
Hz, 0.69 H, Glc-1 H-1 of α form), 4.46-4.60 (m, 2.31 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-
1 H-1 of β form), 4.28-4.43 (m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.07-4.13 (m, 1 H), 
4.02 (d, J = 3.2 Hz, 1 H), 3.39-3.89 (m, 36 H), 3.33-3.38 (m, 1 H), 3.17 (t, J = 8.4 Hz,  1 
H), 1.94 (s, 3 H), 1.91 (s, 3 H), 1.11 (d, J = 6.5 Hz, 3 H). MALDI-MS: [M + Na]+ 
C46H78N2NaO35 calcd for 1241.428, found 1241.435. 
HMO39  
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    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 2.9 Hz, 1 H, Fuc-2 H-1), 5.10(d, J = 3.7 
Hz, 0.39 H, Glc-1 H-1 of α form), 4.97 (d, J = 4.0 Hz, 1 H, Fuc-1 H-1), 4.72-4.78 (m, 1 H), 
4.45-4.58 (m, 2.61 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.40 (m, 
2 H, Gal-1 H-1, Gal-2 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.06 Hz, 1 H), 3.40-3.93 (m, 
33 H), 3.29-3.38 (m, 3 H), 3.16(t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.91 (s, 3 H), 1.08-1.17 
(m, 6 H). MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 1225.433, found 1225.430. 
HMO310  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 3.0 Hz, 1 H, Fuc-3 H-1), 5.09 (d, J = 3.7 
Hz, 0.62 H, Glc-1 H-1 of α form), 4.96-5.01 (m, 2 H), 4.69-4.78 (m, overlap with D2O, 2 
H), 4.47-4.61 (m, 2.38 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.28-4.40 
(m, 3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.2 Hz, 1 H), 
3.32-3.93 (m, 43 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.93 (s, 3 H), 1.90 (s, 3 H), 1.02-1.17 (m, 
9 H). MALDI-MS: [M + Na]+ C46H78N2NaO34 calcd for 1533.544, found 1533.550. 
HMO311  
    1H NMR (D2O, 500 MHz): δ 5.16 (d, J = 3.2 Hz, 1 H, Fuc-2 H-1), 5.10 (d, J = 3.6 
Hz, 0.67 H, Glc-1 H-1 of α form), 4.97 (d, J = 3.9 Hz, 1 H, Fuc-1 H-1), 4.72-4.77 (m, 1 H), 
4.47-4.60 (m, 2.37 H, GlcNAc-1 H-1, GlcNAc-2 H-1, Glc-1 H-1 of β form), 4.29-4.39 (m, 
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3 H, Gal-1 H-1, Gal-2 H-1, Gal-3 H-1), 4.10-4.16 (m, 1 H), 4.02 (d, J = 3.1 Hz, 1 H), 3.39-
3.93 (m, 41 H), 3.30-3.38 (m, 1 H), 3.16 (t, J = 8.4 Hz,  1 H), 1.94 (s, 3 H), 1.91 (s, 3 H), 
1.09-1.17 (m, 6 H). MALDI-MS: [M + Na]+ C52H88N2NaO39 calcd for 1387.486, found 
1387.478. 
This chapter is under review by Journal of Organic Chemistry of American 
Chemical Society. 
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3. Glycosylation of Protein-based Magnetic Resonance Imaging Contrast Agents  
3.1 Introduction 
Magnetic resonance imaging (MRI) is a promising imaging technique that provides 
three dimensional images of organs and structures inside the body by exploiting the 
magnetic properties of water hydrogens and their interactions with an external magnetic 
field. Besides, MRI is a noninvasive technique which has limited side-effects and does 
not require the use of radioactive probes. Owing to these advantages, MRI has become 
one of the most prevalent imaging modalities in clinical and preclinical tests. MRI also 
may show problems that cannot be seen with other imaging methods. It has broad 
applicability in diagnosing and following the treatment of different types of cancers and 
other human diseases, including various cardiovascular diseases, liver diseases, and 
neurodegenerative disorders.1-9 
In addition to its superior soft tissue contrast, MRI also has high resolution 
(approximately 50–100 μm) but relatively low sensitivity. To enhance the contrast and 
sensitivity of imaging, 35% of clinical MRI scans require the injection of Gd3+-based 
(where Gd3+ is gadolinium) MRI contrast agents.10 Current MRI contrast agents are based 
on paramagnetic, ferromagnetic, or super paramagnetic metal ions.  
Currently, clinically approved Gd3+-based MRI contrast agents are formed by one 
Gd3+ ion encapsulated by organic chelators, such as diethylene triamine pentaacetic acid 
(DTPA), 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and their 
derivatives.11-16 Figure 3.1 showed some examples of clinical MRI contrast reagents. 
There are eight nitrogen and oxygen from the chelator binding as Gd3+ ion ligands. In 
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addition, Gd3+ ion in clinical MRI contrast agents coordinated with one water molecule 
through robust Gd–O interactions.  
 
Figure 3.1. Examples of Clinical Gd3+-Based MRI Contrast Agents. 
 
Even if current clinical MRI contrast agents carry many advantages, their shortage 
is also obvious. Clinical contrast agents have a shorter half-life time for approximately 
0.5–3 min in the blood vessels of mice and 1.5 hours in patients, due to their small 
molecular mass.17, 18 Optimizing half-life and pharmacokinetic/ pharmacodynamic 
(PK/PD) properties of these contrast agents would lengthen the time window for MRI data 
collection and eliminate repeated dose injections. The Food and Drug Administration 
(FDA) approved contrast agents have poor organ specificity and no targeting capability. 
Injection of targeted protein based contrast agent can vastly improve diagnosis 
capabilities using MRI by increasing the image enhancement of the specified area, 
increasing relaxivity, rotational correlation time, and having better retention. Jenny 
developed a new generation of protein-based MRI contrast agents with longer half-life 
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time, higher resolution and sensitivity.19 The protein, namely ProCA1, could binding to 
Gd3+ by using amino acid residues as metal coordinating ligands. (Figure 3.2) 
Hepatocellular carcinoma (HCC) is one of the most common cancers around the 
world. Symptoms and signs of HCC include abdominal pain, swelling and weakness, loss 
of appetite, jaundice, fever, or enlargement of liver, which mainly arise in the later stages 
of cancer making early detection or screening highly demanded because the five-year 
survival rate for liver cancer is currently 15%. Early detection could dramatically increase 
the five-year survival rate to 60-70% with liver transplant. Treatment options for patients 
include liver resection or liver transplant depending on the level of cirrhosis in the liver. 
Early detection is key for increasing disease-free survival rates for patients diagnosed 
with this disease. 
 
Figure 3.2. A model structure of ProCA1 with Gd3+ and relaxivity value r1 and r2 of 
ProCA1 
(Left) Gd3+ (purple sphere) chelated by oxygen ligand residues E15, D56, D58, D62 and 
D64. Exchangeable waters (red spheres) are from inner sphere, protein surface and hydration 
water from added glycosylation chain. (Right) Relaxivity value r1 and r2 of ProCA1 are 14 - 30 fold 
greater than clinical approved liver contrast agents at 25 oC. The stability constant for Gd of 
ProCA3 is comparable with DTPA but with 100 to 1011 fold greater metal selectivity and kinetic 
stability than DTPA for physiological metal ions such as Zn2+, Mg2+ and Ca2+.  
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The asialoglycoprotein receptor (ASGPR) is located on hepatocytes and is a Ca2+-
dependent carbohydrate binding protein, or C-type lectin. It is expressed on mammalian 
liver cells.20 The main function is to maintain serum glycoprotein homeostasis by the 
recognition, binding, and endocytosis of asialoglycoproteins (ASGPs), which is 
desialylated glycoproteins with terminal Gal or GalNAc residues. After internalization via 
clathrin-coated pits and their fusion with endosomes, the ASGPs are released in the 
acidic environment of the endosome and transported to lysosomes for degradation, while 
the receptor is recycled back to the cell surface.21, 22 Baenzinger have shown that the 
human receptor exhibits specificity for terminal Gal and GalNAc on desialylated 
glycoproteins.23, 24 Triantennary ligands displayed a higher affinity than their mono- and 
diantennary counterparts. Furthermore, the studies led to the conclusion that only the 
terminal residues are necessary for specific recognition, and that the binding process 
proceeds through a simultaneous interaction of 2-3 sugar residues with 2–3 binding sites 
of the heterooligomeric receptor. On the native receptor on the hepatocyte surface these 
binding sites are 25–30 Å apart. 
Lee further reinforced the binding hierarchy of polyvalent ligands: tetraantennary > 
triantennary >> diantennary >> monoantennary by studies on rabbit hepatocytes using 
synthetic oligosaccharides,.25, 26 The IC50-values from monoantennary to tetraantennary 
oligosaccharides were found to be approximately 1 × 10-3, 1 × 10-6, 5 × 10-9 and 1 × 10-9 
M, respectively. In other words, the inhibitory potency increased 1× 106 -fold although the 
number of Gal residues of ligand increased only 4-fold.   Since the fourth Gal moiety on 
the tetraantennary ligand does not markedly increase the affinity, it was assumed that the 
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binding requirements of the cell-surface receptor are largely satisfied by the triantennary 
structure. 
3.2 Results and Discussion 
In the collaboration program with Jenny’s group, we have recently developed an 
asialoglycoprotein receptor (ASGPR)-targeted protein contrast agent lactose-ProCA1 by 
modifying ProCA1 with a lactose moiety. We have achieved the first observation of 
significant liver MRI enhancement and retention via tail vein injection of lactose-ProCA1, 
which is consistent with high liver expression of ASGPR.27 The goals of this research are 
to develop targeted ProCAs to enable accurate monitoring of the expression and 
distribution of lectins and glycans in living animals and cancer models.  
 
Figure 3.3. Binding model for ASGPR ligands in an optimal conformation to the 
heterooligomeric receptor. 
89 
  
Synthesis and Evaluation of Lactose Conjugated Protein 
The glycosylation of ProCA1 was performed with Lactose NHS donor. The major 
advantages of this method includes: 1. NHS active ester is easy to achieve with 
TSTU/Et3N condition; 2. The active ester carries high reactivity and it could quickly couple 
with amine groups on small molecules as well as macromolecules, including protein and 
DNA; 3. No coupling reagent is needed, which simplifies purification process.  In order to 
achieve lactose-ProCA1 conjugate, the details of synthesis was showed in Scheme 3.1.  
 
Scheme 3.1. Chemical Synthesis of Lac-rProCA1. 
 
To functionalize lactose moiety, an amine group need to be installed at the 
reducing end. The Kochetkov reaction assisted with microwave irradiation was used to 
furnish compound 3-2. The lactose 3-1 was mixed with 15 eq. of ammonium carbonate in 
dry DMSO and mixture was radiated at 30-40 °C for 4 hours. Compound 3-2 was 
furnished at a yield of 85%. After eliminating excess ammonium carbonate, the solution 
was used for next step reaction without further purification. Compound 3-2 and 4-tert-
Butoxy-4-oxobutanoic acid were coupled to form compound 3-3 smoothly with treatment 
of HATU and HOBt under basic condition.  Then deprotection of t-butyl group of 3-3 using 
TFA/Anisole condition to provide compound 3-4 in 90% yield. To transform 3-4 to NHS 
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active ester 3-5, O-(N-Suc-cinimidyl)-1, 1, 3, 3-tetramethyl-uronium tetrafluoroborate 
(TSTU) was used as a coupling reagent under basic condition to achieve a yield of 80%, 
with a mild amount of decomposed byproduct, which will not affect the following 
conjugation with proteins. 
With these NHS Lactose linkers ready, we started investigating the coupling 
reaction with proteins. The glycosylation of ProCA1 was performed in PBS buffer solution 
with PH=7.0. In the neutral condition, conjugation could proceed smoothly and hydrolysis 
of active ester could be inhibited well, which extend the coupling time and increase 
coupling yield. We tested various ratio of Lactose to ProCA1 from 10:1 to 100:1. It was 
found the coupling efficiency is not very high, and majority of NHS lactose linkers was 
hydrolyzed in buffer solution. Therefore, we have to set the NHS lactose linkers: ProCA1 
as high as 100: 1 in order to get full glycosylated proteins. (Figure 3.4) One of the reasons 
accounting for this might be that the linker is too short to make it more difficult to interact 
with amine on the protein. In order to achieve higher coupling efficiency, design and 
synthesis of longer linkers is necessary.  
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Figure 3.4. Glycosylation of rProCA1. 
 
 
Glycosylation of ProCA1 for Improved Stability and Targeting 
Serum stability studies for rProCA1 and Lac-rProCA1 were conducted. In this 
study, previously obtained human serum was used and described in Figure 3.5 for the 
studies of rProCA1 without and with lysine modification. In this figure, ProCA1 without 
modification (Figure 3.5a) is stable up to 2 days; however, ProCA1 with glycosylation 
(Figure 3.5b) it has been found to be stable in human serum up to 6 days. These results 
clearly proved that Glycosylation could significantly improve the stability of proteins in 
vitro.  Glycosylation is a promising way to increase half-life time of many therapeutic 
proteins.  
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Figure 3.5. Serum Stability of rProCA1 and Lac-rProCA1 
 
MRI of rProCA1 without modification was performed and the results of this 
experiment is shown below in Figure 3.6a. In this figure, slight contrast is seen 30 minutes 
and 3 hours after injection of the contrast agent; however, in comparison to lactose 
modified ProCA1-PEG, the intensity of the contrast is drastically increased (Figure 3.6b). 
The biodistribution of Lac-rProCA1 has obviously changed and and uptake of the contrast 
agent can be seen in the liver region, but not in the kidney. This exciting discovery of 
Glyco-rProCA1clearance through the liver provides capability of assigning any possible 
tumors in the liver. 
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Figure 3.6. MR images of CD1 mouse with injection of rProCA1 and Lac-rProCA1. 
 
The comparison of contrast to noise ratio in Figure 3.7a clearly summarizes the 
impact of lysine modification on ProCA improving relaxivity in both the liver and kidney 
regions of interest, ROI, for Glyco-rProCA1 which in turn increases signal intensity. Signal 
is measured as a mean in the ROI and contrast is found by looking at the difference of 
the signal in two regions. Contrast to noise ratio is created by differences in the signal 
and noise in the ROI. In the Lac-ProCA1 shows greater uptake in the liver three hours 
after injection rather than the kidney. Lac-rProCA1 contains not only hydrophilic 
characteristics, but also a lactose targeting moiety which could bind to ASGPR in the liver. 
This targeting moiety and its interaction with ASGPR is pertinent for excretion out the liver 
rather than the kidney region. 
ICP-OES can be used to detect gadolinium concentration in specific organs. This 
is an analytical technique that excites atoms and ions to detect emission at wavelengths 
that are specific to an element. The detection of gadolinium in organs indicates the 
distribution of lysine modified and non-modified ProCA1. The results of this are shown in 
Figure 3.7b.  
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This results makes it clear that Lac-ProCA1 shows an uptake in the liver in order 
to confirm the biodistribution to the liver. It is interesting to note the uptake of the contrast 
agents in other regions of the body indicative of a possible whole body imaging capability 
to aid in the detection of targeted carcinomas using the modified contrast agent. 
 
Figure 3.7. MRI contrast of Lac-rProCA1 in mice 
 
3.3 Conclusion 
Overall, these results demonstrated that our strategy has led to the achievement of 
lactose conjugated ProCA1 with intacted biological activity and will provide us valuable 
experience for the future glycoprotein synthesis. These results about serum stability 
clearly proved that glycosylation could significantly improve the stability of proteins in 
vitro.  Glycosylation is a promising way to increase half-life time of many therapeutic 
proteins. Besides, the liver enhancement by Lac-rProCA1 is significantly higher than 
ProCA1, which proved its strong targeting capability to ASGPR. Lac-rProCA1 is a good 
candidate for regional contrast agent targeting liver.  
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3.4 Experimental Section 
Compound 3-3 
Compound 3-3 (400 mg) and ammonium carbonate (5 g) were dissolved in 20 mL 
DMSO and stirred with microwave tube at 40 °C for 3 hours. TLC showed major lactose 
was transformed to compound 3-2. The excess ammonium carbonate was then removed 
under reduced pressure and the mixture was used for next step’s reaction without further 
purification.   
HATU (889mg, 1.17 mmol), HOBt (315 mg, 1.17 mmo l) and DIPEA (0.81 mL, 4.68 
mmol) were sequentially added to the solution of 3-2 in DMSO.  The reaction mixture was 
stirred at room temperature under nitrogen atmosphere for 24 hours. The solvent was 
removed under reduced pressure. The crude product was purified by C18 reverse phase 
flash chromatography using 0-100% MeOH in water as eluent to afford compound 3-3 as 
white solid (441 mg, 76% over two steps). 1H NMR (D2O, 400 MHz): δ 4.90 (d,J = 9.24 
Hz,1 H), 4.38 (d, J = 7.76 Hz,1 H), 3.86-3.83 (m, 2 H), 3.74 (t, 1 H), 3.71 (t, 1 H),3.69 (m, 
2 H), 3.66-3.57 (m, 5 H), 3.47 (dd, 1 H), 3.36 (m, 1 H), 2.73 (s,1 H), 2.64 (s, 1 H),2.52 (s, 
2 H), 1.36 (s, 9 H). 13C NMR (100 MHz, D2O): δ 176.13, 174.22, 102.87, 82.83, 76.26, 
75.09, 70.94, 68.56, 61.05, 59.88, 59.87, 38.72, 38.00, 30.33, 30.24, 27.18. HRMS: [M + 
Na]+ C20H35NNaO13 calcd for 520.2006, found 520.2026. 
 
Compound 3-4 
Compound 3-3 (200 mg, 0.40 mmol) was added to TFA : DCM : Anisole=4: 1 : 0.2 
with two portions at 0 °C. After stirring for 3 hours at 0 °C, the solution was evaporated 
under reduced pressure. The residue 3-4 (159 mg, 90%)was used for next step’s reaction 
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without further purification. 1H NMR (D2O, 400 MHz): δ 4.88 (d, J = 9.20 Hz, 1 H), 4.35 
(d, J = 7.76 Hz,1 H), 3.84-3.81 (m, 2 H), 3.73-3.66 (m, 4 H), 3.63-3.55 (m, 5 H), 3.45 (t, 1 
H), 3.34 (t, 1 H), 2.61-2.54 (m, 4 H). 13C NMR (100 MHz, D2O): δ 176.90, 176.05, 102.85, 
79.09, 75.03, 71.46, 68.53, 61.02, 59.86, 30.10, 28.69. HRMS: [M - H]- C16H26NO13 calcd 
for 440.1410, found 440.1423. 
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4. Design and Synthesis of Glycoprotein Antigens for Immunotherapy 
4.1 Introduction 
Antibody, also known as immunoglobulin, is a large, Y-shaped protein that is used by 
the immune system to identify and neutralize abnormal cells and pathogens through 
strong interaction with specific antigens, including carbohydrate antigens. Antibody is 
secreted by B cells of the adaptive immune system and it is essential for humoral 
immunity. For instance, numerous studies have demonstrated that increasing the 
production of antibodies can facilitate exterminating cancel cells.1, 2 This attractive effect 
suggested a potential antibody approach to cancer immunotherapy. 
Tumor associated carbohydrate antigens (TACAs) have close relationship with the 
aberrant glycosylation in essentially all tumor cells. There are many TACAs identified and 
characterized by antibodies and lectins, including Globo-H, GM2, GD3, Tn, Tf and STn. 
To date, a few TACA based anti-cancer vaccine have been reported in clinical trials. 
These include Globo-H for prostate cancer,3 GM2 and GD3 for melanoma,4, 5 and STn for 
breast cancer.6 Clinical studies proved that administration of these carbohydrate based 
vaccine actively induced their corresponding antibodies, which in turn suppress tumor 
cells. Based on previous achievements, vaccine development can be applied to any other 
TACAs. Recent development of novel vaccine, such as multivalent unimolecular and 
multi-component vaccine, through conjugation with strong immunogenic carrier such as 
KLH and CRM197 not only increase the antibody response, but also diversifies the 
antibody production. 
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Despite these improvements, current tumor associated antigen based vaccines show 
poor immunogenic effect because of low uptake by antigen-presenting cell (APC). The 
formation of immune complexes is one of the pre-requisites to design vaccines targeting 
APC. α-Gal is the most well-known carbohydrate epitope, which could interacts 
specifically with anti-Gal antibody, contributing 1% of serum lgGs in humans. Previous 
studies has demonstrated that immunogenicity of any microbial vaccine can be markedly 
increased by α-gal epitopes due to in vivo formation of immune complexes with anti-Gal 
antibody existing on APC.7 
 
 
Figure 4.1. Carbohydrate antigen/Antibody-directed vaccine design 
 
Lampreys are primitive jawless vertebrates capable of eliciting specific immune 
responses. Compared with T and B cells of jawed vertebrates, different types of 
lymphocytes could be produced by lampreys, which in turn express somatically diversified 
antibodies, namely variable lymphocyte receptors (VLRs). Evolutionarily, VLRs are the 
oldest adaptive immune receptors.8, 9 There are three distinct antibodies produced by 
lampreys. T-like lymphocytes express and secrete VLRA; VLRB as a multivalent protein 
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is expressed on the surface of B-like lymphocytes; VLRC is expressed by a distinct 
lymphocyte lineage.  VLRs are the only natural antigen receptors to use a non-Ig scaffold, 
which are alternatives to antibodies in applications such as bioimaging, biosensors and 
biopurification.10-12 Site-directed mutagenesis has confirmed the prediction of antigen 
binding through the concave surface residues of VLRs,13 which was also elucidated 
precisely by the structures of recombinant VLRB antibodies in complex with antigens of 
both H-antigen trisaccharide and hen egg white lysozyme (HEL).14, 15 The crystal structure 
of VLRB in complex with the H-trisaccharide has provided structural insight into how VLRs 
recognize their antigens and provides a basis for rational design and modification of other 
antigen-specific VLRs. 
4.2 Carbohydrate antigens based vaccine for activating VLRs in Lampreys 
As long as H-antigen has been identified by previous study, our collaborator, Max 
from Emory University, shows strong interest to develop a novel vaccine targeting VLRs. 
Targeting the vaccine to VLRs through antibody-mediated pathway requires installation 
of carbohydrate antigen on vaccines. Taking advantage of our expertise in carbohydrate 
synthesis, especially chemical and chemoenzymatic synthesis of blood group and α-Gal, 
we are currently developing an efficient strategy to chemically conjugate carbohydrate 
antigens, including O-antigen and α-Gal to carrier proteins. O-antigen is structurally 
similar to H-antigen, so we choose O-antigen as a substitute for H-antigen. These 
synthetic glycoproteins will be subjected to immunogenic studies using lampreys.  
4.3 Design and synthesis of glycoproteins 
The synthesis of glycoprotein by chemical ligation usually consists of two steps 
(Scheme 5.2): (a) Installation of a spacer on sugar moiety; (b) Conjugation of 
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carbohydrate with carrier protein. Several methods have been employed for introducing 
functional spacer on oligosaccharides (Scheme 3-1). Chemical glycosylation has been 
widely employed in the first to install the varied spacers, and has successfully provided 
carbohydrate building blocks for second step. Reductive amination is one of the most 
efficient ways to introduce linkers to the reducing end of the free carbohydrate. While, this 
method would produce open-ring sugar moiety at reducing end and requires reducing 
agent, thus limits its application. Oxime ligation is an alternative way to achieve this goal 
efficiently by introducing stable oxime bond catalyzed by aniline.16 Direct amination by 
Kochetkov reaction is also a very simple and versatile way to install linkers to reducing 
end of sugars. 
 
Scheme 4.1. Chemical Ligation of Glycoproteins 
 
 
In general, there are two approaches to achieve glycoproteins: (1) indiscriminate 
glycosylation, which targets available amines on the protein, typically those of lysine 
residues, and (2) site-selective glycosylation, targeting the thiol groups of cysteine 
residues.  Scheme 4.2 demonstrated some most popular chemical conjugation methods 
of glycoproteins.17, 18  Among these methods, the Huisgen 1,3-dipolar cycloaddition (a) 
and oxime ligation (b) require the installation of artificial groups on the proteins, which 
limit their implication. Michael addition reaction in (e) and (f) is typically site-selective 
glycosylation which requires free thiol groups on lysine residue. Normally, there are very 
limited thiol groups on the surface of proteins as most of them have been reduced to 
102 
construct disulfite bonds. Diethyl squarate coupling (c) requires long reaction time and 
highly basic condition, which also restricts its application. N-hydroxysuccinimide ester 
(NHS) activation (d) is widely used for specific, efficient and permanent ligation to primary 
amines on lysine residues. This method is suitable for adding various molecules, including 
small molecules and PEG, under mild condition. However, the major drawback of this 
method is that NHS ester could be hydrolyzed quickly in acquis condition.  
 
Scheme 4.2. Chemical Synthesis of Glycoprotein 
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In this study, we take advantage of chemical glycosylation and direct amination for 
installation of functionalized spacers (step a), and NHS activation chemistry for 
glycoprotein synthesis (step b).   
4.3.1 Synthesis of α-Gal conjugated proteins 
The synthesis of α-Gal building block was started from chemical glycosylation of 
trichloroacetimidate donor 4-2 with linker 4-3 to harvest compound 4-4, which was 
catalyzed by TMSOTf. 4-4 was globally deprotected by NaOMe and H2 catalyzed by 
Pd(OH)2/C condition to furnish compound 4-5, which was served as substrate for 
enzymatic synthesis of α-Gal building block 4-6. Following our well-established procedure, 
one galactose could be specifically added to 3’-OH of 4-5 to produce compound 4-6, 
which was catalyzed by α1,3-GalT with an excellent yield. (Scheme 4.3) 
 
Scheme 4.3 Chemoenzymatic Synthesis of α-Gal Linker 
 
With compound 4-6 in hand, we could readily convert it to NHS ester by coupling 
amine group with linker 4-7 under basic condition to achieve α-Gal NHS ester 4-8, which 
was subjected to couple with Biotin-BSA or ovalbumin (OVA) in PBS buffer solution 
(Scheme 4.4). Both linkers and proteins were prepared at concentrations of 10 mg/mL in 
1x PBS buffer, and then were mixed at 1:1 (v/v) ratio. The reaction was carried out at 
room temperature for 24 hours.  After ultrafiltration to remove the u nreacted linkers with 
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cut-off at 10 kDa, the collected protein was analyzed by SDS-PAGE. It clearly showed 
the successful conjugation from SDS gel (Figure 4.2A & 4.3A). MALDI-TOF was also 
used to analyze the α-Gal-protein conjugates (Figure 4.2B & 4.3B). From the results, we 
can clearly check the molecular weight of glycoproteins as well as loading ratio of sugar 
moiety.  
 
Scheme 4.4 Preparation of α-Gal Proteins 
 
 
Figure 4.2. Characterization of α-Gal Biotin BSA 
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Figure 4.3. Characterization of α-Gal OVA 
4.3.2 Synthesis of H-antigen conjugated proteins 
After achieving α-Gal-proteins, we attempted to follow the same method to synthesize 
O-antigen linker, but it did not work well. WbsJ could not transfer efficiently Fucose moiety 
to 2’-OH of compound 4-5 (yield<10%), even though there was minor product detected 
by mass spectra (Scheme 4.5A). Therefore, we have to synthesize free H-antigen with 
WbsJ first, then install the linker to H-antigen (Scheme 4.5B). 
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Scheme 4.5 Preparation of H Antigen Proteins 
 
To functionalize lactose moiety, an amine group need to be installed at the 
reducing end. The Kochetkov reaction assisted with microwave irradiation was used to 
furnish compound 4-2. The lactose 4-1 was mixed with 15 eq. of ammonium carbonate in 
dry DMSO and mixture was radiated at 30-40 °C for 4 hours with a yield of (70%). After 
eliminating excess ammonium carbonate, the solution was used for next step reaction 
without further purification. Compound 4-2 and PEG linker 4-11 were coupled smoothly 
with treatment of HATU and HOBt under basic condition, followed by deprotection of 
Fmoc group using piperidine/DMF condition to provide compound 4-12. 4-12 and 4-7 
were coupled under mild condition with treatment of trimethylamine to furnish NHS ester 
4-13, which was subjected to couple with Biotin-BSA or ovalbumin (OVA) in PBS buffer 
solution. The purification process is the same with that of α-Gal-proteins. SDS-PAGE and 
MALDI-TOF were utilized to analyze the H-antigen-proteins (Figure 4.5 & 4.6). 
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Figure 4.4. Characterization of H Antigen Biotin BSA 
 
 
Figure 4.5. Characterization of H Antigen OVA 
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4.4 Conclusion 
Carbohydrate antigens based vaccines for activating VLR antibodies in lampreys 
have been synthesized. The multivalent H antigen glycoproteins are promising vaccine 
candidates to elicit immune response in lampreys’ unique immune system.   Further 
biological tests are needed to validate this novel vaccine design. 
4.5 References 
1. Livingston, P. O.; Wong, G. Y.; Adluri, S.; Tao, Y.; Padavan, M.; Parente, R.; Hanlon, 
C.; Calves, M. J.; Helling, F.; Ritter, G.; et al., Improved survival in stage III melanoma patients 
with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology 1994, 12, 
1036-44. 
2. MacLean, G. D.; Miles, D. W.; Rubens, R. D.; Reddish, M. A.; Longenecker, B. M., 
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic 
breast cancer by pretreatment with low-dose intravenous cyclophosphamide. Journal of 
immunotherapy with emphasis on tumor immunology : official journal of the Society for 
Biological Therapy 1996, 19, 309-16. 
3. Slovin, S. F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; 
Bornmann, W. G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K. O.; Livingston, P. O.; 
Danishefsky, S. J.; Scher, H. I., Carbohydrate vaccines in cancer: immunogenicity of a fully 
synthetic globo H hexasaccharide conjugate in man. Proceedings of the National Academy of 
Sciences of the United States of America 1999, 96, 5710-5. 
4. Helling, F.; Shang, A.; Calves, M.; Zhang, S.; Ren, S.; Yu, R. K.; Oettgen, H. F.; 
Livingston, P. O., GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet 
hemocyanin conjugate vaccines. Cancer research 1994, 54, 197-203. 
5. Helling, F.; Zhang, S.; Shang, A.; Adluri, S.; Calves, M.; Koganty, R.; Longenecker, B. 
M.; Yao, T. J.; Oettgen, H. F.; Livingston, P. O., GM2-KLH conjugate vaccine: increased 
immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. 
Cancer research 1995, 55, 2783-8. 
6. Gilewski, T. A.; Ragupathi, G.; Dickler, M.; Powell, S.; Bhuta, S.; Panageas, K.; 
Koganty, R. R.; Chin-Eng, J.; Hudis, C.; Norton, L.; Houghton, A. N.; Livingston, P. O., 
Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the 
immunologic adjuvant QS-21. Clinical cancer research : an official journal of the American 
Association for Cancer Research 2007, 13, 2977-85. 
7. Abdel-Motal, U. M.; Wigglesworth, K.; Galili, U., Mechanism for increased 
immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal 
antibody. Vaccine 2009, 27, 3072-82. 
8. Pancer, Z.; Amemiya, C. T.; Ehrhardt, G. R. A.; Ceitlin, J.; Gartland, G. L.; Cooper, M. 
D., Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature 
2004, 430, 174-180. 
109 
9. Alder, M. N.; Rogozin, I. B.; Iyer, L. M.; Glazko, G. V.; Cooper, M. D.; Pancer, Z., 
Diversity and function of adaptive immune receptors in a jawless vertebrate. Science 2005, 310, 
1970-1973. 
10. Binz, H. K.; Amstutz, P.; Pluckthun, A., Engineering novel binding proteins from 
nonimmunoglobulin domains. Nature biotechnology 2005, 23, 1257-68. 
11. Skerra, A., Alternative non-antibody scaffolds for molecular recognition. Current opinion 
in biotechnology 2007, 18, 295-304. 
12. Pancer, Z.; Mariuzza, R. A., The oldest antibodies newly discovered. Nature 
biotechnology 2008, 26, 402-3. 
13. Herrin, B. R.; Alder, M. N.; Roux, K. H.; Sina, C.; Ehrhardt, G. R. A.; Boydston, J. A.; 
Turnbough, C. L.; Cooper, M. D., Structure and specificity of lamprey monoclonal antibodies. 
Proceedings of the National Academy of Sciences of the United States of America 2008, 105, 
2040-2045. 
14. Velikovsky, C. A.; Deng, L.; Tasumi, S.; Iyer, L. M.; Kerzic, M. C.; Aravind, L.; Pancer, 
Z.; Mariuzza, R. A., Structure of a lamprey variable lymphocyte receptor in complex with a 
protein antigen. Nature structural & molecular biology 2009, 16, 725-30. 
15. Han, B. W.; Herrin, B. R.; Cooper, M. D.; Wilson, I. A., Antigen recognition by variable 
lymphocyte receptors. Science 2008, 321, 1834-7. 
16. Dirksen, A.; Hackeng, T. M.; Dawson, P. E., Nucleophilic catalysis of oxime ligation. 
Angewandte Chemie 2006, 45, 7581-4. 
17. Davis, B. G., Synthesis of glycoproteins. Chem Rev 2002, 102, 579-601. 
18. Gamblin, D. P.; Scanlan, E. M.; Davis, B. G., Glycoprotein Synthesis: An Update. Chem 
Rev 2009, 109, 131-163. 
 
110 
5. Facile Preparation of Amylose-Proteins by Phosphorylase-catalyzed 
Polymerization 
5.1 Introduction 
Carbohydrates are ubiquitous in nature, and there is little doubt that the elaborate 
carbohydrate constructs observed on the surface of cells and proteins hold the key to 
understanding many complex biological processes. In particular, protein folding and 
stability are deeply influenced by the co- and post-translational glycosylation.1-3 
Many proteins could not fold correctly without proper glycosylation. Evidences has 
showed that incorrect glycosylation on the surface of proteins could fail the trimming 
process of proteins and proteins would be expulsed via the endoplasmic reticulum-
associated protein degradation (ERAD) pathway.4 Therefore, correct glycosylation is a 
great indicator of correct protein structure. Besides, carbohydrates could also stabilize 
tertiary structure of proteins. 5 
In nature, glycoproteins present as a mixture of glycoforms that has the same 
peptide sequence but different carbohydrates, which limited the studies about the 
enhanced proteolytic stability of glycosylation. For instance, RNase B, a glycosylated 
pancreatic ribonuclease at Asn34, demonstrated higher dynamic stability and functional 
activity than unglycosylated RNase A.6 Chemical glycosylation of proteins can provide 
practical alternative to achieve pure glycoforms for detailed structural and functional 
studies, with numerous variation in carbohydrate type and attachment site.7, 8 
The majority of our work presented herein focuses on developing novel 
methodology for the glycosylation of proteins to enhance proteins’ stabilities against 
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proteolysis, thermolysis and other forms of degradation, as well as future potential to 
serve in various medical settings. 
5.1.1 PEGylation and Glycosylation of Therapeutic Proteins 
Therapeutic proteins, such as insulin and Granulocyte-colony stimulating factor 
(G-CSF), are becoming rising stars in the pharmaceutical sciences.  More than 100 
genuine and similar number of modified therapeutic proteins are approved for clinical use 
in the European Union and the USA with 2010 sales of $108 bln.9 However, the major 
drawbacks of therapeutic proteins, including, antigenicity, short circulation half-life time 
and easy excretion from human body, are waiting for be solved in current stage. So far, 
the most practical and popular method employed are PEGylation, which involves the 
conjugation of poly (ethylene glycol) (PEG) with functional groups of proteins. In 1970s, 
Davies and Abuchowsky first investigated the PEGylation of protein and reported in two 
papers.10, 11 Since then, the practice of PEGylation has grown dramatically and several 
PEGylated therapeutic proteins has been approved by FDA. There is no doubt that 
PEGylation can increase the efficiency of therapeutic proteins.12-15 For instance, PEG 
could increase the size of proteins, effectively shielding proteins’ surface and limit the 
recognition by the reticuloehdothelial system. Major benefits of PEGylation include 
increase solubility of proteins, increase circulation half-life time and limit degradation by 
metabolic enzymes (Figure 5.1).  
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Figure 5.1. Benefits of PEGylated therapeutic proteins 
 
Despite of numerous benefits of PEGylation, its shortages are also obvious. In 
some cases, PEGylation could promote decreased biological activities and accumulate 
in the human body, giving rise to macromolecular syndrome.13 There are some concerns 
about generation of antibodies against PEG. All of these concerns stem from the fact that 
PEG is non-degradable and unnatural material.  
Therefore, there are needs and necessities to develop novel materials to substitute 
PEG in terms of modification of therapeutic proteins. Inspired by nature, glycosylation 
with even small oligosaccharides could play the similar roles in increasing the solubility 
and half-life time compared with PEGylation (Figure 5.2).16, 17 Like PEGylation, 
glycosylation also provides a large-size hydration shell which increase solubility and 
protect proteins from proteolysis.1 Besides, carbohydrate could increase thermal stability 
and decrease precipitation and aggregation.13, 18 Furthermore, unlike PEG, carbohydrate 
is natural and bio-degradable material which could be hydrolyzed and removed by 
glycosidase, making glycosylation an attractive alternative to improve performance of 
therapeutic proteins. 
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Figure 5.2. Benefits of glycosylated therapeutic proteins 
5.1.2 Phosphorylase-catalyzed enzymatic polymerization 
Phosphorylase (EC 2.4.1.1) is an exotype enzyme, which catalyzes in vivo reversible 
phosphorolysis catalyzes the reversible phosphorolysis of α-(1→4)-glucans, such as 
amylose and glycogen, at the non-reducing end, giving a glucose 1-phosphate (Glc-1-P). 
The enzyme can be utilized for glycosylation reaction because the substrate of a 
glycosylphosphate is activated and possesses the relatively low bond energy, compared 
to that of a glycosyl-nucleotide (Figure 5.3). 
 
Figure 5.3. Phosphorylase-catalyzed enzymatic polymerization 
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 Indeed, the enzyme catalyzes both reactions, phosphorolysis and glycosylation.19 In 
vitro synthesis of polysaccharides was performed via phosphorylase-catalyzed 
polymerization.20 The phosphorylase-catalyzed reaction was adapted to various 
polymerizations. For example, the formation of amylose-polymer inclusion complexes is 
synthesized by vine-twining polymerization catalyzed by phosphorylase(Scheme 5.1).21 
Phosphorylase-catalyzed polymerization was also utilized to synthesize amylose grafted 
chitin.22, 23  
 
Scheme 5.1 Application of phosphorylase-catalyzed polymerization 
 
Previous work in our group demonstrated feasibility of conjugating hemoglobin (Hb) 
with carbohydrate of variable molecular weights, up to 10,000.24 Furthermore, biophysical 
properties of glycosylated Hb are highly conserved compared with native Hb, suggesting 
glycosylation of Hb is a promising way to increase therapeutic proteins. However, this 
methodology requires tedious preparation of linker, free cysteine on the surface of 
proteins and the coupling efficiency of dextran with Hb is low due to bulky size of dextran.  
115 
In this chapter, we developed a novel method to generate variable MW carbohydrate-
coated proteins based on three key tools: direct amination, NHS-ester chemistry and 
phosphorylase-catalyzed enzymatic polymerization.  
5.2 Results and Discussion 
Concerning convergent glycoprotein synthesis, generally two approaches are taken: 
(1) indiscriminate glycosylation, which targets available amines on the protein, typically 
those of lysine residues, and (2) site-selective glycosylation, which targets the thiols of 
cysteine residues or amide of glutamine residues.  This report focuses on employing 
oligosaccharides for the indiscriminate glycosylation of therapeutic proteins. Significantly, 
the methods developed and presented within hold the potential for glycosylation—with 
high MW carbohydrates—to be used as a viable alternative to PEGylation. 
A substantial fraction of the currently approved protein pharmaceuticals need to be 
properly glycosylated to exhibit optimum therapeutic efficacy. This is due to the fact that 
glycosylation can influence a variety of physiological properties at both the cellular (e.g. 
intracellular targeting) and protein levels (e.g. protein solubility, protein molecular 
stability). As mentioned before, phosphorylase-catalyzed polymerization is promising way 
to generate novel amylose-coated materials, including amylose-proteins.25 Figure 5.4 
demonstrated the substrate specificity of phosphorylase. Vial 1 and 3 were 
maltopentaose and maltoheptaose, respectively. Vial 2 and 4 were maltopentaose mixed 
with phosphorylase and G-1-P, maltoheptaose mixed with phosphorylase and G-1-P, 
respectively.  After one hour reaction, KI-I2 was added into each vial and only vial 4 
changed to blue color, which indicated the formation of amylose. Based on this 
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experiment, we chose maltoheptaose as primer attached to proteins for further 
polymerization.  
 
Figure 5.4. Model Reaction of Polymerization catalyzed by Phosphorylase  
 
 Scheme 5.2 displayed our design of synthesizing amylose-proteins catalyzed by 
phosphorylase. We decided to use the microwave-assisted Kochetkov Reaction to 
introduce amine group at the reducing end of malheptaose. Of the various solvents 
tested, only DMSO resulted in good yields. Gratifyingly, the reaction was found to be 
efficient with only 15-fold excess of ammonium carbonate over sugar compared to the 40-
50-fold excess needed under thermal conditions. Another key step is to install proper 
spacer which is ready for conjugating amine groups of lysines on surface of proteins. After 
conjugating maltoheptaose with proteins, phosphorylase could polymerize the primer on 
the surface of proteins to afford amylose-proteins. 
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Scheme 5.2 Design of enzymatic polymerization of maltoheptaose-proteins 
 
Squaric acid can be applied as act ive reagent to couple two amino-functional 
compounds. Consecutive coupling of two primary amines could furnish synthesis of  
asymmetric squaric acid bisamides with either small molecules but also biomolecules 
or polymers.26 Af ter the f irst amidation step of the squaric acid, the 
result ing ester-amide carries reduced reactivity, which is the key feature 
of  squaric acid mediated coupling.  We prepared two squaric acid-conjugated 
maltoheptaose (Scheme 5.3). Free maltoheptaose 5-3 could add one amine group at 
the reducing ending with microwave-assisted Kochetkov Reaction to afford compound 
5-4, followed by coupling with squaric condition under mild condition to generate 
compound 5-1. In order to study whether the linker length could affect the coupling and 
polymerization or not, we decided to synthesize maltoheptaose-PEG-squaric acid 5-2, 
which has more flexible linker and reduced stereo hindrance to increase coupling 
efficiency.  
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Scheme 5.3 Synthesis of Maltoheptaose Donors 
 
Then these two compound were subjected to conjugation of BSA under basic 
condition (Scheme 5.3). Since these two compounds has lower reactivity as mentioned 
before, the coupling reaction with BSA requires higher PH value and longer time.  PH 
should increase to 8.5-9.0 and reaction time was extended to 24 hours.  
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Scheme 5.4 Conjugation and polymerization of Glyco-BSA 
 
Based on the SDS gel (Figure 5.5), compound 5-2 indeed result higher coupling 
efficiency than compound 5-1, making 5-2 more suitable molecules for future’s 
experiment. Expect longer chain, high hydrophilicity of PEG chain might also increase 
the efficiency of compound 5-2.   Interestingly, we have   difficulties to get the MALDI-
MS result from the glycosylated BSA because of   the interference of ionization 
imposed by the large oligosaccharide, a trait commonly seen with proteins bearing large 
oligosaccharides.24, 27 The following elongation were promoted by addition of 
phosphorylase with ratio of G-1-P to glycosylated BSA equal to 1000:1. After 24 hours, 
the resulting amylose-BSA showed from the SDS gel (add figure). Comparison of lane 
3 and lane 5, as well as lane 4 and lane 6, indeed proved the polymerization of the 
glycol-BSA.  
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Figure 5.5. SDS gel of Glycosylation and Polymerization of BSA  
 
5.3 Conclusion 
Overall, phosphorylase has been shown to catalyze the synthesis of amylose-
protein conjugates from their corresponding maltoheptaose-protein primer. The 
maltoheptaose-BSA conjugates has been synthesized in this study. Methods of 
synthesizing and assaying amylose-BSA with higher molecular weights has been 
developed. This methodology provides a novel access to achieve polysaccharide-protein 
conjugates, which could be a promising substitute for PEGylation.  
 
5.4 Experimental Section 
General Methods 
The synthetic Sugars in solution (10 mg/mL in 3x PBS) were added to the same 
volume of protein solution (10 mg/mL in 3xPBS) and was stirred at RT for 1 h. Then the 
resultant solution was ultrafiltrated and washed with 1x PBS using Amicon Centrifugal 
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Filter Devices (Ultracel 10,000). The collected glycoprotein solution was quantitated by 
Pierce BCA Protein Assay Kit (Pierce) and stored at 4 degrees. 
 
The SDS-PAGE was performed with standard conditon. Protein conjugates were 
suspended in 12 μL of sample buffer (5% (w/v) SDS, 10% (v/v) glycerol, 25 mM Tris-
Cl, pH 6.8, 10 mM DTT, 0.01% (w/v) bromophenol blue), loaded on different lanes of 
a 1.5-mm-thick, 12% (w/v) SDS-PAGE gel, and visualized by Coomassie Brilliant Blue 
R-250 staining.  
 
Compound 5-7 
Compound 5-3 (400 mg) and ammonium carbonate were dissolved in 20 mL DMSO 
and stirred with microwave tube at 40 °C for 3 h. TLC plate showed the formation of 
compound 5-4. The solvent was then removed under reduced pressure without further 
purification.   
To a 25ml round-bottom flask containing a solution of compound 5-4 (90mg, 
0.078mmol) in anhydrous DMSO was added compound 5-5 (139mg, 0.31mmol), HOBt 
(20mg, 0.153mmol) and HATU (58mg, 0.153mmol).  The reaction mixture was stirred at 
room temperature under nitrogen atmosphere for 24hrs. The solvent was removed under 
reduced pressure. The crude product was purified by C18 reverse phase flash 
chromatography using 0-100% MeOH in water as an eluent to afford compound 5-6 as a 
white solid with a yield of 70%.  
Compound 5-6 was added to a solution of 20% piperidine in DMF After 2 hours, the 
TLC plate showed the fully deprotection. The reaction was then concentrated, the residue 
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was added 0.5 mL water, extracted with EtOAc (1 mL x 4). The aqueous layer was 
lyophilized to give compound 5-7 as a white power. 
 
Compound 5-2 
 The compound was dissolved in EtOH/H2O (1:1). 3, 4-Diethoxy-3-
cyclobutene-1, 2-dione (1.0 equiv) was added. Then 5 µL solution of sat. Na2CO3 was 
added in intervals of 5 min, until a pH of 8 was reached. After stirring for 1.5 hours at room 
temp, the reaction mixture was neutralized by adding HOAc. The organic solvents were 
removed in vacuum. The residues were purified by C18 reverse phase flash 
chromatography using 0-100% MeOH in water as an eluent to afford compound 5-2 as a 
white solid with a yield of 85%.  
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6. Preparation of α-Gal-aptamer Conjugates for anticancer therapy  
6.1 Introduction 
Nucleic acids are the foundation of life. It is well-known that defined sequences 
translate certain genetic traits, protein expression and cellular function. Except that, they 
can be very useful for the recognition of biomolecules. When these nucleic acids are in 
single-stranded form, they are called aptamers, which have attracted much attention by 
carrying the ability of nucleic acids to binding certain biological molecules, including 
tumor-associated proteins, due to their stable three-dimensional structure.  
The word “aptamer” derives from the Latin word aptus, which means to fit, and the 
Greek meros, meaning region. Ellington and Gold published the first papers on aptamers 
in 1990.1, 2 The length of nucleic acid aptamers is in the range of 10−100 nucleotides, 
which are produced from a process called “systematic evolution of ligands by exponential 
enrichment” (SELEX) (Figure 6.1). SELEX employed enriching for single stranded RNA 
or DNA sequences based on retention of this sequence by binding a target of interest. 
SELEX could achieve high-affinity aptamers to be selected against many targets including 
extracellular domain of prostate-specific membrane antigen (PSMA),3 MUC1 peptides,4 
P-selectin,5 and protein tyrosine phosphatase 1B (PTP1B).6 DNA and RNA are not limited 
in function to storing and translating genetic information. Aptamers have highly stable 
tertiary structure, which allows them to form solid complexes with different targets, such 
as proteins.7-11 Aptamers can be referred to as “antibodies”, but aptamers has a number 
of functional advantages over antibodies. Aptamers are easy to synthesize and modify, 
inexpensive, long-term stability, have low immunogenicity, and possess greater tissue 
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penetration than antibodies.12, 13 Besides, antibodies need to be developed in vivo, but 
aptamers can be developed in vitro making aptamer production much easier and more 
feasible. 
 
Figure 6.1. Screen RNA Aptamer-the SELEX process 
 
The application of nucleic acid aptamers has greatly expanded since their 
inception about two decades ago. Even though many of these developments, especially 
those for biomedical applications such as diagnostics, biomarker discovery, therapeutics, 
and drug delivery, are still at the research stage, results are promising.14 One promising 
area is therapeutics. Due to their binding affinity and high specificity, aptamers could 
directly interrupt the activities of target proteins making them promising therapeutic 
agents for the treatment of diseases. Furthermore, aptamers binding cell surface proteins 
are well suited for the targeted delivery of other therapeutics, such as conjugated small 
interfering RNAs (siRNA) that induce RNA interference (RNAi). Thus, aptamer-siRNA 
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complex may offer dual-functions, in which the siRNA internalizes into the cell to target a 
specific mRNA, while the aptamer block a receptor function.15 
The therapeutic aptamers could modulate downstream signaling pathways 
through bounding with a specific target molecule on the surface of cell. The major 
inhibition mechanisms includes inhibiting dimerization to associated molecules, 
preventing structural changes in the target moleculs, or phosphorylatin of downstream 
proteins.16, 17 Due to these properties, anti-tumor therapy is one of the most popular 
application of aptamers. Aptamers are screened and designed to distunguish between 
normal and tumorigenic cells based on specific binding of aptamer and targeted protein. 
Tumor-targeting aptamers can be useful and highly specific in tumor cell detection and 
eliminations, which is needed for cancer treatment, as current chemotherapeutics present 
significant side effects such as massive deatch of normal and depletion of immune cells 
to fight infection. Hence, aptamer therapies could minimize these adverse effects by 
highly specific on tumorigenic cells and assisting patients to maintain homeostasis.10, 18 
Gilboa, one of our collabrator,  is focusing on  the cancer therapeutics based on highly 
specific aptamers. His group have developed several promising conjugated aptamers to 
detect tumor cells and suppress growth of tumor cells in mice models.19-21 Our group has 
rich expirence on synthesis of biologically important  carbohydrate epitopes such as α-
Gal, SLex and Globo H, which involves in humoral immunity, especially in anti-cancer 
immunotherapy. However, nobody has ever combined these two powerful tools, aptamer 
and carbohydrate, together to explore the potentias of developing anti-cancer therapies. 
This project is to fulfill this blank field to design, synthesize and imunologically evaluate 
the carbohydrate-aptamer conjugates on anti-cancer therapies.   
127 
6.2 Results and Discussion 
Monoclonal antibodies such as Rituximab or Trastuzamab mediated their antitumor 
effects in large part through the recognition of the tumor bound antibodies by complement 
or macrophages. It is however only partially effective and therefore improving the immune 
recognition of tumor bound antibodies is paramount to improve this promising platform of 
immune therapy of cancer. In a recent study, Carmi and colleagues have shown that 
“coating” tumor cells with polyclonal antibodies present in the patient is remarkably 
effective in eliminating the said tumor cells.22 We aim at developing a clinically applicable 
methods of coating the patient’ resident tumor cells with polyclonal antibodies induced in 
the cancer patient. 
Human individuals have high titers of polyclonal antibodies that recognize a small 
molecular weight trisaccharide antigen, Galα1-3Galβ1-4Glc (α-Gal), most likely as a 
result of postnatal exposure to harmless microbes.23 To “coat” tumor cells in situ with the 
anti-α-Gal antibodies, we will use an oligonucleotide aptamer that binds to a tumor cell 
specific products such as PSMA or Her2 that will be conjugated to α-Gal trisaccharide. 
Oligonucleotide aptamers represent a novel and emerging platform of ligands with 
desired specificity that offer potentially significant advantages over monoclonal antibodies 
in terms of development, manufacture, and cost. Upon injection of the aptamer-α-Gal 
conjugate into patient or experimental mouse, it will bind specifically to the tumor cells 
and the α-Gal moiety will attract the pre-existing anti-α-Gal antibodies present in the 
patient, thereby in effect coating the tumors with polyclonal anti-α-Gal antibodies. To 
conjugate the α-Gal moiety to the aptamer we will first conjugate α-Gal to a short 
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oligonucleotide that will be hybridized to the aptamer engineered to contain a 
complementary sequence.(Figure 6.2) 
43
43
43
43
43
43
 
Figure 6.2. Anticancer Mechanism of α-Gal-aptamer Conjugates 
 
Carbohydrate-oligonucleotide conjugates (COCs) has been extensively studied 
during last decade since these conjugates not only improve oligonucelotide’s properties 
but also create new ones. However, preparation of COCs is also challenging because the 
chemical characteristics of the oligonucleotide and the carbohydrate to be attached are 
not fully compatible. Several synthetic approaches have been developed for facile 
preparation of COCs, which can be grouped into several major categories: 1. solid-
support synthesis, where carbohydrate phosphoramidite derivatives are coupled to 
oligonucleotes moiety by automated DNA synthesis method;24 2. Copper catalyzed 
azide–alkyne cycloaddition (CuAAC), where ligation of azido-carbohydrates and alkyene-
oligonucleotides are catalyzed by Cu(I) to afford triazole rings;25 3. Reductive amination, 
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where amine-terminated DNA is coupled with reducing end of carbohydrate in the 
presence of NaCNBH3;26 4. Nucleophilic addition on unsatuated carbon through thiol-
oligonucleotide is added an unsaturated carbonyl on carbohydrate via Micheal addition 
to form thioether bond;27 5. EDC/NHS coupling, carbohydrates bearing carbonic acid 
coupled with amine-modified oligonucleotides by EDC/NHS condition.28 (Figure 6.3) 
 
Figure 6.3. Methods of Synthesis of Carbohydrate-Oligonucleotide Conjugates 
(COCs) 
 
Based on our experience of glycoprotein synthesis, we attempted to utilize NHS ester 
chemistry to couple α-Gal epitope with amine-modified ssRNAs which were purchased 
from Trilink company. The aforementioned NHS ester is very active due to its 
electrophilicity and amine group can attach it to form stabile a amide bond at weak base 
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condition. This method is simple and efficient as no tedious manipulation and harsh 
condition are needed. But the drawbacks are also obvious because NHS ester are too 
reactive that water can attack the ester bond to form corresponding acid. Scheme 6.1 
demonstrated our design of synthesis of COCs in PBS buffer. Carbohydrate NHS ester 
mixed with amine-C6-ssRNA with a ratio of 50:1 in PBS buffer with PH at 7.5. To avoid 
potential thermolysis of ssRNA, the coupling was performed under 4 °C. After 24 hours, 
the mixture was detected with MALDI-TOF spectremery. Unfortunately, only a few 
prodcut was detected for the coupling of α-Gal and 5’P-ssRNA. No product was deteced 
for the coupling of α-Gal and 3’P-ssRNA. There was no improvement of the result even 
though the ratio of carbohydrate to ssRNA was increased to 100:1. The major reason of 
this failure might be short carbon linker terminated with amine was shielded by ssRNA 
backbone and bulky carbohydrates NHS ester has fewer chance to access the amine 
group.  
 
Scheme 6.1. ssRNA Conjugation Reaction 
 
In order to prove this assumption, we performed a model reaction in which small-size 
biotin-NHS was mixed with the aforementioned ssRNA. It turned out this coupling reaction 
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is highly efficient and all of ssRNA was conjugated with biotin tag according to MALDI-
TOF result (Figure 6.4). The size of biotin-NHS is much smaller than α-Gal that it could 
penetrate the shields of RNA backbone and access the amine group more easily. Six 
carbon linker is too short to react with bulky carbohydrate NHS ester.  
 
Figure 6.4. MALDI Result for Biotin-ssRNA conjugation 
Based on previous experiements, longer linker should overcome this coupling issue. 
Another DNA modified with C12 linker terminated with amine group was for modeling 
reaction. We used lactose NHS and maltoheptaose NHS to couple with the amine-C12-
DNA.(Figure 6.5) Carbohydrate NHS ester mixed with amine-C12-DNA with a ratio of 
50:1 in PBS buffer with PH at 7.5. The HPLC result showed that the coupling reaction did 
work well. The retension time of starting material is about 22.58 min, After glycosylation, 
the retension time of lactose-C12-DNA was shifted to 3.20 min, and the retension time of 
maltopentataose-C12-DNA was shifted to 6.73 min (add HPLC fig). However, we have 
some difficulties to detect the carbohydrates-C12-DNA with MALDI-TOF, even though 
amine-C12-DNA could be detected very well. The traditional matrix for detecting 
oligonucleotides are Hydroxypicolinic Acid (HPA) or 2 ′ ,4 ′ ,6 ′ -
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Trihydroxyacetophenone monohydrate (THPA). HPA used in this project is compatible 
with ssRNA and unconjugated DNA, but has some difficulties to detect COCs prepared 
prepared by us. Some literatures suggested HPA in acetonitrile/water (1:1, v/v) containing 
10% of ammonium citrate and few beads of DOWEX 50W-X8 ammonium sulfonic acid 
resin were added.29  Further work is needed to figure out the proper MALDI detection 
method for our COCs samples. 
 
Figure 6.5. Modeling Reaction of COCs 
6.3 Conclusion 
A method of synthesis of carbohydrate-oligonucleotide conjugates has been 
developed based on NHS ester chemistry. Amine terminated linker should be long 
enough to expose on the surface of oligonucleotides for NHS ester coupling. Short chain 
will be shielded by oligonucleotides backbones. Further investigation is needed to detect 
COCs by MALDI spectrometry. We will conjugate α-Gal NHS ester with the coming 
amine-C12-ssRNA in the future. 
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ESI HRMS of 1-1 and active ester modified pentasaccharide 
 
 
 
19-Jun-201317:08:39
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MALDI–TOF mass (A) and SDS–PAGE (B) analysis of CRM197 and 
pentasaccharide–CRM197  
 
MALDI–TOF mass (A) and SDS–PAGE (B) analysis of BSA and 
pentasaccharide–BSA  
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1H NMR of Compound 2-6 
 
13C NMR of Compound 2-6 
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1H NMR of Compound 2-7 
  
13C NMR of Compound 2-7 
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1H NMR of Compound 2-1 
 
13C NMR of Compound 2-1 
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1H NMR of Compound 2-9 
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13C NMR of Compound 2-9 
 
 
 
1H NMR of Compound 2-3 
155 
 
13C NMR of Compound 2-3 
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1H NMR of Compound 2-13 
 
13C NMR of Compound 2-13 
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1H NMR of Compound 2-14 
 
13C NMR of Compound 2-14 
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1H NMR of Compound 2-15 
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13C NMR of Compound 2-15 
 
 
 
1H NMR of Compound 2-16 
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13C NMR of Compound 2-16 
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1H NMR of Compound 2-19 
 
13C NMR of Compound 2-19 
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1H NMR of Compound 2-20 
 
13C NMR of Compound 2-20 
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1H NMR of Compound 2-21 
 
13C NMR of Compound 2-21 
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1H NMR of Compound 2-22 
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13C NMR of Compound 2-22 
 
 
1H NMR of Compound 2-23 
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13C NMR of Compound 2-23 
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1H NMR of Compound 2-24 
 
13C NMR of Compound 2-24 
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1H NMR of Compound 2-25 
 
13C NMR of Compound 2-25 
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170 
NMR, and HPLC data of purified HMOs 
1H NMR of HMO1 
 
13C NMR of HMO1 
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HMO11 
1H NMR 
 
 
HILIC-ELSD, TR =11.946 min 
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HMO12 
1H NMR 
 
 
HILIC-ELSD, TR = 17.063min 
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HMO13 
1H NMR  
 
 
HILIC-ELSD, TR = 19.767min 
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HMO14 
1H NMR 
 
 
HILIC-ELSD, TR =15.606 min 
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HMO15 
1H NMR 
 
 
HILIC-ELSD, TR = 13.605min 
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HMO16 
1H NMR 
 
 
HILIC-ELSD, TR =17.718 min 
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HMO2 
1H NMR 
 
13C NMR of HMO2 
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HMO21 
1H NMR 
 
 
HILIC-ELSD, TR =12.722 min 
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HMO22 
1H NMR 
 
 
HILIC-ELSD, TR = 13.927min 
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HMO23 
1H NMR 
 
 
HILIC-ELSD, TR = 11.877min 
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HMO24 
1H NMR 
 
 
HILIC-ELSD, TR =10.566 min 
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HMO25 
1H NMR 
 
 
HILIC-ELSD, TR =14.747 min 
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HMO26 
1H NMR 
 
 
HILIC-ELSD, TR = 15.796min 
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HMO27 
1H NMR 
 
 
HILIC-ELSD, TR =13.933 min 
 
 
 
Dataf ile Name:1.13.16 HMO27.lcd
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 min
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mV
ELSD 
185 
HMO28 
1H NMR 
 
 
HILIC-ELSD, TR = 13.581min 
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HMO29 
1H NMR 
 
 
HILIC-ELSD, TR = 13.993min 
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HMO210 
1H NMR 
 
 
HILIC-ELSD, TR =16.260 min 
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HMO211 
1H NMR  
 
 
HILIC-ELSD, TR =15.076 min 
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HMO3 
1H NMR 
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HMO31 
1H NMR 
 
 
HILIC-ELSD, TR =12.548 min 
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HMO32 
1H NMR 
 
 
HILIC-ELSD, TR =13.710 min 
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HMO33 
1H NMR 
 
 
HILIC-ELSD, TR =11.576 min 
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HMO34 
1H NMR 
 
 
HILIC-ELSD, TR =10.512 min 
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HMO35 
1H NMR 
 
 
HILIC-ELSD, TR =14.547 min 
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HMO36 
1H NMR 
 
 
HILIC-ELSD, TR =15.697 min 
 
 
 
 
Dataf ile Name:1.13.16 HMO36.lcd
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 min
0.0
2.5
5.0
7.5
10.0
12.5
mV
ELSD 
196 
 
HMO37 
1H NMR 
 
 
HILIC-ELSD, TR =13.611 min 
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1H NMR 
 
 
HILIC-ELSD, TR =12.437 min 
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1H NMR 
 
 
HILIC-ELSD, TR =12.303 min 
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HMO310 
1H NMR 
 
 
HILIC-ELSD, TR =16.506 min 
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HMO311 
1H NMR 
 
 
HILIC-ELSD, TR =14.544 min 
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